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Preface 
 
Neuropathic pain is pain that arises as a direct consequence of a lesion or diseases affecting 
the somatosensory system [1]. Despite the abundant availability of drugs and guidelines for 
the treatment of neuropathic pain, it remains a disorder often under- or untreated. Over 
the past 5 decades, spinal cord stimulation (SCS) has become a safe and effective, last-
resort, therapeutic tool for the treatment of intractable neuropathic pain conditions. 
Literature shows that Tonic (or conventional) SCS is clinically effective for the management 
of failed back surgery syndrome (FBSS) and complex regional pain syndrome (CRPS); two 
neuropathic pain disorders infamous for their resistance to pharmacological treatment. 
Although effective, roughly 50-70% of patients implanted with a SCS-device experiences 
adequate pain relief, there still remains a need for improvement, as 30-50% of patients do 
not achieve adequate pain relief and/or experiences loss of efficacy over time. 
Unfortunately, the reported success rate of Tonic SCS in treatment of FBSS and CRPS has 
improved little over the past decade and SCS remains an indispensable, though suboptimal, 
treatment method for chronic neuropathic pain. Additionally, the presence of paresthesia, 
a tingling sensation experienced in the stimulated limb or area with Tonic SCS, has hindered 
the design of double-blind placebo-controlled study designs. 
In an effort to improve the efficacy of SCS, several alternative stimulation paradigms 
have been developed over the last decade. One such example is the Burst paradigm, a SCS-
mode that uses periodic bursts of pulses rather than continuous pulses as seen with Tonic 
SCS. Burst stimulation is paresthesia-free and suggested to induce additional pain relief over 
Tonic stimulation. Literature suggests that the distinct analgesic effect of Burst SCS is due 
to the modulation of cognitive-emotional aspects of pain. Initial studies on Burst SCS 
indicate great potential for this novel stimulation paradigm, yet, also address a need for 
further optimization. To this end, experimental studies should be performed in order to 
acquire more Insight into the underlying mechanism and, along the way, uncover the full 
potential of Burst stimulation in the treatment of neuropathic pain.  
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In view of the physiological and neurological aspects involved in neuropathic pain, this 
chapter will firstly summarize the pathophysiological and epidemiological characteristics. 
(1.1) This is followed by a short summary on two intractable neuropathic pain disorders 
frequently treated with spinal cord stimulation (SCS) (1.2). Next, treatment of neuropathic 
pain with Tonic SCS will be described (1.3). Novel SCS paradigms will be introduced (1.4). 
Clinical and experimental findings on Burst SCS will be discussed (1.5). Lastly, the aims, 
outline, and research questions of this academic thesis will be presented (1.6). 
 
1.1 Neuropathic pain and pathophysiology 
 
Neuropathic pain (NPP) has been described as ‘the most terrible of all tortures, which a 
nerve wound may inflict’ [2]. NPP is characterized by sensory abnormalities such as 
abnormal unpleasant sensation (dysesthesia), an increased sensitivity to painful stimuli 
(hyperalgesia) and pain in response to normally innocuous stimuli (allodynia) [3, 4]. Over 
the years, various definitions of NPP have been used. Yet, the most recent and widely 
accepted definition is stated by the International Association for the Study of Pain (IASP) 
[5]: 
“Pain caused by a lesion or diseases of the somatosensory system”. 
 
The somatosensory system allows for the perception of touch, pressure, pain, temperature, 
movement and vibration. Nerves endings from the somatosensory nerves arise in the skin, 
muscles, joints and fascia and include nociceptors, mechanoreceptors and chemoreceptors. 
When stimulated, these receptors send signals to the spinal cord and eventually to the brain 
for further processing. Lesions or diseases that affect the somatosensory nervous system 
can lead to altered or disordered transmission to the central nervous system. Distorted 
signal transmission and processing can, if not treated promptly, lead to the development of 
NPP. At that point, the distorted processing of somatosensory signals goes beyond normal 
plasticity and enters an aberrant state. Nerve lesions or diseases that lead to the 
development of NPP can have various etiologies, such as infection, peripheral nerve injury, 
nerve compression, failed back surgery, diabetic neuropathy, chemotherapy, and 
amputation. Based on the location of the injury or disease, in the peripheral of central 
nervous system, NPP is classified as either peripheral NPP or central NPP. However, it is 
likely that at a progressed, chronic, state NPP involves both peripheral and central 
mechanisms. Importantly, NPP is seen as mechanistically dissimilar to other chronic pain 
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conditions such as inflammatory pain where the primary cause is inflammation with altered 
chemical signaling at the site of inflammation [6]. 
 
Patients diagnosed with NPP typically experience a distinct set of symptoms, such as 
burning, stabbing or electric shock-like sensations [7]. These experiences can either be of a 
spontaneous nature or triggered by an external stimulus. Stimulus-evoked pain can be 
classified as pain in response to non-painful stimuli: allodynia, or as an increased response 
to painful stimuli: hyperalgesia. Generally, NPP-patients experience both allodynia and 
hyperalgesia together. The aforementioned collection of symptoms makes that NPP is 
associated with a significant decrease in patients’ health related quality of life (HRQol) [8, 
9]. Furthermore, studies on NPP-patient populations report an increase in drug 
prescriptions and visits to health care providers [8, 10]. Sleep disturbances, anxiety and 
depression are frequent comorbidities in patients with NPP, and quality of life is more 
impaired in patients with chronic neuropathic pain than in those with chronic non-
neuropathic pain that does not originate from damaged or irritated nerves  [3]. 
 
1.1.2 Epidemiology of neuropathic pain     
 Making an adequate estimation of the incidence and prevalence of NPP has always been 
difficult due to the lack of simple diagnostic criteria for large epidemiological surveys in the 
general population. Hence, the prevalence of NPP in the population has mainly been 
estimated on the basis of studies [3, 11] conducted by specialized centers that focus on 
specific NPP-conditions; such as failed back surgery syndrome (FBSS) [12-15], complex 
regional pain syndrome (CRPS) [16-19], postherpetic neuralgia [20, 21], painful diabetic 
polyneuropathy [22-24], post-surgery neuropathic pain  [25], spinal cord injury [26], stroke 
[27] and cancer [28, 29]. 
Chronic NPP tends to be more frequent in women (8% versus 5.7% in men) and in patients 
over 50 years of age (8.9% versus 5.6% in those <49 years of age). It most commonly affects 
the lower back and lower limbs, and neck [30]. Lumbar and cervical painful radiculopathies 
are estimated to be the most frequent cause of chronic NPP. In line with this, a survey of 
>12,000 patients with chronic pain with both nociceptive and neuropathic pain types, 
referred to pain specialists in Germany, revealed that approximately 40% of all patients 
experienced at least some characteristics of NPP (such as burning sensations, stabbing 
sensations, numbness and tingling). Patients with chronic back pain and radiculopathy were 
particularly affected by the aforementioned symptoms [31]. The incidence rate of NPP is 
8.2 per 1000 [32],  and is expected to significantly increase in the near future as the Western 
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population is aging. Treatment remains challenging as it is often refractory to first-line 
pharmacological treatment [3, 4, 8, 32-34] and NPP-management should always be placed 
in context of its underlying cause and aberrant physiological mechanisms. As 
pharmaceutical treatment of neuropathic pain disorders such as CRPS and FBSS is often 
limited and accompanied by severe side effects, interventional neuromodulation 
techniques, such as Tonic SCS, have become a well-established last resort treatment option 
for the aforementioned intractable neuropathic pain disorders [35-48]. 
 
1.2.1 Failed Back Surgery Syndrome (FBSS) 
FBSS is a term used to describe a clinical entity subsequent to the advent of spinal surgery 
[49]. The term FBSS is used to describe a constellation of conditions characterized by 
persistent or recurring low back pain, with or without sciatica following spine surgery. [50]. 
Follett described FBSS in 1993 as the “surgical end stage after one or several interventions 
on the lumbar neuraxis indicated to relieve lower back pain, radicular pain or the 
combination of both, without effect” ( Follett, 1983). [51]. FBSS has a prevalence of 
approximately 0.61% of the general population, which makes up approximately 45 million 
people worldwide [12]. With the number of spine surgeries steadily increasing, the 
prevalence of FBSS is only expected to rise [52, 53]. Symptoms usually include a sharp, 
regular or recurring pain shooting or radiating down one or both legs, potentially 
accompanied by, partial, muscular dysfunction. The pharmacological treatment of 
neuropathic pain symptoms in FBSS patients follows a standardized treatment algorithm, 
and may include a wide variety of commercially available pain killers (such as paracetamol), 
antidepressants, anticonvulsants, N-methyl-D-aspartate antagonists, and opioids [34, 54]. 
Although these drugs have proven to alleviate up to 50% of neuropathic pain symptoms in 
FBSS patients, pharmacological treatment is often accompanied by (severe) side effects, 
such as sedation, cardiac arrhythmias, postural hypotension, and behavioral changes [55-
57]. Furthermore, a subset of FBSS patients do not receive adequate pain relief (less than 
50%) with pharmacological treatment. Therefore, more invasive and expensive treatment 
options like stimulation of the dorsal columns of the spinal cord (SCS) are frequently applied 
[38, 50, 58, 59].    
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1.2.2 Complex regional pain syndrome (CRPS) 
CRPS type 2, or causalgia, is a condition that generally results from (surgical) injury to 
somatosensory nerves [60]. The most common triggers are fractures, sprains/strains, soft 
tissue injury, limb immobilization (due to a cast), surgery, or even minor medical procedures 
such as needle prick. Yet, it is not uncommon that the precipitating event cannot clearly be 
identified. CRPS is an aberrant response that magnifies the normal physiological response 
to an injury and is characterized by a rapid onset (usually 24 hours) of spontaneous constant 
burning pain that is exacerbated by several factors such as light touch (allodynia), changes 
in temperature and/or movement of the affected limb [61, 62]. Apart from the 
aforementioned neuropathic symptoms, studies have also proposed neurogenic 
inflammation as an underlying mechanism for a subset of CRPS-symptoms [63, 64]. CRPS 
syndrome can be divided into two types: 
 
CRPS Type 1; absence of any form of nerve injury 
 
CRPS Type 2; lesion to a major nerve has been identified  
 
The reported incidence of CRPS is highly variable. Among the Dutch population the 
estimated incidence of CRPS was reported to be 26.2 per 100,000 [16]. Like most syndromes 
that are neuropathic in nature, CRPS type I responds poorly to conventional 
pharmacological analgesic therapy. Besides conventional pain medication, physical therapy, 
sympathetic blocks, and transcutaneous electrical stimulation of nerves have all been 
applied in an attempt to reduce the intensity of pain, generally with suboptimal results. Only 
one in five affected patients is able to return to a normal level of functioning [65]. As a 
consequence, adequate treatment of CRPS often requires more invasive treatment options 
like SCS [43]. 
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1.3 Tonic Spinal Cord Stimulation in neuropathic pain               
Spinal cord stimulation requires surgical placement of electrodes on top of the dorsal 
columns of the spinal cord. Electrodes are carefully inserted, either transcutaneous or via 
laminectomy, in the epidural space on top of the dura mater surrounding the spinal cord. 
Then, electrical pulses are administered to the dorsal columns of the spinal cord, via an 
implantable pulse generator or an external stimulation device. Tonic, conventional, SCS 
(Tonic SCS) settings vary within a range of 30-80 Hz, 100-500 µs pulse width, and amplitude 
above sensory threshold [66, 67]. The concept of Tonic SCS emerged as a direct spin-off 
from the Gate Control Theory, formulated by Melzack and Wall in 1965 [68, 69]. From this, 
it was postulated by Shealy, Mortimer and Reswick, that antidromic stimulation of the non-
nociceptive Aβ-fibers in the dorsal columns could close the ‘spinal gate’, located in the 
dorsal horn of the spinal cord. Meanwhile, orthodromic stimulation of the Aβ-fibers in the 
dorsal columns also caused paresthesia (i.e., abnormal tingling sensation) in the area 
innervated by the stimulated fibers (figure 1). Nowadays, during surgical implantation of 
the SCS-lead the physician makes sure the paresthesia overlaps the painful area and 
provides adequate pain relief [70]. Closing of the ‘spinal gate’ is facilitated by inhibitory 
interneurons located in the dorsal horn. In line with the Gate Control Theory those 
inhibitory interneurons, when antidromically activated by Tonic SCS, modulate the 
nociceptive signal through the release of gamma-amino-butyric acid (GABA). Indeed, 
experimental research has demonstrated that Tonic SCS decreased intracellular GABA-
immunoreactivity in the dorsal horn of chronic neuropathic rats [71]. At the same time, 
spinal microdialysis in Tonic SCS stimulated chronic neuropathic rats has demonstrated that 
SCS increases extracellular GABA levels in the dorsal horn of chronic neuropathic rats [72-
74]. Thus, enhanced GABA release in the dorsal horn seems to be a vital aspect of the 
mechanisms underlying Tonic SCS. The mechanism of segmental GABA release was further 
elucidated by the administration of pharmacological agents in chronic neuropathic rats that 
received Tonic SCS. Local perfusion with a GABAB-receptor antagonist in the dorsal horn 
transiently abolished the stimulation-induced effect in neuropathic rats [74], and rats not 
receiving adequate pain relief with Tonic SCS (non-responders), were turned into 
responders by administration of the GABAB-receptor agonist baclofen [75]. The 
aforementioned preclinical findings were successfully translated to the clinic where 
neuropathic pain patients not responding to Tonic SCS were turned into responders with 
additional intrathecal administration of subeffective doses of baclofen [76].  
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 Experimentally, it has been demonstrated by Smits and colleagues that Tonic SCS results 
in a much better pain relieving effect when administered at the level where the injured 
fibers enter the spinal dorsal horn, as compared to SCS administered at more rostral levels 
[77]. This emphasized the fact that Tonic SCS in treatment of neuropathic pain primarily acts 
through a segmental, spinal, site of action (see Figure 1).Yet, besides the segmental mode 
of action, Tonic SCS also invokes activation of supraspinal mechanisms, via orthodromic 
activation of the Aβ-fibers (via the so-called supraspinal feedback loop). Once activated, 
these supraspinal cell regions modulate the incoming nociceptive signals at the spinal level 
via descending fiber projections. Brainstem nuclei such as the locus coeruleus and the raphe 
nucleus, are activated by Tonic SCS and in their turn modulate the spinal pain signal via 
descending adrenergic and serotonergic projections respectively [78, 79].  Moreover, it has 
been shown that SCS can modulate activation patterns in brain areas at a subcortical and 
cortical level. Early clinical fMRI-work on the supraspinal effects of Tonic SCS has 
demonstrated modulation of brain regions associated with the lateral spinothalamic tract 
(STT) [80-82]. The lateral STT is responsible for the transmission of objective pain-aspects 
such as the intensity and location of the painful stimulus. This lateral STT pathway projects 
from the dorsal horn, via the thalamus, to cortical areas such as the somatosensory cortex 
[83, 84]. An fMRI study performed in eight patients receiving Tonic SCS demonstrated that 
Tonic stimulation increased Blood Oxygen Level-Dependent (BOLD)-signals in 
somatosensory cortices, the sensorimotor cortex and the insula [81]. Furthermore, a more 
recent fMRI-study with twenty patients who received Tonic-SCS as treatment for FBSS, 
reported deactivation of the bilateral medial thalamus and its connections to the rostral and 
caudal cingulate cortex, and the insula [80]. In conclusion, over the years, literature on Tonic 
SCS has provided evidence for spinal as well as supraspinal mechanisms.  Yet, the principal 
mechanism of action seems to be situated at a segmental, spinal, level [77].  
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Figure 1: A representation of the spinal nociceptive network and mechanism of Spinal Cord 
Stimulation (SCS). The dorsal horn of the spinal cord contains two major types of projection neurons: 
the Nociceptive-Specific projection neurons located in the superficial laminae I, and the Wide Dynamic 
Range projection neurons located in the deeper laminae (IV, V and VI). These projection neurons 
receive input from primary afferents, descending (aminergic) pathways, and spinal interneurons. The 
spinal nociceptive network contains numerous interneurons, both of excitatory and inhibitory 
(gamma-amino-butyric acid [GABA]-ergic) nature, which modulate the processing of pain signals at 
the ‘‘gate’’ to the brain (‘‘Gate-Control theory’’). Electrical stimulation of the DCs results in an action 
potential propagating in both directions: orthodromically in rostral direction to supraspinal areas, and 
antidromically via Aβ fibers back into the spinal cord nociceptive network. Antidromic stimulation of 
the Aβ fibers results in changed (decreased) release of glutamate and at the same time an increased 
release of the inhibitory neurotransmitter GABA. From Smits et al. (2012) with permission [85]. 
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1.4 Novel Spinal cord stimulation paradigms 
 
Despite the many successes that have been achieved with Tonic-SCS, including treatment 
of various chronic neuropathic pain conditions such as FBSS and CRPS, up to 30% of patients 
remain unresponsive to SCS treatment, or experience loss of adequate pain relief over time 
[35-37, 40, 42, 44-47, 86-93]. In 2012, prospective long-term follow-up data on SCS in CRPS-
I revealed that 63% of patients still received adequate pain relief with SCS-treatment 12 
years after implantation of the device [45]. However, 59% of patients experienced less than 
30% of pain relief at the last follow-up measurement as compared to pain scores reported 
at first intake. For FBSS, two Randomized Clinical Trials (RCT’s) have reported that 58% and 
47% of patients who received SCS-treatment for FBSS experienced adequate pain relief at 
24 and 36 months follow-up respectively [58, 59]. In general, the reported success rate for 
Tonic SCS has remained suboptimal, with roughly 50% pain relief on the VAS/NRS score for 
approximately 50-70% of the patients [90, 94]. As a direct consequence, the interventional 
SCS-field started to investigate novel targets and novel SCS-paradigms that might further 
improve or sustain pain relief.  
A recently introduced novel target for SCS treatment is the dorsal root ganglion (DRG). 
In contrast to dorsal column SCS, the electrode is steered toward the lateral epidural space 
near the DRG. It has been found that DRG stimulation offers several potential benefits over 
Tonic dorsal column SCS, including a more targeted approach with paresthesia and the 
ability to stimulate areas that are difficult to reach with dorsal column SCS, such as the low 
back and foot [95-99]. 
Next to novel physiological targets for SCS, novel SCS-paradigms were introduced in 
order to bridge to gap between current and desired pain relief. Two prominent examples, 
High Frequency SCS (HF SCS) and Burst SCS, were recently introduced in order to optimize 
the efficacy of SCS-treatment for chronic neuropathic pain [67, 89, 100-105]. Both Burst SCS 
and HF SCS are generally applied at stimulation amplitudes below sensory threshold, which 
means the patient does not experience paresthesia during stimulation. This has offered 
researchers, the opportunity to perform double-blind placebo-controlled clinical studies, 
for the first time since SCS was introduced in 1967 [41, 106-108]. HF SCS is generally applied 
at a frequency above 1000 Hz, up until 10 kHz, with a pulse width at approximately 30 
microseconds (µs) and amplitude typically 1–5 mA [109]. Hypotheses about the underlying 
mechanism of HF SCS vary. It is suggested that 1) temporal summation could play a role, 
where multiple pulses build on each other to achieve neuronal activation; 2) depolarization 
blockade could occur, where propagating action potentials are blocked by the high 
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frequency stimulation; and 3) desynchronization could result in pseudo-spontaneous or 
stochastic neuronal activity in the spinal “gate” [110-112].  Till today, the optimal frequency 
for HF SCS has not yet been determined, and clinical evidence suggests that different HF-
frequencies, ranging from 1000 Hz to 10 Khz, can yield clinically significant pain relief [100, 
102, 108, 109, 113-115].  
The Burst-paradigm was introduced in 2010 by de Ridder and colleagues as ‘BurstDR’- 
SCS [103, 104, 116]. The BurstDR-waveform consists of five closely spaced monophasic 
spikes administered at 40Hz inter-burst mode and 500Hz intraburst frequency, with a pulse 
width of 1 ms and 1 ms interspike interval, delivered in constant current mode. The 
cumulative charge of the five 1 ms spikes is balanced during the 5 ms after the spikes, in a 
so called passive recharge phase, which differentiates it from HF SCS and Tonic SCS, in which 
each pulse is immediately charge balanced after each spike, in a so called active recharge 
phase [104, 116]. The BurstDR-pattern was chosen because it supposedly mimics naturally 
occurring neural bursting patterns in the central nervous system. Indeed, neurons 
responsible for encoding aspects of pain signaling from peripheral neurons [117-119] and 
the thalamus [120-122] have been reported to fire in bursting patterns. However, it is 
important to mention that “BurstDR™” is a registered trademark and only one of an infinite 
number of possible Burst waveforms [123]. Interestingly, like HF SCS, the Burst paradigm 
has been reported to produce pain relief without inducing paresthesia in the majority of 
patients. Paresthesia is the sensation that results from activation of sensory-specific dorsal 
column fibers [124], so absence of paresthesia suggests that stimulation is not activating 
dorsal column Aβ-fibers [125, 126]. However, even though stimulation at low amplitude 
may be subthreshold with respect to neuronal activation, and sub-perception with respect 
to the patient’s experience, large amounts of charge are still delivered to dorsal horn fibers, 
providing the pulse width and/or frequency are sufficiently large [112]. This could 
potentially set in motion, additional, dorsal horn mechanisms that are not activated with 
suprathreshold Tonic SCS. Yet, the key difference between Tonic-SCS and Burst SCS is 
thought to be located higher up the neuraxis, at a supraspinal level. Clinical evidence 
suggests that Burst SCS, unlike Tonic SCS, activates brain areas associated with the 
processing of cognitive-emotional aspects of pain such as the amygdala, the anterior 
cingulate cortex, and the insula. The aforementioned brain areas are linked to the medial 
STT [116, 127] (Figure 2). In 2013, a small clinical study demonstrated that patients who 
received BurstDR SCS improved on pain aspects like ‘the amount of attention the patients 
pay to pain’ and ‘changes in pain’ in a statistically significant way, as measured by the Pain 
Vigilance and Awareness Questionnaire (PVAQ) [116]. Meanwhile, patients who received 
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Tonic or placebo stimulation showed no significant effect on the aforementioned pain 
aspects. Subsequently, a source-localized electroencephalography study in patients who 
received Burst or Tonic SCS showed that Burst SCS was able to normalize the pain 
supporting/ suppressing balance by having a greater effect on the dorsal anterior cingulate 
cortex [127]. This further supports the notion that Burst SCS has an effect on brain areas 
associated with the processing of cognitive-emotional aspects of pain. 
Although the aforementioned studies have helped shed light on the (supraspinal) 
mechanisms underlying Burst SCS, the preponderance of mechanisms underlying the pain 
relieving effect of Burst SCS is still largely unknown. It is a firm belief that it is pivotal that 
more insight is acquired into the role of supraspinal brain areas associated with the pain 
relieving effect of (Burst and Tonic) SCS. 
 
1.5.1 Burst SCS: clinical evidence 
Early clinical studies have demonstrated that BurstDR stimulation is able to provide clinically 
relevant pain relief, which, in a subset of patients, may surpass the pain relief provided by 
Tonic stimulation [41, 116, 128, 129]. Although additional pain reduction during BurstDR 
stimulation was found to be only marginally greater as compared with Tonic stimulation, 
BurstDR stimulation was preferred by the majority of patients. The preference for BurstDR 
stimulation is most likely correlated to the lack of paresthesia. It has been demonstrated 
that BurstDR SCS produces paresthesia only in a subset of patients, approximately 17–25%, 
and anecdotal reports indicate that paresthesia during BurstDR stimulation may be 
perceived as qualitatively different from paresthesia experienced during Tonic SCS [104, 
128, 129]. Additionally, there are studies that suggest the ability of BurstDR SCS to recover 
patients that no longer achieve adequate pain relief with Tonic SCS anymore, as well as the 
ability to reduce the affective aspects of chronic neuropathic pain [104, 116, 130]. Yet, these 
early studies evaluating Burst SCS enrolled relatively small cohorts of patients, over a short 
period of time, and there remained a lack of randomized, placebo-controlled clinical trials. 
Therefore, a larger controlled study was necessary in order to demonstrate the safety and 
efficacy of BurstDR stimulation, compared to Tonic stimulation. The primary objective of 
the ‘success using neuromodulation with Burst’ (SUNBURST) study was to establish the 
noninferiority of pain intensity after three months of Burst SCS compared to three months 
of Tonic SCS [131]. The SUNBURST study demonstrated that BurstDR SCS is indeed 
noninferior to Tonic SCS, and superiority of BurstDR SCS was also achieved. In addition, 
significantly more subjects (70.8%) preferred BurstDR stimulation over Tonic stimulation, 
and this preference was sustained throughout the first year: 68.2% of subjects preferred 
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BurstDR stimulation, 23.9% of subjects preferred Tonic stimulation, and 8.0% of subjects 
had no preference. At the same time, evidence suggests that pain relief with BurstDR SCS is 
not necessarily better than with Tonic-SCS, and different SCS-modalities might be preferred 
with different indications [131, 132]. Such contradictory findings suggest that Burst SCS still 
remains to be optimized and to this end more research into the underlying mechanisms is 
required.  Parameter variations within the Burst waveform, that would require specific 
deviations from the patented BurstDR-waveform, could potentially generate additional pain 
relief. A few studies have attempted to elucidate the mechanisms, and/or optimize the 
parameters, of Burst SCS. With respect to the mechanisms underlying BurstDR SCS potential 
immunomodulatory properties were investigated in a small cohort of CRPS-patients [133]. 
It was found that BurstDR SCS, but also Tonic SCS and HF SCS attenuates T-cell activation, 
improves peripheral tissue oxygenation and decreases anti-angiogenetic activity. The 
possible immunomodulatory effects of SCS could bring new therapeutic possibilities in 
diseases that involve the immune system, and deserves further research [133]. Havenbergh 
and colleagues investigated the effect of parameter changes on the analgesic efficacy of 
BurstDR SCS [134]. Fifteen patients who were being treated with Burst SCS for failed back 
surgery syndrome participated to verify whether their pain suppression could be further 
improved by changing the Burst pattern. Burst stimulation with packets of five electrical 
pulses delivered at 500 Hz with 1000-μsec pulse width 40 times per second (BurstDR) was 
compared to an alternate Burst mode delivering five spikes at 1000 Hz with 500-μsec pulse 
width 40 times a second. No statistically significant differences in pain relief were found 
between the two modes of Burst stimulation. The authors therefore concluded that 
increasing the frequency from 500 to 1000 Hz does not add any extra benefit in suppressing 
pain. Further studies should verify whether adjusting other parameters within the Burst 
design might have an (beneficial) effect on its efficacy. Currently, studies are being 
performed in which patients receive an alternate Burst mode which differs from BurstDR-
SCS in that charge-balancing is performed directly, during the intraburst period, in a so-
called active recharge manner. At this point in time, no clear consensus has been reached 
regarding the optimal Burst-paradigm, and no data from clinical or preclinical studies 
support the claim that either passive recharge Burst SCS (BurstDR) or active recharge Burst 
SCS is superior [123, 135]. Therefore, further research into, and exploration of, new and 
innovative Burst paradigms is required and might help pave the way towards better pain 
relief. 
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Figure 2. Anatomy of the Pain Pathways: Primary afferent nociceptors transmit noxious information 
to projection neurons in the dorsal horn of the spinal cord. A subset of these projection neurons 
transmits information via the lateral spinothalamic tract (depicted in green) via the thalamus to the 
somatosensory cortex, providing information about the location and intensity of the painful stimulus. 
Other projection neurons send nociceptive signals along the medial spinothalamic tract (depicted in 
blue), which runs via connections in the brainstem (parabrachial nucleus) to the cingulate and insular 
cortices, and the amygdala, contributing to the affective component of the pain experience. 
Meanwhile, ascending information also activates neurons of the rostral ventral medulla and midbrain 
periaqueductal gray, which results in descending feedback able to regulate nociceptive processing in 
the spinal cord. From Basbaum et al. (2009) with permission ([84]. 
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1.5.2 Burst Spinal Cord Stimulation: experimental 
A few experimental studies have aimed to investigate the mechanisms underlying the 
analgesic effects of Burst SCS in neuropathic pain. In a preclinical setting, it was shown that 
the presence of a GABAB-receptor antagonist CGP35348 blocked attenuation of dorsal horn 
neuronal firing during Tonic SCS (see section 1.3) but not Burst SCS. From this, the authors 
concluded that Burst SCS might not act via spinal GABAergic mechanisms [136]. However, 
it should be mentioned that the aforementioned study was performed not only in a most 
uncommon rat model for chronic neuropathic pain, the Painful Cervical Nerve Root 
Compression model, but these experiments were also terminal and thus no behavioral 
testing during the conscious state of the animals was performed [31]. This makes 
interpretation of these data in the context of understanding the role of spinal GABA in a 
chronic neuropathic pain model difficult, as most experimental data on pain relief and the 
spinal GABAergic mechanism underlying Tonic SCS have been documented and studied in 
the well-described and validated partial sciatic nerve ligation (PSNL) model or a similar 
nerve injury model for peripheral mononeuropathy. Therefore, the question remains if and 
how Burst SCS acts on GABAergic mechanisms at the spinal level when using a well-validated 
and widely used chronic neuropathic pain model that allows for comparison with past 
literature (demonstrating the role of spinal GABA release in the mechanism of Tonic SCS) 
[71, 74, 137]. In 1990, Seltzer and colleagues presented a behavioral model of causalgia in 
rats: the partial ligation of the sciatic nerve (PSNL). The PSNL-model was originally 
introduced as a behavioral model of CRPS (causalgia) (see section 1.2.2), though it was soon 
after acknowledged as an animal model for FBSS (see section 1.2.1). The model shows many 
of the symptoms that characterize neuropathic pain in humans, including rapid onset of 
allodynia to touch, hyperalgesia, spontaneous occurrence of pain, and mirror pain. The 
plantar surface of the animals’ paw is hyperesthetic to non-noxious and noxious stimuli, and 
the hyperestheticy is evenly distributed. These symptoms are characterized by a sharp 
decrease in the withdrawal thresholds in response to repetitive Von Frey hair stimulation 
at the plantar side. Light touch with innocuous stimuli elicit aversive responses, which 
suggests allodynia to touch, and suprathreshold noxious stimuli elicit an exaggerated 
response unilaterally, which suggests hyperalgesia [62]. Furthermore, Seltzer and 
colleagues saw that none of the animals showed signs of autotomy, which was a major 
improvement as compared to existing animal models for chronic NPP at that time  [2, 138, 
139]. Based on this, it was concluded that the PSNL-model was a valid model for syndromes 
of the causalgiform variety that are triggered by partial nerve injury and maintained by 
sympathetic activity. Since its introduction in 1990, the PSNL-model has become a 
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renowned and widely recognized animal model for CRPS and FBSS which is reflected by its 
use inside, and outside, the SCS-field [2, 71, 74, 77, 138, 140-143].  
Experimental electrophysiological studies indicate that Burst SCS can be optimized by 
adjusting stimulation parameters closely related to the energy delivered to the spinal cord, 
such as amplitude and pulse width, with reports that the energy delivered to the spinal cord 
was found to be correlated with a reduction of ‘wide dynamic range neuronal’ firing in the 
dorsal horn following noxious stimuli [126]. Other studies have shown that Burst-SCS and 
Tonic SCS have a different effect on the suppression of lumbosacral neural responses when 
applied with a high-intensity (90% MT) when compared with standard-intensity (60% MT) 
[125]. However, the aforementioned studies did not assess the behavioral effect of 
parameter variations on the pain relieving efficacy of Burst SCS. In general, on a behavioral 
level, the literature remains rather restricted, with only one study demonstrating that Burst-
SCS reduces hyperalgesia and restores physical activity levels more so than Tonic SCS in the 
spared nerve injury model[144]. Hence, a better understanding of the behavioral anti-
nociceptive effect of Burst SCS as compared to Tonic SCS in an experimental neuropathic 
pain model is needed. This is important in view of further optimization of the Burst-SCS 
paradigm and then also might have serious implications for its clinical use in the treatment 
of neuropathic pain. Furthermore, literature shows that behavioral analysis and thus 
assessment of the pain relieving effect is known to be the most important indicator of a 
treatment’s translational value [138]. Therefore, it is imperative that parameter variations 
are always assessed by means of behavioral testing before translation towards the clinical 
setting is considered. 
Testing of reflexes such as paw withdrawal testing is well established as the standard for 
evaluating nociceptive behavior and its modulation in preclinical animal studies [145]. 
Concerns about the extensive use of, and overreliance on, this approach have been 
dismissed for practical reasons: reflex-based testing requires no training of the animals, and 
the method is simple to instrument. Yet, many are frustrated with the lack of translational 
progress in the pain field, in which huge gains in basic science knowledge obtained using 
animal models have not led to the development of proportionate new clinically effective 
compounds [138]. It has been suggested that the use of operant testing methods, such as 
place preference  and escape testing, in addition to reflex-based assessment methods could 
aid translation to the clinic [145, 146]: comparison of studies that applied either reflex-
based testing or operant escape measures as assessment method for pain showed that 
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results of operant testing measures were more often consistent with clinical evidence [145]. 
Though, to this day, the majority of preclinical SCS studies still rely on reflex-based von Frey 
analysis, a technique unable to assess supraspinal aspects of pain [77, 141-144, 147-150].            
Meanwhile, the preclinical pain-field has ventured into the domain of operant testing. 
Learned escape from electric footshock in shuttle boxes for example is a very old technique 
[151], often used in studies of learning and memory, yet, also used to study pain itself. 
Conflicts between positive and negative reinforcement have long been exploited for 
operant testing methods, with modern versions featuring painful stimuli or positioning of 
inflamed or neuropathic body parts as the price for food or water [152-154]. 
Self‑administration of analgesic drugs has been used as an indirect measure of pain [155], 
and conditioned place preference (to an analgesic in the presence of pain159) or 
conditioned place aversion strategies have been applied to investigate pain behavior [156-
158]. Recently, an operant testing method was introduced which assesses cognitive and 
motivational aspects of pain in animals: the Mechanical Conflict-Avoidance System (MCAS) 
[159]. With the MCAS the animal is placed in a brightly lit compartment which leads to a 
passage with a height-adjustable array of nociceptive probes. The animal needs to cross the 
nociceptive probes to enter the innately preferred dark area. The “lesser of two evils 
principle” forces the animal to choose between two opposing motivational drives: to stay 
in the aversive, yet non-noxious, brightly lit compartment, or, to cross the noxious probes, 
which is rewarded by the innately preferred dark compartment. In order to resolve this 
conflict it is hypothesized that the animal applies a “cost-benefit” analysis including the level 
of ongoing pain, the height of the probes, and the averseness of the light (= negative 
reinforcement) [160]. In general, as ongoing pain intensity and/ or probe height increases, 
animals require more time to exit the light chamber. Latency to exit the light chamber 
(defined as time from light being turned on to having all four paws on the probe bed), as a 
behavioral representation of cognitive-motivational aspects of pain, has been shown to be 
a stimulus-dependent measure in the Coy-MCAS system. Chronic neuropathic pain, induced 
by chronic constriction of the sciatic nerve, has been shown to affect latency to exit the 
bright compartment in the MCAS [161]. However, other neuropathic pain models still 
remain to be validated in the MCAS-setup. The MCAS operant testing system could be an 
important step towards improved translation in the experimental pain field. Furthermore, 
with the introduction of SCS-paradigms able to modulate supraspinal properties, it is of 
great interest to the preclinical  SCS-field to assess whether the MCAS can shed light on the 
supraspinal mechanisms of Burst and Tonic SCS by addressing the cognitive-motivational 
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aspects of pain that are becoming increasingly important for the evaluation of novel SCS 
waveforms. 
In a recent review it was hypothesized that HF SCS (10 kHz) and Burst SCS might be 
fundamentally similar neurostimulation designs [162]. It was stated that clinical data, 
quantitative sensory testing, cellular investigations, and comparative animal and human 
studies all point in the same direction, namely that HF SCS and Burst SCS might both 
modulate the medial STT, and thus, have fundamentally similar working mechanisms. In line 
with this, a computer modeling study indicated that SCS frequency (at least partly) 
determines the firing of wide dynamic range (WDR) neurons projecting to the brain [163]. 
Analysis showed that SCS with frequencies above 100 Hz does not result in inhibition of 
WDR signaling; this strongly suggests that higher SCS frequencies, as applied with HF SCS 
and Burst SCS, induce pain relief via alternative mechanisms. In another study, it was 
reported that the orthodromic activation of Aβ-fibers in the dorsal columns might differ 
between Burst and Tonic SCS: Burst SCS was found not to increase spontaneous activity of 
gracile nucleus neurons in the brainstem, whereas Tonic SCS did [125], further supporting 
the notion that different mechanisms are recruited with different SCS-paradigms. 
Moreover, a behavioral  study reported a delayed wash-in of the analgesic effect of HF SCS 
(500 Hz), as compared with standard Tonic SCS (50 Hz), in animals with chronic painful 
diabetic polyneuropathy [150]. Building on the hypothesis that HF SCS and Burst SCS might 
be fundamentally similar neurostimulation designs, the delayed onset effect could reflect 
the activation of the ‘slower’ medial STT pathway. Investigating the onset effect of Burst 
SCS by assessment of its analgesic effect over time could shed more light on the 
aforementioned hypothesis. Interestingly, a potential difference in effect onset for Burst 
SCS and Tonic SCS would be in line with unpublished clinical anecdotes.  
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1.6 Aims and Research questions 
The primary aim of this academic thesis is to improve the analgesic efficacy of Burst SCS in 
an experimental neuropathic pain model, based on an improved understanding of the 
underlying mechanism.  
RESEARCH QUESTIONS (RQ) 
Based on the aim of this academic thesis, the following research questions are formulated: 
1. What is the effect of amplitude on the analgesic efficacy of Burst- and Tonic SCS in an 
experimental animal model of chronic neuropathic pain? 
 As clinical observations suggested a delayed wash-in effect of Burst SCS, and in order to 
further optimize the Burst SCS paradigm and understand the underlying mechanism, it 
is important to understand the pain relieving effect in detail, both in time and in 
magnitude as compared to Tonic SCS. Therefore, we formulated the following RQ: 
 
2. Does the anti-nociceptive effect over time differ for Burst SCS and Tonic SCS? 
 From a mechanistic point of view, and in light of the Gate Control Theory, it is important 
to elucidate the role of GABA in the modulation of the pain with Burst SCS in a well-
validated and widely used animal model of chronic neuropathic pain. Hence, we 
formulated the next RQ: 
 
3. Is GABA involved in the spinal pain relieving mechanism of Burst SCS? 
With the introduction of novel SCS-paradigms such a Burst SCS which are suggested to 
modulate supraspinal (brain) regions, it is of great interest to the preclinical SCS-field to 
analyze the role of supraspinal regions, and brain areas involved in the pain relieving 
effect of SCS. It is therefore that we formulated the following research questions: 
 
4. Is it possible to discriminate between Burst and Tonic SCS on cognitive-motivational 
aspects of pain relief, with use of MCAS operant testing? 
 
5. Which brain areas are involved in the pain relieving effect of Burst SCS, as compared 
to Tonic SCS, in an animal model of chronic neuropathic pain? 
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In order to acquire more insight into the relation between amplitude, a pivotal SCS 
parameter, and the therapeutic analgesic effect of Burst SCS, we studied behavioral effects 
of chronic neuropathic animals in response to various amplitudes of Burst SCS and Tonic 
SCS. This study will be addressed in Chapter 2 (see RQ 1). 
With RQ2 we investigated the effect of Burst SCS and Tonic SCS on mechanical 
hypersensitivity during stimulation (wash-in and maximum effect; 60 minutes), and 30 
minutes post stimulation (wash-out effect). The mechanisms responsible for the difference 
in delayed wash-in of the pain relieving effect observed for Burst SCS as compared to Tonic 
SCS is described in Chapter 3. 
Insight into the spinal GABAergic mechanisms of Burst SCS will be provided in Chapter 4 (see 
RQ3). By use of quantitative immunohistochemical analysis of intracellular GABA-levels in 
the dorsal spinal cord of chronic neuropathic rats, and intrathecal administration of 
pharmacological agents (phaclofen and baclofen) prior to stimulation, we were able to 
investigate the spinal GABAergic mechanisms responsible for the analgesic effect of Burst 
SCS and Tonic SCS. These experiments were performed in a well-established chronic 
neuropathic animal model, and are further described in Chapter 4. 
The behavioral effect of Burst SCS and Tonic SCS on cognitive-motivational aspects of pain 
were investigated in a recently developed operant testing-system known as the Mechanical 
Conflict Avoidance (MCAS) setup (RQ4). Use of Burst SCS or Tonic SCS in the MCAS-setup 
allowed us to study its effect on escape latencies; a behavioral measurement of cognitive-
motivational pain processing. This study will be addressed in Chapter 5. 
In order to investigate which brain areas are involved in the establishment of the pain 
relieving effect of Burst SCS, as compared to Tonic SCS (see RQ5), we used fMRI in order to 
assess the Blood-Oxygenation-Level Dependent (BOLD) levels in the brains of chronic 
neuropathic animals that received SCS in the scanner. The results are presented in Chapter 
6. 
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Abstract 
 
OBJECTIVE: Various spinal cord stimulation (SCS) modes are used in the treatment of 
chronic neuropathic pain disorders. Conventional (Con) and Burst-SCS are hypothesized to 
exert analgesic effects through different stimulation-induced mechanisms. Preclinical 
electrophysiological findings suggest that stimulation intensity is correlated with the 
effectiveness of Burst-SCS [1]. Therefore, we aimed to investigate the relation between 
amplitude (charge per second) and behavioral effects in a rat model of chronic neuropathic 
pain, for both Con-SCS and biphasic Burst-SCS. 
 
METHODS: Animals (n=12 rats) received a unilateral partial sciatic nerve ligation, after 
which they were implanted with quadripolar electrodes in the epidural space at thoracic 
level 13. Mechanical hypersensitivity was assessed using paw withdrawal thresholds (WTs) 
to von Frey monofilaments, at various SCS intensities (amplitudes) and multiple time points 
during 60 minutes of stimulation and 30 minutes post stimulation. 
 
RESULTS: Increasing amplitude was shown to improve the efficacy of Con-SCS, whereas the 
efficacy of Burst-SCS showed a non-monotonic relation with amplitude. Con-SCS at 66% MT 
(n=5) and Burst-SCS at 50% MT (n=6) were found to be equally effective in normalizing 
mechanical hypersensitivity. However, in the assessed time period Burst-SCS required 
significantly more mean charge per second to do so (p < 0.01). When applied at comparable 
mean charge per second, Con-SCS resulted in a superior behavioral outcome (p < 0.01), 
compared to Burst-SCS.                          
 
CONCLUSIONS: Biphasic Burst-SCS requires significantly more mean charge per second in 
order to achieve similar pain relief, as compared with Con-SCS, in an experimental model of 
chronic neuropathic pain. 
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Introduction 
 
Over the last four decades, spinal cord stimulation (SCS) has become a safe and effective 
therapeutic tool for the treatment of various neuropathic pain disorders that fail to respond 
to pharmacological intervention [2-4]. Conventional (Con-) SCS delivers tonic pulses of 
electrical stimulation to the dorsal columns of the spinal cord, typically using frequencies of 
40-60 Hz [5, 6] and pulse widths of 200–450 μSec [7, 8]. However, despite considerable 
improvements, the therapeutic effect of Con-SCS remains moderate, providing 
approximately 50% pain relief for 50% of patients [9, 10]. Consequently, in an effort to 
improve the efficacy of SCS, several alternative SCS-modes have been developed, including 
high frequency spinal cord stimulation (HF-SCS) (>500 Hz; most often 10 kHz) [11-13] and 
burst spinal cord stimulation (Burst-SCS) [14, 15]. Unlike Con-SCS, Burst-SCS and HF-SCS 
provide pain relief without eliciting paresthesia in the painful area. However, the 
mechanisms underlying the analgesic effects of the various SCS-modes continue to remain 
unclear. Preclinical studies suggest that Burst-SCS does not act via spinal GABAergic 
mechanisms in which Con-SCS acts, and might rely on different biochemical pathways [16]. 
Additional electrophysiological preclinical studies indicate that Burst-SCS can be optimized 
by adjusting stimulation parameters closely related to the energy delivered to the spinal 
cord, such as amplitude and pulse width, with reports that  the energy delivered to the 
spinal cord was found to be correlated with a reduction of ‘wide dynamic range neuronal’ 
firing in the dorsal horn following noxious stimuli [1]. Other studies have shown that Burst-
SCS and Con-SCS have a different effect on the suppression of lumbosacral neural responses 
when applied with a high-intensity (90% MT) when compared with standard-intensity (60% 
MT) [17]. To elucidate the relation between current delivery and the therapeutic effects of 
Burst-SCS, we studied the relation between amplitude and mean current delivered (charge 
per second), and the behavioral effect on mechanical hypersensitivity in a rat model of 
chronic neuropathic pain. 
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Methods 
 
Ethics Statement 
All experiments were performed in accordance with the European Directive for the 
Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes 
(86/609/EU). The protocol was approved by the Animal Research Committee of the 
Maastricht University Medical Centre (DEC-protocol 2014-086). 
 
Animals 
All experiments were performed using male Sprague Dawley rats (n=12), which were 
classified as young-adult (5 weeks of age) at the start of the experiment (150–200 g). 
Animals were housed in groups of 2 in filter-top polycarbonate cages situated within a 
climate-controlled vivarium (21 ± 1°C) with relative humidity (55±15%), artificial lighting 
(12:12 light/dark cycle). Distilled water and rodent food were available ad libitum. The 
vivarium was equipped with a mobile radio, continuously producing background music at 
45 decibel, in order to desensitize the animals for translocation and experimenter related 
noise. All procedures were conducted between 09:00 and 16:00 hours.  
 
 Neuropathic Pain model 
 A unilateral ligation of the left sciatic nerve was performed as described by Seltzer et al. 
1990 [18] according to the standard protocol used in our institution  [19, 20]. Animals were 
anesthetized with 3–5% isoflurane (Abbott Laboratories Ltd., Kent, U.K.) and air enriched 
with 100% oxygen at a constant flow rate of 250 ml/min. Body temperature was maintained 
at 37.5°C using an automatic heating pad. The sciatic nerve from the left hind paw was 
exposed by blunt dissection. Upon discovery the nerve was carefully freed from surrounding 
connective tissue and partially (approximately 1/3) ligated by an 8/0 non-absorbable silk 
suture with a reverse cutting micro needle. Post ligation, the wound was closed with a 4/0 
silk suture, and the development of tactile hypersensitivity (mechanical allodynia) was 
monitored over the following 14 days. The presence of mechanical hypersensitivity was 
confirmed at 14 days post-surgery, only if the log (50% withdrawal threshold (WT)) was 
decreased by 0.2 units compared to baseline (day 0) [21].   
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Assessment of mechanical hypersensitivity (von Frey assay)      
Mechanical hypersensitivity was assessed using von Frey filaments. Von Frey testing was 
always conducted in the same room, which was isolated from all external sound and light 
sources, maintained under controlled temperature (21 ± 1°C) and relative humidity 
(55±15%). Prior to testing, rats were placed in the behavioral set-up and were given 15 min. 
to acclimate to the new surroundings. The test-room was equipped with a mobile radio, 
continuously producing background music at 45 decibels. WT to von Frey filaments was 
assessed using the ‘up-down method’ [22] whereby von Frey filaments with approximately 
linearly incrementing stiffness on a logarithmic scale (bending forces 0.6, 1.2, 2.0, 3.6, 5.5, 
8.5, 15.1g and 28.84 g) were applied to the plantar surface of the hind paws of the rats for 
5 seconds. Following a negative response (the hind paw was not withdrawn), the next 
filament with greater bending force was applied, whereas a positive response (the hind paw 
was withdrawn) was followed with application of a previous filament with lower bending 
force. After completion of a sequence of six consecutive responses the 50% WT was 
calculated [22]. A predetermined cut-off value was set at 28.84 g. For statistical analysis the 
50% WTs were logarithmically transformed to yield a linear scale.  
 
Implantation of spinal cord stimulation device 
The implantation of the SCS device was performed according to the standard protocol used 
in our institution [20, 23-25], and is identical to the method originally developed at the 
Karolinska Institute [26]. In short, a small laminectomy was made at level Thoracic 13 
(Th13), after which the spinal cord was exposed by use of a surgical rotary tool. A custom-
made cylindrical 4-contact lead (0.72mm diameter; Boston Scientific Neuromodulation, 
Valencia, CA, USA) was inserted in the epidural space, in the caudal direction. Electrode 
configuration was set at alternating cathode and anode settings (rostral to caudal: + - + -). 
Subsequently, the electrode was secured to a spinous process with tissue adhesive 
(Histoacryl®, B Braun Medical BV, Oss, the Netherlands) to prevent electrode migration. The 
electrode wires were tunneled subcutaneously to the animal’s neck and the stimulator-
connectors were attached to the skin. After implantation of the electrodes, the rats were 
given 3 days for recovery prior to the initiation of SCS.  
 
Spinal cord stimulation 
For stimulation of the dorsal columns, an A-M systems stimulator (MultiStim: 
Programmable 8-Channel Stimulator (Model 3800) 220 V/50 Hz) fitted with an additional 
stimulus Isolator (Model 3820 for A-M Systems MultiStim). For all experiments, the 
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stimulator was set to deliver constant current biphasic stimulation for both the 
Conventional and Burst modes. Con-SCS motor threshold (MT) was determined at the 
following settings: pulse width of 200 µS and frequency of 2 Hz. Burst-SCS MT was 
determined using a pulse width of 1000 µS, where five pulses (449 Hz intraburst frequency) 
were administered at an inter-burst frequency of 2 Hz. The amplitude was gradually 
increased until symmetrical contractions of the lower trunk and/or hind limbs were visually 
observed or perceived by hand. Then, either a Con-SCS-modes (frequency 50 Hz, pulse 
width 200 µS) [20], or a Burst-SCS modes (inter-burst frequency 40 Hz, 5 pulses at 449 Hz 
intraburst, pulse width 1000 µS) (Fig.1), was applied for 60 minutes [20, 27]. In all 
experiments, the WT to von Frey filaments was assessed before the start of SCS treatment, 
at 15’, 30’, 45’ and 60’ min after stimulation was turned on, and at 30 min after stimulation 
was turned off (90 min after the start of SCS). Stimulation was applied for 60 minutes per 
day on three consecutive days. A different amplitude (66%, 50% or 33% MT) was used each 
day, and the order was randomized.  The investigator was blinded to the stimulation 
condition during behavioral testing. Furthermore, after the experiment, 3 animals of the 
Burst-group as well as 3 animals of the Con-SCS group were administered SCS at an 
amplitude in order to provide a comparable delivery of current (Coulomb per second). Mean 
current was calculated, as charge per second, by use of the following formula:  Imean = 
amplitude x pulse width x frequency.  
 
 
Fig.1: Constant current biphasic burst mode (µA): 1-ms biphasic spikes with a 1.1-ms spike interval 
(449-Hz spike mode) at 40 Hz (40-Hz burst mode). Stimulation delivered by the A-M systems 
stimulator (MultiStim: Programmable 8-Channel Stimulator (Model 3800). 
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Timeline of experiments 
After acclimatization to the vivarium, 12 animals underwent a partial sciatic nerve ligation 
(PSNL) (as described in section 2.3). During the subsequent 14-day observation period, 
animals received Von Frey measurements in order to assess the development of tactile 
hypersensitivity (see section 2.3). All 12 animals successfully developed tactile 
hypersensitivity and received implantation of an SCS-electrode at day post ligation (DPL) 14, 
as described in section 2.5. Animals for which the SCS-electrode was successfully implanted 
(n=11) were given two days to recover from the surgery before the Motor-Threshold (MT) 
was assessed at DPL17. All implanted animals showed a robust MT (n=11). At DPL18, 19, 20 
animals received SCS for 60 minutes (Fig.2). Mechanical hypersensitivity was assessed based 
on WT to von Frey filaments, at 15, 30, 45 and 60 minutes of stimulation, and 30 minutes 
post stimulation. 
 
 
Fig.2: Timeline of experiments. 
 
Data-analysis 
The WTs to von Frey filaments are presented as mean ± standard error of the mean (SEM). 
For statistical analysis von Frey data were logarithmically transformed to account for 
Weber’s Law [28]. For analysis of differences in the withdrawal thresholds over time, a one-
way repeated measures ANOVA was conducted and followed by a Dunnett’s multiple 
comparisons test. For the analysis of differences in the withdrawal thresholds between 
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groups within stimulation modes (Burst- or Con-SCS), a two-way repeated measures ANOVA 
was conducted and followed by Tukey’s multiple comparisons test for each individual time 
point. For the analysis of differences in the withdrawal thresholds between groups and 
stimulation modes a two-way ANOVA was applied, followed by Tukey’s multiple 
comparisons test. All statistical analyses were performed with α = 0.05 using IBM SPSS 
statistics 23.  
 
 
Results 
 
General observations 
No significant differences were observed between ipsilateral pre-SCS withdrawal thresholds 
(WTs) between amplitude groups, within modes of stimulation (Con-SCS groups: p = 0.7308; 
Burst-SCS groups: p = 0.5920) or between modes of stimulation (Con-SCS vs. Burst-SCS 
groups: p = 0.4227). The order of amplitudes (percentages of MT) had no significant effects 
on the Con-SCS group (p = 0.7770), the Burst-SCS group (p = 0.8423), or the Burst-SCS groups 
compared with Con-SCS groups (p = 0.2020). The average motor thresholds for Con-CS (120 
± 3.8 µA) and Burst-SCS (49 ± 2.7 µA) were statistically different (p < 0.007) (Fig.3). 
 
 
Fig.3: Motor threshold (MT) assessed by means of Conventional and Burst stimulation. Con-SCS MT 
was determined at the following settings: pulse width of 200 µS administered at a frequency of 2 Hz. 
Burst-SCS MT was determined at the following settings: pulse width of 1000 µS, five pulses (500 Hz 
intraburst frequency) administered at an interburst-frequency of 2 Hz. (* p < 0.05 for Con-MTs versus 
Burst-MTs). 
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Development of tactile hypersensitivity 
Pre-nerve injury (baseline) mean withdrawal threshold of the ipsilateral hind paws were 
comparable to the contralateral hind paws (ipsilateral 11.2 ± 0.3g vs contralateral 10.1 ± 
0.4g; p = 0.3777) in all animals (Fig. 4). Fourteen days after the partial ligation of the sciatic 
nerve, the mean withdrawal threshold of the ipsilateral paw (1.4 ± 0.02g) was significantly 
lower than baseline (p < 0.001). All 12 animals qualified as hypersensitive to mechanical 
stimulation by von Frey filaments (see Methods section 2.3) and were therefore included 
for further analysis (Fig.2+4). No significant effect of the ipsilateral ligation on 
contralateral paw withdrawal thresholds could be detected (10.1 ± 0.4g pre-surgery vs 
12.5 ±0.5g post-surgery; p = 0.1963). The implantation of the SCS electrode at DPL14 did 
not affect the withdrawal thresholds of the ipsilateral hind paws (DPL14; 1.4 ± 0.02g vs 
DPL17; 1.3 ± 0.05g; p = 0.4227). 
 
 
Fig.4: Development of tactile hypersensitivity, based on paw withdrawal threshold s (WTs) based on 
sensitivity to von Frey filaments, after unilateral sciatic nerve ligation in adult rat (n=12). (* p < 0.05 
for ipsilateral versus contralateral WT’s). 
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Within modes of stimulation 
Stimulation was delivered at 66%, 50% and 33% of MT for the Con-SCS group (n = 5) and 
Burst-SCS group (n = 6). In order to assess differences in the withdrawal thresholds over 
time a one-way repeated measures ANOVA was applied for each individual amplitude group 
within one SCS mode (Conventional or Burst SCS). After 15 minutes of SCS in the Con-SCS 
groups, only the 66% MT group significantly differed from baseline (2.0 ± 0.3g vs 8.4 ± 1.5g; 
p = 0.0031) (Fig.5A). Thirty minutes of SCS significantly increased WTs compared to baseline 
for both the 66% MT and 50% MT groups (50% MT; 1.8 ± 0.3g vs 7.2 ± 1.2g; p = 0.002 , 66% 
MT; 2.0 ± 0.3g vs 11.4 ± 0g; p = 0.0013), and both groups remained significantly different 
(from baseline) until 60 min of SCS (see Table 1). This was corroborated by a significant main 
effect of time for Con-SCS applied at 50% MT (p = 0.0003), and 66% MT (p < 0.0001). Post 
SCS, 30 minutes after the stimulator was turned off, only the 66% MT group was still 
significantly different from baseline (2.0 ± 0.3g vs 6.0 ± 0.6g; p = 0.008). The 33% MT group 
did not demonstrate an overall analgesic effect and was only significantly different from 
baseline at 45 minutes of SCS (1.6 ± 0.2g vs 2.9 ± 0.2g; p = 0.0125). This was consistent with 
absence of a (significant) main effect of time for Con-SCS applied at 33% of the MT (p = 
0.1025) (Fig.5A). 
 
After 15 minutes of SCS in the Burst-SCS groups, none of the groups significantly differed 
from baseline. In contrast, all three groups significantly differed from baseline after 30 
minutes of SCS (33% MT; 1.5 ± 0.2g vs 5.0 ± 0.6g; p = 0.0056, 50% MT; 1.4 ± 0.2g vs 10.1 ± 
0.9g; p = 0.0001, 66% MT;1.2 ±  0.2g vs 6.3 ± 0.7g; p = 0.0025), and remained significantly 
different (from baseline) until 60 min of SCS (see Table 1). This was in line with significant 
main effect of time for Burst-SCS applied at 33%MT (p < 0.0001), 50% MT (p < 0.0001), and 
66% MT (p < 0.0001). (Fig.5B). Post SCS, 30 minutes after the stimulator was turned off, 
both the 66% MT and 50% MT group were still significantly different from baseline (50% 
MT;1.4 ± 0.2g vs 3.1 ± 0.4g; p = 0.0074, 66% MT; 1.2 ± 0.2g vs 2.4 ± 0.3g; p = 0.0121).  
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Fig 5. (A+B): The effect of Con-SCS (n=5) and Burst-SCS (n=6) on the WTs based on sensitivity to von 
Frey filaments. WTs were assessed at 15, 30, 45, and 60 mins. of stimulation and 30 mins. post 
stimulation. The dotted line represents the average WT baseline prior to sciatic nerve ligation. (* p < 
0.05 for 66% MT time points compared to pre-SCS baseline WTs, # p < 0.05 for 50% MT time points 
compared to pre-SCS baseline WTs, ^ p < 0.05 for 33% MT time points compared to pre-SCS baseline 
WTs). 
 
Maximum effect of stimulation modes 
Con-SCS at 66% MT amplitude stimulation resulted in the most optimal behavioral outcome 
for Con-SCS, significantly increasing ipsilateral WTs from 2.0 ± 0.3g (pre-SCS baseline 
withdrawal thresholds) to 14.1 ± 2.6g after 45 minutes of SCS (p = 0.0024).  WTs of 66% MT 
Con-SCS after 45 minutes also significantly differed from the WTs of Con-SCS at 50% and 
33% MT after 45 minutes of SCS (two-way repeated measures ANOVA, followed by Tukey’s 
multiple comparisons test: 66% vs 50%; p = 0.0015, 66% vs 33%; p < 0.0001) (Fig.5A). Burst-
SCS at 50% MT resulted in the most optimal behavioral outcome for Burst-SCS, significantly 
increasing ipsilateral WTs from 1.4± 0.2g (pre-SCS baseline withdrawal threshold) to 14.8 ± 
2.6g after 60 minutes of SCS (p = 0.0013), reaching pre-surgery WTs.  WTs of 50% MT Burst-
SCS after 60 minutes was also significantly different from the WTs of Burst-SCS at 66% and 
33% MT after 60 minutes of SCS (two-way repeated measures ANOVA, followed by Tukey’s 
multiple comparisons test:50% vs 66%; p < 0.0123, 50% vs 33%; p < 0.0001) (Fig. 5B). 
Interestingly, Burst- SCS at 50% MT after 60 minutes was not significantly different from 
Con-SCS at 66% MT after 45 minutes of SCS (Burst 14.8 ± 2.6g vs Con 14.1 ± 2.6g; p = 0,9744), 
which indicates that Burst-SCS and Con-SCS are equally effective in normalizing mechanical 
hypersensitivity.  
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Fig. 6A: The effect of Con-SCS and Burst-SCS on WTs, at comparable charge per second (Con: 1200 
mC/s; Burst: 1600 mC/s), (n = 3 per group). WTs were assessed at 30, and 60 mins. of stimulation and 
30 mins. post stimulation. (*p < 0.05 for Con-SCS WTs versus Burst-SCS WTs per time point, **p < 0.01 
for Con-SCS WTs versus Burst-SCS WTs per time point). B: Area under the curve (AUC) for WTs of Con-
SCS and Burst-SCS, at comparable mean charge per second (Con: 1200 mC/s, Burst: 1600 mC/s), (n = 
3 per group).  
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Between modes of stimulation 
WTs of the Conventional 66% MT group significantly differed from the Burst 66% MT group 
(p < 0.001). Tukey’s multiple comparisons test for specific time points shows that the 
Conventional 66% MT group and Burst 66% MT group significantly differ after 15 minutes 
of SCS (8.4 ± 1.5g vs 2.4 ± 0.2g; p < 0.0001), after 30 minutes of SCS (11.4 ± 0g vs 6.3 ± 0.7g; 
p= 0.0397), and 30 minutes post SCS (6.0 ± 0.6g vs 2.4 ± 0.2g  p= 0.0003).  Overall the WTs 
of the Conventional 50% MT group did not significantly differ from the Burst 50% MT group 
(p = 0.2893). WTs of the Conventional 33% MT group significantly differed overall from the 
Burst 33% MT group (p < 0.001). Tukey’s multiple comparisons test for specific time points 
shows that the Conventional 33% MT group and Burst 33% MT group significantly differed 
after 30 minutes of SCS (2.4 ± 0.7g vs 4.9 ± 0.6g; p= 271 0.0028), and after 45 minutes of 
SCS (2.9 ± 0.2g vs 6.2 ± 0.5g; p= 0.0082). The most optimal amplitudes for both modes, 
Conventional 66% MT and Burst 50% MT group did not significantly differ overall (p = 
0.1203). However, Tukey’s multiple comparisons test for specific time points showed that 
WTs of the Conventional 66% MT group significantly differed from the Burst 50% MT group 
after 15 minutes of stimulation (8.4 ± 1.5g vs 3.2 ± 0.6g; p < 0.0002), and 30 minutes post 
stimulation (6.0 ± 0.6g vs 3.0 ± 0.4g; p < 0.0277). This suggests a slower wash-in of the 
analgesic effect for Burst-SCS. Interestingly, when Burst-SCS (n=3) and Con-SCS (n=3) were 
applied at comparable charge per second (Con-SCS:1200 mC/s, Burst-SCS: 1600 mC/s), Con-
SCS resulted in a superior behavioral outcome (30 minutes: Con-SCS:14.9 ± 5.5g vs Burst-
SCS: 3.1 ± 0.7g; p < 0.01, 60 minutes: Con-SCS:13.0 ± 3.0g vs Burst-SCS: 3.4 ± 0.5g; p < 0.05) 
(Fig. 6A).   
 
Mean current was calculated, as charge per second, by use of the following formula:  Imean 
= amplitude x pulse width x frequency. Mean charge per second for Con-SCS was 
significantly lower as compared with Burst-SCS for 33% MT (p < 0.01) , 50% MT  (p < 0.01), 
and 66% MT (p < 0.01) (Fig. 7).   
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Fig. 7: The mean charge per second delivered to the spinal cord, in milliCoulomb, calculated per 
percentage of motor threshold for Con-SCS and Burst-SCS. (*p < 0.05 for mean charge per second for 
Con-SCS vs. Burst-SCS). 
 
 
Fig.8: Area under the curve for the withdrawal thresholds per amplitude for Con-CS and Burst-SCS.  
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Table1: Significance values of within stimulation mode analysis. 
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Discussion 
 
In the present study, it was demonstrated that Burst-SCS requires significantly more charge 
per second in order to achieve similar pain relief compared to Con-SCS in an experimental 
model of chronic neuropathic pain. Increasing amplitude with Con-SCS improved its 
efficacy, whereas the efficacy of Burst-SCS showed a non-monotonic relation with 
amplitude (Fig.8). Interestingly, Con-SCS at 66% MT and Burst-SCS at 50% MT were found 
to be equally effective in normalizing mechanical hypersensitivity. However, Burst-SCS 
required greater mean charge per second in order to achieve pain relief (Fig.7). Moreover, 
when Burst-SCS and Con-SCS were applied at a comparable mean charge per second Con-
SCS had a superior behavioral outcome. The amplitudes required to obtain motor 
thresholds were found to be significantly different, with Burst-SCS requiring significantly 
less amplitude in order to induce motor responses (Fig.3). The difference between Con-SCS 
and Burst-SCS motor thresholds, and possibly the difference in the effect of these 
waveforms on withdrawal thresholds, can be partially explained by their distinctive effects 
on affected neural structures.  In particular, we note that the pulse width (PW) of the 
clinically-based Burst-SCS waveform (1000 µS) is substantially higher than that of the 
clinically-based Con-SCS waveform (200 μs pulse width).  According to classical strength-
duration relationships, active neurites will exhibit lower activation thresholds in response 
to waveforms with longer pulse widths [29, 30]. As motor responses evoked by electrical 
stimulation are more likely due to neural activation than to direct muscular stimulation, the 
observation that MT was lower with longer PW Burst-SCS vs. shorter PW Con-SCS is 
expected and is consistent with findings from prior studies [17]. The importance of pulse 
width for the efficacy of the burst waveform was also highlighted by a recent study of Crosby 
and colleagues who demonstrated that  burst parameters closely associated with charge 
delivery (pulse width, pulse number, and amplitude) were correlated with the suppression 
of neuronal firing of wide dynamic range neurons in the dorsal horn, whereas parameters 
indirectly associated with charge delivery (pulse frequency, burst frequency) did not 
correlate with the suppression of neuronal firing in the dorsal horn [1]. Our findings further 
demonstrate that Burst- and Con-SCS exhibit an essentially different behavioral pattern of 
pain relief, in relation to amplitude (at 66%, 50% and 33% MT). For Con-SCS the amplitude 
is positively correlated with the behavioral outcome, as an increase in amplitude is 
accompanied by an increase in pain relief. Contrarily, Burst-SCS amplitude does not appear 
to have a positive correlation with the behavioral outcome, as 66% MT, the highest applied 
amplitude, did not produce optimal pain relief which implies a non-monotonic relation with 
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amplitude. To explain this phenomenon, we first note, that the duty cycle—defined as the 
product of the number of stimuli with the pulse width of each stimuli divided by the total 
inter-burst interval—of Burst-SCS (20 %) is substantially greater than that of Con-SCS (1 %).  
Recently, it was hypothesized that the different outcomes of various SCS modes might be 
related to the active stimulation period; the balance between the ON and OFF period, i.e., 
Duty Cycle [31]. It is proposed that SCS could have a soothing effect on the (aberrant) dorsal 
horn electrical fields, potentially diminishing the (aberrant) activity of neurons that 
pathologically remain in a hyperactive state. [31, 32]. In line with this hypothesis, an SCS 
mode with a larger duty cycle like Burst-SCS will be more likely to have a substantial impact 
on dorsal horn electrical fields. The increased duty cycle and the high intraburst frequency 
of the Burst-SCS waveform act to lengthen the effective PW of the Burst-SCS waveform and 
preclude traditional strength-duration and charge-duration relationships from defining the 
relationship between single pulse parameters and neural activation thresholds [30]. Most 
importantly, stimulation using waveforms with longer effective pulse widths such as that 
used for Burst-SCS will polarize dendrites and axon terminals to a greater extent, and if 
stimulation is of sufficient amplitude to be supra-threshold, long effective PW waveforms 
may produce multiple action potentials [33]. As well, neurite polarization can alter synaptic 
transmission in a manner dependent on the strength of the applied stimulus [34]. With 
these observations in mind, we postulate that the differences in neuron polarization or 
activation by Burst-SCS applied at 66 % MT vs. 50 % may have contributed to the difference 
in the behavioral response of the animals to different amplitudes of Burst-SCS. However, 
further research is warranted to confirm ‘the polarization hypothesis’, as direct recordings 
of neuron activity were not performed in this study and it is unclear if the neural elements 
closest to the stimulation electrode—the dorsal columns—are actually activated or 
polarized by Burst-SCS [17, 35]. Along these lines, the range of amplitudes for Burst-SCS in 
order to achieve an optimal behavioral effect (therapeutic window) appeared to be 
relatively narrow given that the behavioral outcome was shown to decline rather rapidly 
once 50% MT (optimal Burst MT) is surpassed. This is consistent with Courtney and 
colleagues’ finding that the therapeutic range of Burst-SCS is considerably smaller 
(perception amplitude 0.3mA, max tolerable amplitude 2.5mA) compared to Con-SCS 
(perception amplitude 4.2mA, max tolerable amplitude 8.9mA) [36]. However, we cannot 
exclude the assumption that a gradual decrease of the behavioral outcome is enclosed 
within the two highest amplitudes applied with Burst-SCS. It is further interesting that for 
Burst-SCS the analgesic effects of the two less optimal amplitudes (66% and 33% MT) are 
relatively close when compared with the less optimal amplitudes of Con-SCS (50% and 33% 
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MT). In addition, 33% MT Burst stimulation is able to significantly increase WTs compared 
to baseline WTs, whereas 33% MT Conventional stimulation does not. Thus, Burst-SCS is 
effective at smaller amplitudes, yet the overall charge per second necessary to obtain a 
therapeutic effect is significantly higher when compared to Con-SCS. Remarkably, the large 
quantities of charge delivered with Burst-SCS do not result in a superior behavioral 
outcome, compared with Con-SCS (the maximum WT of the optimal Burst amplitude (50%) 
and Conventional amplitude (66%) did not significantly differ). This is in line with recent 
clinical findings from which it was concluded that stimulation with Con-SCS and Burst-SCS 
are equally effective in relieving neuropathic pain related to complex regional pain 
syndrome  [37]. Furthermore, a recent systematic review concluded that the evidence for 
Burst-SCS in treating chronic intractable pain is considered fair and limited, AAN 
recommendation level U, with no sufficient evidence to recommend against or for Burst-
SCS for chronic pain reduction without paresthesia [38]. On the other hand, a 2-center 
comparative study on Con- versus Burst-SCS demonstrated that Burst-SCS could rescue an 
important amount of non-responders to conventional stimulation and could further 
improve pain suppression in responders to Con-SCS [14]. A possible explanation for the 
opposing findings was brought forward by De Ridder and Vanneste (2016), who stated that 
the current AAN guidelines used to assess (new) neuromodulation therapies might be an 
outdated methodology, and therefore the cause of negative reviews for new stimulation 
designs [39]. It is therefore reasonable to assume that both Con- and Burst-SCS modes are 
able to induce significant pain relief; despite there being significant differences in charge 
per second necessary for similar pain relief (Fig.7). Hence, the large pulse duration in 
combination with the higher pulse frequency as is required in Burst-SCS, will result in an 
increased energy consumption and accelerated battery depletion [38]. The significant 
difference in charge delivery (milliCoulomb per second) between Burst-SCS and Con-SCS 
seems to suggest that the amount of charge delivered to the spinal cord with SCS might not 
be the most important factor in pain relief. This is in line with our findings which 
demonstrate that when Burst-SCS and Con-SCS are applied at a comparable quantity 
(charge per second), Con-SCS results in a superior behavioral outcome. Recent clinical 
source-localized electroencephalography (EEG) data analysis suggested that burst 
stimulation normalizes the pain supporting/suppressing balance in contrast to tonic mode 
by a greater effect on the  dorsal anterior cingulate cortex [35]. This is in line with previous 
EEG-analysis showing a more-selective modulation of the medial pain pathways by burst 
stimulation [40]. It was proposed that this activation normalizes a potential imbalance 
between ascending pain signals via the medial system and descending pain inhibitory 
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activity, thereby producing superior results in comparison with conventional stimulation. 
This was furthermore corroborated by significant differences on the pain vigilance and 
awareness questionnaire following burst stimulation, which was found to improve the 
attention to pain and changes in pain throughout the day [40]. In this study we did not 
observe superior results of Burst-SCS, in comparison with Con-SCS. However, Von Frey 
analysis as applied in our study is a reflex-based analysis, which primarily assesses pain 
stimuli processed on a segmental/spinal level [41-43]. Therefore, it is likely that such a 
difference between Burst and Con-SCS is observed with the use of operant testing methods, 
addressing cognitive and motivational processing, possibly uncovering a rodent-like 
equivalent of pain vigilance [41, 44].  However, it should be noted that the investigation of 
supraspinal pathway systems remains a research question on its own. Moreover, it is 
important that unambiguous parameters, such as amplitude, are assessed by means of a 
straightforward assessment method such as Von Frey measurement.  
 
 
Conclusion 
 
Altogether, our findings suggest that a more complex relationship defines the interplay 
between the parameters of SCS, the charge delivered to the spinal cord, and the 
therapeutic efficacy of SCS. Therefore, it is imperative that further insight is acquired into 
the relationship between the analgesic efficacy of Burst-SCS and its parameters (number 
of pulses per burst, the intraburst-interval, and the possible influence of periodicity of 
intraburst-interval) [45].  
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Abstract  
 
OBJECTIVE: Two well-known spinal cord stimulation (SCS) paradigms, Conventional (Con) 
and Burst-SCS, are hypothesized to exert their anti-nociceptive effects through different 
stimulation-induced mechanisms. We studied the course of the behavioral anti-nociceptive 
effect during 60 minutes of SCS and 30 minutes post SCS, in a rat model of chronic 
neuropathic pain. 
MATERIAL AND METHODS:  Animals received a unilateral partial sciatic nerve ligation, after 
which they were implanted with quadripolar electrodes into the epidural space at vertebral 
level T13 (n=43 rats). While receiving either Con-SCS or biphasic Burst-SCS, pain behavior of 
the rats was assessed by means of Paw Withdrawal Thresholds (WT) in response to the 
application of Von Frey monofilaments. 
RESULTS: After 15 minutes of Con-SCS (n=21), WT’s significantly differed from baseline (p = 
0.04), whereas WT’s of the Burst-SCS (n=22) group did not. After 30 minutes of SCS, WT’s 
of the Con-SCS and Burst SCS group reached similar levels, both significantly different from 
baseline, indicating a comparable anti-nociceptive effect for these SCS-paradigms. Yet, the 
WT’s of the Burst-SCS group were still significantly increased compared with baseline at 30 
minutes post stimulation, whereas the WT’s of the Con-SCS group did not. 
CONCLUSIONS: To conclude, biphasic Burst-SCS results in a delayed anti-nociceptive effect 
after onset of the stimulation, as compared with Con-SCS, in a chronic neuropathic pain 
model. Furthermore, biphasic Burst-SCS seems to exhibit a delayed wash-out of analgesia 
after stimulation is turned off. 
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Introduction 
 
Over the last four decades, spinal cord stimulation (SCS) has become a safe and effective 
therapeutic tool for the treatment of various chronic pain conditions [1-3]. Conventional 
(Con), or tonic, SCS has proven to be effective for the management of various selected 
chronic neuropathic pain conditions, often refractory to pharmacological tools, like Failed 
Back Surgery Syndrome and Complex Regional Pain Syndrome [2-5]. Con-SCS administers 
continuous pulses of electrical stimulation to the dorsal columns of the spinal cord with 
frequencies within the range of 40-60 Hz [6, 7]. The SCS effect emerges from electrodes 
implanted in the epidural space between the spinal cord and the vertebral column. Despite 
the positive outcome, the reported success rate of Con-SCS in clinical studies has improved 
little over the last decade and therefore remains suboptimal, with roughly 50% pain relief 
for 50% of the patients [4, 8]. In an effort to improve the efficacy of SCS several alternative 
stimulation paradigms have been developed. One such example is Burst-SCS; a paradigm 
which uses periodic bursts of pulses rather than the continuous pulses as used in Con-SCS 
[9, 10]. Clinical studies, including placebo controlled studies, have suggested that Burst-SCS 
decreases pain intensity to a greater degree than Con-SCS [9, 11]. However, recent evidence 
shows that pain relief with Burst-SCS is not necessarily better than Con-SCS, and different 
patients might have a preference for different SCS-modalities [12, 13]. It thus seems that 
Burst-SCS remains to be optimized, and to that end fundamental research is required. 
Preclinical studies have already provided insights into the working mechanisms of Burst-SCS 
by investigating its electrophysiological effects in the spinal cord [14] and describing the 
associated neurochemical mechanisms [15]. Yet, on a behavioral level the literature 
remains rather restricted, with one study demonstrating that Burst-SCS reduces 
hyperalgesia and restores physical activity levels more so than Con-SCS, and one study 
which assesses the effect of various amplitudes on mechanical hypersensitivity for Burst- 
and Con-SCS  [16, 17]. Therefore, a better understanding of the behavioral anti-nociceptive 
effect of Burst-SCS as compared to Con-SCS in an experimental neuropathic pain model is 
needed. This is important in view of further optimization of the Burst-SCS paradigm and 
might have serious implications for its clinical use in the treatment of neuropathic pain. 
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Materials and Methods 
 
Ethics Statement 
All experiments were performed in accordance with the European Directive for the 
Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes 
(86/609/EU). The protocol was approved by the Animal Research Committee of the 
Maastricht University Medical Centre (DEC-protocol 2014-086). 
 
Animals 
All experiments were performed using male Sprague Dawley rats (n=52, which were young-
adult (5 weeks of age) at the start of the experiment (150–200 g). Animals were housed in 
groups of 2, in filter-top polycarbonate cages in a climate-controlled vivarium maintained 
under controlled temperature (21 ± 1°C), relative humidity (55±15%) and artificial lighting 
(12:12 light/dark cycle) with distilled water and rodent food available ad libitum. The 
vivarium was equipped with a mobile radio, continuously producing background music at 
45 decibel, in order to desensitize the animals for translocation and experimenter related 
noise. All procedures were conducted between 09:00 and 16:00 hours.  
 
Partial Sciatic Nerve Ligation (PSNL) 
A unilateral ligation of the left sciatic nerve was performed as described by Seltzer et al. 
1990 [18], and previously applied in our laboratory  [19, 20]. In short, animals were 
anesthetized with 3–5% isoflurane (Abbott Laboratories Ltd., Kent, U.K.) and air enriched 
with 100% oxygen at a constant flow rate of 250 ml/min. Body temperature was maintained 
at 37.5°C using an automatic heating pad. The sciatic nerve from the left hind paw was 
exposed by blunt dissection. Upon discovery the nerve was carefully freed from surrounding 
connective tissue and partially (approximately 1/3) ligated by an 8/0 non-absorbable silk 
suture with a reverse cutting micro needle. Post ligation, the wound was closed with a 4/0 
silk suture, and the development of tactile hypersensitivity (mechanical allodynia) was 
monitored over the following 14 days. The presence of mechanical hypersensitivity was 
confirmed at 14 days post-100 surgery, only if the log (50% withdrawal threshold (WT)) was 
decreased by 0.2 units compared to 101 baseline (day 0) [21].   
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Assessment of mechanical hypersensitivity (von Frey assay)      
Mechanical hypersensitivity was assessed using von Frey filaments, as described in Van 
Beek et al. [22]. Von Frey testing was always conducted in the same room, which was 
isolated from all external sound and light sources, maintained under controlled 
temperature (21 ± 1°C) and relative humidity (55±15%). The test-room was equipped with 
a mobile radio, continuously producing background music at 45 decibels. WT to von Frey 
filaments was assessed using the ‘up-down method’ [23] whereby von Frey filaments with 
approximately linearly incrementing stiffness on a logarithmic scale were applied to the 
plantar surface of the hind paws of the rats for 5 seconds. For statistical analysis the 50% 
WTs were logarithmically transformed to yield a linear scale.  
 
Implantation of spinal cord stimulation device 
The implantation of the SCS device was performed according to the standard protocol used 
in our institution [20, 24, 25], which was based on the method originally developed at the 
Karolinska Institute [26]. In short, the spinal cord was exposed by a midline, lumbar incision, 
after topical administration of 0.5% lidocaine (Xylocain, 50mg/g, AstraZeneca) followed by 
laminectomy at level T13. During the full procedure, the dura was kept intact. A custom-
made cylindrical 4-contact lead (0.72mm diameter; Boston Scientific Neuromodulation, 
Valencia, CA, USA) was introduced into the epidural space. The electrode was put caudally 
below the adjacent 1 or 2 lamina. Electrode configuration was set at alternating cathode 
and anode settings (rostral to caudal: + - + -). Subsequently, the electrode was secured to a 
spinous process with tissue adhesive (Histoacryl®, B Braun Medical BV, Oss, the 
Netherlands) to prevent electrode migration. The electrode wires were tunneled 
subcutaneously to the animal’s neck and the stimulator-connectors were attached to the 
skin. After implantation of the electrodes, the rats were given 2 days for recovery prior to 
the initiation of SCS. 
 
Spinal cord stimulation 
For stimulation of the dorsal columns an A-M systems stimulator (MultiStim: Programmable 
8-Channel Stimulator (Model 3800) 220 V/50 Hz) fitted with a stimulus Isolator (Model 3820 
for A-M Systems MultiStim) was used. For all experiments, the stimulator was set to deliver 
constant current biphasic stimulation for both the Conventional and Burst modes. Con-SCS 
Motor Threshold (MT) was determined at the following settings: pulse width of 200µS 
administered at a frequency of 2 Hz. Burst-SCS MT was determined at the following settings: 
pulse width of 1000µS, five pulses (449 Hz intra-burst frequency) administered at an 
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interburstfrequency of 2 Hz. The amplitude was gradually increased until symmetrical 
contractions of the lower trunk and/or hind limbs were visually observed or perceived by 
hand. Then, either a Con-SCS paradigm (frequency 50 Hz, pulse width 200 µS) [20], or a 
biphasic Burst-SCS paradigm (interburst-frequency 40 Hz, pulse width 1000 µS, 5 spikes at 
449 Hz intra-burst frequency), was applied at 66% MT for 60 minutes [10, 17] (Fig.1). In 
contrast to literature of de Ridder et al., who applies monophasic BurstDR-stimulation, we 
applied biphasic Burst-stimulation [9-11, 27]. In all experiments, the WT to von Frey 
filaments was assessed before the start of SCS treatment, at 15’, 30’, 60’ min. after 
stimulation was turned on, and at 30 min. after stimulation was turned off (90 min, after 
the start of SCS).  The investigator was blinded to the stimulation condition during 
behavioral testing. 
 
 
Fig.1: Constant current burst mode (µA): 1-ms biphasic spikes with a 1.1-ms spike interval (449-Hz 
spike mode) at 40 Hz (40-Hz burst mode). Stimulation delivered by the A-M systems stimulator 
(MultiStim: Programmable 8-Channel Stimulator (Model 3800). © 2018 Wiley & Sons, Inc. all rights 
reserved. 
 
Timeline of experiments 
After acclimatization to the vivarium, 52 animals underwent a partial sciatic nerve ligation 
(PSNL) (as described in section 2.3). During the subsequent 14 day observation period, 
animals received Von Frey measurements in order to assess the development of tactile 
hypersensitivity (see section 2.3 and Fig.2). Animals that had not developed tactile 
hypersensitivity at day 14 post ligation (DPL14) were excluded from the study and did not 
receive implantation of the SCS electrode. The 46 animals which had successfully developed 
tactile hypersensitivity received implantation of an SCS-electrode at DPL14, as described in 
section 2.5. Animals for which the SCS-electrode was successfully implanted (n=45) were 
given two days to recover from the surgery before the Motor-Threshold (MT) was assessed 
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at DPL17.  Prior to MT-assessment, animals were connected to the stimulator as if to receive 
stimulation. Animals with a MT deviating more than two standard deviations from the mean 
and/or animals with a MT which deviated more than 500 µA over the MT-assessment days 
were excluded from the study. Animals which did not show a robust MT, were excluded 
from the study and did not receive SCS (two animals did not show a robust MT). The 
remaining animals that showed a robust MT (n=43), at DPL17, were randomly divided over 
the Con-SCS or Burst-SCS group. Mechanical hypersensitivity was assessed, by Von Frey WT 
assessment, at 15, 30, 40 and 60 stimulation of sham-stimulation (amplitude was set at 0), 
and 90 minutes post sham-stimulation. At DPL18 animals received SCS for 60 minutes. 
Mechanical hypersensitivity was assessed based on WT to von Frey filaments, at 15, 30, 40 
and 60 of stimulation, and 90 minutes post stimulation. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Timeline of experiments 
 
 
Data Analysis 
The WT’s to von Frey filaments are presented as mean ± standard error of the mean (SEM). 
For statistical analysis von Frey data were logarithmically transformed to obtain a linear 
scale and to account for Weber’s Law [28]. For statistical analysis of differences in the 
withdrawal thresholds over time within groups, the non-parametric Friedman test was used 
followed by followed by Dunn’s post hoc test. For the analysis of differences in the 
withdrawal thresholds between groups, ipsilateral and contralateral withdrawal thresholds, 
the nonparametric Mann–Whitney-U-test was used.  All statistical analyses were performed 
with α = 0.05 using IBM SPSS statistics 23.  
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Results 
 
Development of tactile hypersensitivity  
Pre-nerve injury, WT’s of the ipsilateral hind paws were comparable with the WT’s of the 
contralateral hind paws (ipsilateral 12.4 ± 0.8g vs. contralateral 12.3 ± 1g) in all animals. 
Out of a total of 52 animals that received a unilateral partial ligation of the sciatic nerve, 6 
animals did not develop tactile hypersensitivity, and were excluded from the study. The 
remaining 46 animals qualified as hypersensitive to mechanical stimulation by von Frey 
filaments (p < 0.01; ipsilateral average WT’s: 12.4 ± 0.8g (pre-lesion) to 1.2 ± 0.4g (DPL14)) 
(see Methods section 2.3 and Fig.3) and were selected for the implantation of the SCS 
electrodes study. Of the 46 animals which received an SCS-electrode, 43 were found 
eligible for the SCS-experiments (Fig. 2). The ipsilateral ligation had no significant effect on 
the withdrawal thresholds of the contralateral WT’s (p = 0.42; pre-surgery 12.3 ± 1g (n=43) 
vs. post-surgery 13.1 ± 0.8g contralateral WT’s (n=43)).  
 
 
Fig.3: Development of tactile hypersensitivity for the SCS-selected animals, based on paw withdrawal 
threshold to von Frey hair stimulation after unilateral sciatic nerve ligation in adult rat (n=43). * p < 
0.05 for ipsilateral versus contralateral WT’s. 
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Spinal Cord Stimulation 
Animals received 60 minutes of SCS at 66% MT (n=43; see section 2.6 of Methods and Fig.2). 
The average motor thresholds for Con-CS (135 ± 4 μA) and Burst-SCS (57 ± 3.5 μA) were 
found to be statistically different (p < 0.01) (Fig.4). WTs to von Frey filaments was assessed 
before the start of SCS treatment, at 15’, 30’, 60’ min. after stimulation was turned on, and 
at 30 min. after stimulation was turned off (90 min, after the start of SCS). No significant 
differences were observed in ipsilateral paw withdrawal thresholds (WT’s) at baseline, pre-
SCS, between groups (p = 0.62; Con-SCS 1.2 ± 0.4g [n=21] vs. Burst-SCS 1.5 ± 0.7g [n=22]). 
During SCS WT’s of both the Con-SCS group (X2=89.7; p < 0.001) and Burst-SCS group 
(X2=90.5; p < 0.001) significantly differed over time, while the Sham-SCS did not (X2=15.9; p 
= 0.7). After 15 mins of SCS WT’s of the Con-SCS group were significantly increased, 
compared with baseline WT’s (p = 0.03; 1.2 ± 0.4g vs 8.6 ± 1.3g). Meanwhile, after 15 mins 
of SCS, WT’s of the Burst-SCS group did not significantly differ from baseline WT’s (p = 0.16; 
1.5 ± 0.7g vs 3.5 ± 1.7g). Furthermore, after 15 mins of stimulation WT’s of the Con-SCS 
group and Burst-SCS group significantly differed (p = 0.04; Con-SCS: 8.6 ± 1.3g vs Burst SCS: 
3.5 ± 1.7g) (Fig.5+6). After 30 mins of stimulation, 45 mins of stimulation, and 60 mins of 
stimulation WT’s of both the Burst-SCS group (p = 0.02, p = 0.03 and p = 0.02 respectively) 
and Con-SCS group (p = 0.03, p = 0.03 and p = 0.03 respectively) significantly differed from 
baseline WT’s. Also, WT’s of the Burst-SCS group and Con-SCS group did not significantly 
differ at 30 mins of stimulation (p = 0.63), 45 mins of stimulation (p = 0.75), and 60 mins of 
stimulation (p = 0.47) (Fig.5). However, at 30 mins post stimulation WT’s of the Burst-SCS 
group were still significantly higher as compared with baseline (p = 0.04; 1.5 ± 0.7g vs 5.5 ± 
2.6g), whereas WT’s of the Con-SCS group were not (p = 0.5; 1.2 ± 0.4g vs 1.9 ± 1.1g). 
Furthermore, at 30 mins post stimulation we observed a strong trend for the difference 
between WT’s of the Con-SCS group and Burst-SCS group (p = 0.06; Con-SCS: 1.9 ± 1.1g vs 
Burst SCS: 5.5 ± 2.6g) (Fig.5+6). 
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Fig.4: Motor threshold (MT) assessed by means of Conventional and Burst stimulation. Con-SCS MT 
was determined at the following settings: pulse width of 200 μS administered at a frequency of 2 Hz. 
Burst-SCS MT was determined at the following settings: pulse width of 1000 μS, five pulses (500 Hz 
intraburst-frequency) administered at an interburst-frequency of 2 Hz. (* p < 0.05 for Con-MTs versus 
Burst-MTs). 
 
 
Fig.5: The effect of Con-SCS (n=21) and Burst-SCS (n=22) on the paw withdrawal thresholds (WT’s) 
based on sensitivity to von Frey filaments. WT’s were assessed at 15, 30, 45, and 60 mins of stimulation 
and 30 mins. post stimulation. The dotted line represents the average WT baseline prior to sciatic 
nerve ligation (# p < 0.05 for Burst-SCS vs. baseline; ^ p < 0.05 for Con-SCS vs. baseline; * p < 0.05 for 
Burst-SCS vs Con-SCS). 
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Fig.6 Boxplot of the WT’s of Con-SCS and Burst-SCS for the wash-in period (15 minutes of SCS) and 
wash-out period (30 minutes post-SCS).  (* p < 0.05 for Burst-SCS vs Con-SCS, # p < 0.07 for Burst-SCS 
vs. Con-SCS) 
 
 
Discussion 
 
The aim of this study was to evaluate the behavioral anti-nociceptive effect of biphasic 
Burst-SCS, as compared with Con-SCS, on mechanical hypersensitivity in an experimental 
chronic neuropathic pain model. We report a delayed anti-nociceptive effect of Burst-SCS 
after onset of the stimulation, as compared with Con-SCS. Furthermore, Burst-SCS seems to 
exhibit a delayed wash-out of analgesia after stimulation is turned off. However, no 
difference in maximum anti-nociceptive effect of Burst-SCS, as compared with Con-SCS, was 
noted in this model of chronic neuropathic pain. The amplitudes required to obtain motor 
thresholds were found to be significantly different, with Burst-SCS requiring significantly 
less amplitude in order to induce motor responses (Fig.4). This is in line with a recently 
published study of Meuwissen et al. (2018), where a similar difference between Burst-MT 
and Conventional-MT was reported [17].  Since the introduction of Burst-SCS for the 
treatment of chronic neuropathic pain in 2010, several mechanistic studies have been 
performed in order to define the working mechanisms and improve its effectiveness [14, 
15]. On the other hand, the behavioral anti-nociceptive effect of Burst-SCS in experimental 
studies has received little attention. A recent behavioral study demonstrated that Biphasic 
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Burst-SCS requires significantly more mean charge per second in order to achieve similar 
pain relief, as compared with Con-SCS, in an experimental model of chronic neuropathic 
pain  [17]. In this study the researchers observed that with increasing amplitude Con-SCS 
improved its efficacy, whereas the efficacy of Burst-SCS showed a non-monotonic relation 
with amplitude. Furthermore, a non-significant delayed effect of Burst-SCS was observed.  
However, due to the small number of animals this effect was not substantiated. Another 
behavioral study demonstrated  that Burst-SCS reduces hyperalgesia and restores physical 
activity levels more than tonic stimulation at standard frequencies in a neuropathic animal 
model based on spared nerve lesions[16]. Animals showed an increase in paw withdrawal 
threshold and physical activity levels during stimulation with Burst-SCS, which was found to 
be more effective than sham and tonic SCS.  Thus, in contrast to our findings they reported 
a superior anti-nociceptive effect of Burst-SCS, as compared with Con-SCS. However, it is 
important to note that neuropathic pain was induced using the spared nerve injury model, 
which is known to be more severe as compared with the partial sciatic nerve ligation model 
applied in our study [29, 30]. This seems to support the idea that specific waveforms may 
be selectively beneficial for specific conditions [9, 31].  This is reflected in the clinical setting 
where Burst-SCS was demonstrated to be more effective in providing additional pain 
reduction for specific conditions [13].  Secondly, the pulse width of Con-SCS applied in our 
study was less than half the pulse width used by Gong and colleagues (200 µsec vs 500µsec 
respectively) [16]. As Con-SCS is generally applied with a pulse width of ±200 µsec, it is 
conceivable that the animals in their study experienced more side-effects during SCS 
(paresthesia), prohibiting an optimal anti-nociceptive effect of Con-SCS [32].  Remarkably, 
Gong and colleagues did also not report a delayed effect of Burst-SCS, as compared with 
Con-SCS [16]. However, it should be noted that, during SCS, paw withdrawal thresholds 
(WT’s) were not assessed in a repeated fashion. Therefore, it is plausible that a potential 
delayed effect of Burst-SCS remained undetected. Interestingly, a delayed behavioral effect 
of High Frequency SCS (HF-SCS; 500Hz), as compared with standard tonic SCS (50Hz), has 
been reported in chronic painful diabetic polyneuropathy animals [22]. Interestingly, in a 
recent review it was hypothesized  that 10 kHz and Burst-SCS might both modulate the 
medial pain pathway, and could be fundamentally similar neurostimulation designs [33]. 
The similarity regarding (delayed) effect onset observed in our study and the study by Van 
Beek et al. does seem to suggest that Burst-SCS and High-Frequency-SCS rely on similar 
neuronal pathways and it would be interesting to further investigate the mechanisms 
involved with these SCS-paradigms. Being as the latter findings are related to diabetic 
polyneuropathy it was hypothesized that the HF-SCS increased vasodilation via antidromic 
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stimulation of unmyelinated C-fibers, treating the pain etiotropically [34]. In contrast, Con-
SCS is considered a symptomatic treatment, which covers the affected painful area with 
paresthesia. It thus seems that SCS delivered with specific parameter settings does affect 
different physiological processes. Indeed, computer modelling has indicated that SCS 
frequency, at least partly, determines the firing of Wide Dynamic Range (WDR) neurons 
projecting to the brain [35]. It was demonstrated that SCS with frequencies above 100 Hz 
do not result in inhibition of WDR signaling; this strongly suggests that higher SCS 
frequencies induce pain relief via alternative mechanisms. Although it should be taken into 
account that the frequencies tested were most likely applied at supra-perception 
amplitudes, in contrast to the sub-perception amplitudes at which Burst-SCS was applied in 
our study. Along these lines, it has been suggested that Burst-SCS and Con-SCS mediate their 
anti-nociceptive effect through different underlying mechanisms [9]. This is corroborated 
by preclinical electrophysiological studies, indicating that Burst-SCS might not rely on the 
activation of GABAB receptors and thus not on presynaptic modulation of GABA release for 
the inhibition of nociceptive C- and Ad-fiber, whereas Con-SCS does [15, 36].  Furthermore, 
the effect of orthodromic stimulation of the Aβ-fibers in the dorsal columns is suggested to 
differ between Burst- and Con-SCS: Burst-SCS was found not to increase spontaneous 
activity of gracile nucleus neurons in the brainstem, whereas Con-SCS did [37]. These 
findings suggest that the anti-nociceptive effect of Burst-SCS and Con-SCS might be 
established via modulation of fundamentally different pain pathways. This is in line with 
clinical studies, which, based on fMRI and EEG analyses, demonstrate that the anti-
nociceptive effect mediated via Burst-SCS includes the modulation of the medial pain 
pathways, whereas Con-SCS does not [9, 38]. The medial pain pathway is associated with 
the supraspinally processed affective and attentional components of pain. Following this 
line of reasoning, it might be possible that the stimulation of specific pathways via different 
SCS-paradigms requires a different timeframe in order to fully establish its anti-nociceptive 
properties. Thus, this might underlie the onset timing difference between the behavioral 
effects of Burst- and Con-SCS as observed in our study. A difference in effect-onset for Burst-
SCS and Con-SCS is furthermore in line with unpublished clinical anecdotes. Furthermore, it 
is known that the medial pain pathway is associated with attention (for pain), which has led 
to the hypothesis that Burst-stimulation might exert its main effect by an attention-
modulating effect [9]. Building on this hypothesis it is conceivable that such an attention-
modulation effect, mediated by brain structures associated with the limbic system, 
reverberates after cessation of stimulation, as compared to the processing of sensory-
discriminative components of pain as seen with Con-SCS. Therefore, one could hypothesize 
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that the attention-modulating effect of Burst-SCS might echo on after the stimulation is 
terminated, which is reflected by a delayed wash-out effect, as compared with Con-SCS. 
Yet, future experiments should be performed in order to shed more light on the differences 
in pathway activation associated with different waveforms.  However, it should be noted 
that the biphasic Burst-waveform, as applied in our study, has not yet been demonstrated 
to modulate the medial pain pathway. Future studies should elucidate whether there is a 
difference in pathway activation for monophasic BurstDR-SCS and biphasic Burst-SCS. In this 
study we did not observe superior results of Burst-SCS, in comparison with Con-SCS. Yet, 
Von Frey analysis as applied in our study is known to be a reflex-based assessment method 
which primarily assesses pain stimuli processed on a segmental/spinal level [39-41]. Future 
studies assessing the effect of Burst- versus Con-SCS by means of a non-reflex based operant 
testing method, in which supraspinal aspects of pain are assessed, could potentially uncover 
a superior effect for Burst-SCS.  An innovative example is the Mechanical Conflict-Avoidance 
System (MCAS), an operant testing method for preclinical pain assessment, which uses pain-
motivated behavior to capture cognitive and motivational aspects of pain in rodents [42]. It 
should be noted that the investigation of supraspinal elements of pain remains a research 
question on its own. Hence, it is important that unambiguous stimulation aspects, such as 
a wash-in and/or wash-out effect, are assessed by means of a straightforward assessment 
method such as Von Frey measurement. 
 
Limitations  
Only one behavioral assessment method was used. As Burst-SCS is hypothesized to recruit 
the medial-spinothalamic tract future studies should include the analysis of emotional-
affective aspects of pain in animal studies. An innovative example is the Mechanical 
Conflict-Avoidance System (MCAS), an operant testing method for preclinical pain 
assessment, which uses pain-motivated behavior to capture cognitive and motivational 
aspects of pain in rodents [42]. 
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Conclusion 
 
To conclude, biphasic Burst-SCS results in a delayed anti-nociceptive effect after onset of 
the stimulation, as compared with Con-SCS. Furthermore, Burst-SCS seems to exhibit a 
delayed wash-out of analgesia after stimulation is turned off. Yet, the maximum anti-
nociceptive effect based on paw withdrawal responses did not differ between Burst- and 
Con-SCS. The maximum anti-nociceptive effect based on paw withdrawal responses did not 
differ between Burst- and Con-SCS. As the anti-nociceptive effect of Burst- and Con-SCS 
might be related to modulation of fundamentally different pain pathways, the use of 
operant testing methods, addressing cognitive and motivational aspects of pain, is highly 
recommended to further elucidate the behavioral differences between Burst-SCS and Con-
SCS. 
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Abstract 
 
Background: Experimental and clinical studies have shown that Tonic Spinal Cord 
Stimulation (SCS) releases GABA in the spinal dorsal horn. Recently, it was suggested that 
Burst SCS does not act via spinal GABAergic mechanisms. Therefore, we studied spinal 
GABA-release during Burst and Tonic SCS, both anatomically and pharmacologically, in a 
well-established chronic neuropathic pain model.  
 
Methods: Animals received a partial sciatic nerve ligation (PSNL). Quantitative 
immunohistochemical (IHC) analysis of intracellular GABA-levels in the lumbar L4-L6 dorsal 
spinal cord was performed after 60 min of Burst, Tonic or Sham SCS in PSNL rats (n=16). In 
a second pharmacological experiment the effect of intrathecal administration of the GABAA-
antagonist bicuculline (5µg) and the GABAB -antagonist phaclofen (5µg) was assessed. Paw 
withdrawal thresholds to von Frey filaments of PSNL-rats (n=20) were tested during 60 
minutes of Burst and Tonic SCS, 30 mins post intrathecal administration of the drugs. 
 
Results: Quantitative IHC-analysis of GABA-immunoreactivity (IR) in spinal dorsal horn 
sections of animals that had received Burst SCS (n=5) showed significantly lower 
intracellular GABA-levels, when compared to Sham SCS sections (n=4) (p = 0.0201) and Tonic 
SCS sections (n=7) (p = 0.0077). Intrathecal application of GABAA-antagonist bicuculline 
(5µg) (n=10) or the GABAB -antagonist phaclofen (5µg) (n=10) resulted in ablation of the 
analgesic effect for both Burst SCS and Tonic SCS. 
 
Conclusions: In conclusion, our anatomical and pharmacological data demonstrate that, in 
this well-established chronic neuropathic animal model, the analgesic effect of both Burst 
SCS and Tonic SCS is mediated via spinal GABAergic mechanisms.   
 
 
 
 
  
Burt and Tonic SCS: Spinal GABAergic mechanisms 
77 
Introduction 
 
Tonic Spinal Cord Stimulation (SCS) is a last-resort treatment method for patients that suffer 
from intractable chronic neuropathic pain [1-6]. The standard Tonic SCS-protocol consists 
of continuous, tonic, electrical stimulation applied to the dorsal columns of the spinal cord 
with a frequency within the range of 40-80 Hz and a pulse width in between 200-500 µSec 
[2, 7, 8]. The concept of SCS emerged as a direct application of the ‘Gate Control Theory’, 
by Melzack and Wall in 1965 [7, 9]. It was postulated that antidromic stimulation of the non-
nociceptive Aβ-fibers could close the ‘spinal gate’, located in the dorsal horn of the spinal 
cord. Closing of the ‘gate’ is facilitated by inhibitory interneurons located in the superficial 
laminae of the dorsal horn and it is believed that the neurotransmitter γ-aminobutyric acid 
(GABA) plays a pivotal role in this process [8, 10, 11]. During the development of 
neuropathic pain Janssen and colleagues observed, in a partial sciatic nerve ligation (PSNL)-
model, increased intracellular levels of GABA in the dorsal horn [12]. Later, it was 
demonstrated that Tonic SCS decreased intracellular GABA-immunoreactivity in the dorsal 
horn of these PSNL-rats [13]. At the same time, extensive experimental microdialysis-work 
has demonstrated that Tonic SCS increases extracellular GABA levels in the dorsal horn of 
allodynic PSNL-rats [14-16]. Thus, GABAergic interplay seems to be an important aspect of 
the analgesic mechanisms underlying Tonic SCS in the PSNL-model of chronic neuropathic 
pain. The role of GABA in segmental SCS-mechanisms was further elucidated by the 
administration of pharmacological agents that specifically modulate GABA-release in the 
dorsal horn during Tonic SCS in PSNL-neuropathic rats. Local perfusion with a GABAB-
receptor antagonist in the dorsal horn transiently abolished the SCS-induced effect in 
neuropathic rats [16] and rats not receiving adequate pain relief with Tonic SCS (non-
responders) were turned into responders by administration of the GABAB-receptor agonist 
Baclofen [17]. The aforementioned preclinical findings were successfully translated to the 
clinic where neuropathic pain patients with a deficient Tonic SCS effect had improved pain 
relief following the intrathecal administration of baclofen [18], further confirming  the 
theory that local spinal GABAergic mechanisms are pivotal for the effects of Tonic SCS. 
While GABA plays a role in the underlying mechanism of Tonic SCS, the neurotransmitters 
involved in other stimulation paradigms, such as Burst SCS, have not been clearly identified. 
As patients show different responses to different stimulation paradigms, the underlying 
mechanisms may be different [19]. The Burst waveform consists of closely spaced pulses 
delivered in a packet or burst, directly followed by a quiescent period or interburst interval 
[20]. Burst SCS has proven to be effective in FBSS and Radiculopathy patients, and clinical 
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trials have demonstrated its ability to help patients to reduce their analgesic intake [21-23]. 
In addition, Burst SCS reduces neuropathic pain without generating paresthesia in the 
affected limb or area [24-26]. Yet, from a mechanistic point of view, the Burst waveform is 
still in its infancy. Source-localized EEG-studies and patient questionnaires suggest that 
Burst SCS preferentially activates the medial pain pathway, hence modulates emotional-
affective pain aspects [25, 27]. On a segmental level, an experimental electrophysiological 
study has aimed to elucidate the involvement of GABA in the spinal mechanism underlying 
Burst-SCS [28]. It was found that the presence of a GABAB-receptor antagonist blocked 
attenuation of dorsal horn neuronal firing during Tonic SCS but not Burst SCS. Furthermore, 
blood serum GABA measurements showed that systemic GABA levels were not increased 
following Burst SCS. From this, the authors concluded that Burst SCS might not act via spinal 
GABAergic mechanisms [31]. However, it should be mentioned that the aforementioned 
study was performed not only in an uncommon rat model for chronic neuropathic pain, the 
Painful Cervical Nerve Root Compression model, but these experiments were also terminal 
and thus no behavioral testing during the conscious state of the animals was performed 
[31]. This makes interpretation of these data in the context of understanding the role of 
spinal GABA in a chronic neuropathic pain model difficult, as most experimental data on 
pain relief and the spinal GABAergic mechanism underlying Tonic SCS have been 
documented and studied in the well-described and validated partial sciatic nerve ligation 
(PSNL) model or a similar nerve injury model for peripheral mononeuropathy [13-17, 29]. 
Therefore, in order to further understand the spinal mechanism underlying Burst-SCS we 
aimed to study, both anatomically and pharmacologically, the role of GABA in behavior and 
pain relieving mechanisms underlying Burst and Tonic SCS, in a well-established chronic 
neuropathic PSNL model.  
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Material and Methods 
 
Ethics Statement 
The experiments were performed in accordance with the European Directive for the 
Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes 
(86/609/EU). The protocol was approved by the Animal Research Committee of the 
Maastricht University Medical Centre (Project License number: 2017-022). 
 
Animals 
All experiments were performed using male Sprague Dawley rats (n=36, which were young-
adult (5 weeks of age) at the start of the experiment (150–200 g). Sixteen animals were used 
in the first experiment in which we assessed the quantitative immunohistochemical (IHC)-
analysis of GABA- immunoreactivity (IR) in spinal dorsal horn sections of animals after SCS 
(n=16). Twenty animals were used in the second experiment in which we intrathecally 
administered GABAA/B-antagonists before SCS in order to assess the effects of these 
pharmacological agents on behavioral pain relieving effects of SCS (n=20). Animals were 
housed in groups of 2, in polycarbonate cages in a climate-controlled vivarium maintained 
under controlled temperature (21 ± 1°C), relative humidity (55±15%) and artificial lighting 
(12:12 reversed light/dark cycle) with distilled water and rodent food available ad libitum. 
The vivarium was equipped with a central radio system, continuously producing background 
music at 45 decibel, in order to desensitize the animals for experimenter related noise. All 
procedures were conducted between 09:00 and 16:00 hours. Experiments were conducted 
during the dark, active, phase of the rodent circadian rhythm.  
 
Partial Sciatic Nerve Ligation (PSNL) 
A unilateral ligation of the left sciatic nerve was performed as described by Seltzer et al. 
1990 [29], and previously applied in our laboratory  [30-33]. In short, animals were 
anesthetized with 3–5% isoflurane (Abbott Laboratories Ltd., Kent, U.K.) and air enriched 
with 100% oxygen at a constant flow rate of 250 ml/min. By use of an automatic heating 
pad body temperature was maintained at 37.5°C. The nervus ischiadicus from the left hind 
paw was exposed by blunt dissection and carefully freed from surrounding connective 
tissue. Subsequently, the nerve was partially (approximately 1/3) ligated using 8/0 non-
absorbable silk suture. The wound was then closed with 4/0 silk sutures. Development of 
mechanical hypersensitivity (mechanical allodynia) was monitored with the use of von Frey 
assays for 14 consecutive days. At day 14, presence of mechanical hypersensitivity was 
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confirmed if the log (50% paw withdrawal threshold (PWT)) was decreased by 0.2 units 
compared to  baseline (day 0) [34].   
 
Assessment of mechanical hypersensitivity (von Frey assay)      
Mechanical hypersensitivity was assessed by use of von Frey filaments. Von Frey 
assessment was always conducted in the same room, isolated from external sounds and 
equipped with artificial red light sources (temperature: 21 ± 1°C, and relative humidity 
:55±15%). Prior to testing, animals were placed in the behavioral set-up for 15 mins in order 
to acclimate to the new surroundings. The assessment-room was equipped with a mobile 
radio, continuously producing background music at 45 decibels. PWTs to von Frey filaments 
were assessed using the ‘up-down method’ [35]. Von Frey filaments of linearly incrementing 
stiffness (bending forces 0.6, 1.2, 2.0, 3.6, 5.5, 111 8.5, 15.1g and 28.84 g) were applied to 
the plantar surface of the hind paw of the rats for 5 consecutive seconds. A negative 
response (the hind paw was not withdrawn) was followed by the subsequent filament with 
greater bending force. In contrast, a positive response (the hind paw was withdrawn) was 
followed by application of the previous filament with a lower bending force. After 
completion of a sequence of six consecutive responses the 50% PWT was calculated [35]. 
The predetermined cut-off value was set at 28.84g. For statistical analysis the 50% PWTs 
were logarithmically transformed to yield a linear scale.  
 
Tissue preparation 
For immunohistochemistry experiments, sixteen animals in experiment 1 were divided into 
three groups: sham SCS (n =4) and Tonic SCS (n=7) and Burst SCS (n=5). Animals were 
sacrificed 60 mins after the start of (sham-) SCS. Tissue perfusion was performed 
transcardially with a mixture of 4% paraformaldehyde and 15% picric acid in 0.2 M 
phosphate buffer (PBS; pH 7.6) after anesthesia with pentobarbital (100 mg/kg body 
weight). Then, lumbar spinal cord regions L4–L6 were removed by a laminectomy, post-
fixated overnight at 4°C and cryoprotected for 24 h in 10% sucrose. This was followed by at 
least 72 h incubation in 25% sucrose (in 0.1 M PBS; pH 7.6) at 4°C. Subsequently, tissues 
were frozen in solid carbon dioxide. Thirty µm thick transverse cryosections were mounted 
on gelatine-coated glass slides and stored at -20°C until staining procedures were 
performed. 
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Immunohistochemical detection of GABA 
The immunohistochemistry-protocol was performed as described in Janssen et al. (2012) 
[13]). In short, staining procedures were performed at room temperature unless stated 
otherwise. Firstly, glass slides were air-dried for 2 hours and subsequently washed in Tris-
buffered saline (TBS, 0.1 M, pH 7.6) including 0.3% Triton X-100 (TBS-T), TBS and TBS-T. 
Blocking was performed with 2% normal donkey serum (Sigma-Aldrich, Zwijndrecht, The 
Netherlands).  The serum was diluted in TBS-T and applied for a 1-h incubation period. Then, 
the sections were incubated with a polyclonal rabbit anti-GABA antibody (1:5000 diluted in 
TBS-T; Sigma- Aldrich, Zwijndrecht, The Netherlands, A2052) for a time period of 48 hours. 
After 48 hours, excess of primary antibody was removed by use of TBS after which sections 
were incubated with the secondary alexa fluor 488 donkey anti-rabbit IgG antibody (1:100 
diluted in TBS-T; Invitrogen, Breda, The Netherlands, A21206) for 2 hours. Subsequently, 
sections were rinsed with TBS, and coverslipped with TBS/glycerol (20%/80%). 
 
Quantification of immunostaining 
Quantitative immuhistochemical analysis of spinal dorsal horn GABA staining was 
performed as as described by Janssen et al. (2012) [12, 13]. Photomicrographs were taken 
of both ipsi- and contralateral lumbar L4-L6 spinal cord immunostained sections using a 
Provis AX70 fluorescent microscope (Olympus, Hamburg, Germany). The microscope was 
connected to a digital black and white video camera (U-CMAD-2, Olympus), equipped with 
CellP© software. Lamina of Rexed 1-3 of the dorsal horn were determined as regions of 
interest for the GABA-IR analysis [36].  Grayscale values were calculated for these laminae. 
Analysis of gray scale spinal cord pictures was performed by a blinded observer by use of 
the AnalySIS software program CellP© (Soft Imaging Systems, Münster, Germany). 
 
Implantation of spinal cord stimulation device 
The implantation of the SCS device was performed according to the standard protocol used 
in our institution [31-33, 37, 38]. In short, a small laminectomy was made at level Thoracic 
13 (Th13), after which the spinal cord was exposed by use of a surgical rotary tool. A custom-
made cylindrical 4-contact lead (0.72mm diameter; Boston Scientific Neuromodulation, 
Valencia, CA, USA) was inserted into the epidural space, in the caudal direction. Electrode 
configuration was set at alternating cathode and anode settings (rostral to caudal: + - + -). 
Then, the electrode was secured to a spinous process with tissue adhesive (Histoacryl®, B 
Braun Medical BV, Oss, the Netherlands) to prevent electrode migration. The electrode 
wires were tunneled subcutaneously to the neck of the animal and the stimulator-
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connectors were attached with 4/0 silk sutures.  Animals were given 2 days for recovery 
prior to the initiation of SCS-experiments. 
 
Intrathecal implantation 
After successful implantation of the SCS device twenty animals in experiment 2 received a 
small laminectomy was made at level Thoracic 12 (Th12), after which the spinal cord was 
exposed by use of a surgical rotary tool. The membrane was carefully opened after which a 
polyethylene catheter from Instech Laboratories (27ga, length 1.5 cm) was inserted and 
tunneled intrathecally to the level of the L3–L5 spinal segments as described by Truin et al. 
(2011) [30]. The catheter was secured to a spinous process with tissue adhesive 
(Histoacryl®, B Braun Medical BV, Oss, the Netherlands) to prevent migration. 
Subsequently, the catheter was slowly flushed with 10 µl of saline and the wound was 
closed with 4/0 silk sutures. Animals with signs of paralysis directly after the surgery were 
excluded. Correct placement of the catheter was confirmed when lidocaine 2% injection (10 
mg/ml) resulted in paralysis or dragging of the hind limbs [30]. 
 
Spinal cord stimulation 
For stimulation of the dorsal columns an A-M systems stimulator (MultiStim: Programmable 
8-Channel Stimulator (Model 3800) 220 V/50 Hz) fitted with a stimulus Isolator (Model 3820 
for A-M Systems MultiStim) was used. The stimulator was set to deliver constant current 
biphasic stimulation for both the Tonic and Burst SCS modes. Tonic SCS Motor Threshold 
(MT) was determined at the following settings: pulse width of 200µS administered at a 
frequency of 2 Hz. Burst SCS MT was determined at the following settings: pulse width of 
1000µS, five pulses (449 Hz intra-burst frequency) administered at an inter-burst frequency 
of 2 Hz. The amplitude was gradually increased until symmetrical contractions of the hind 
limbs were perceived by hand and/or visually observed. Then, either a Tonic SCS paradigm 
at 66% of MT (frequency 50 Hz, pulse width 200 µS) [20], or a biphasic Burst-SCS paradigm 
at 50% MT (inter-burst-frequency 40 Hz, pulse width 1000 µS, 5 spikes at 449 Hz intra-burst 
frequency) was applied for 60 minutes [24, 33]. The SCS-parameters were based on 
previously determined optimal settings for pain relief with Burst SCS (50% MT) and Tonic 
SCS (66% MT) [31, 33]. In all experiments, the PWTs to von Frey filaments were assessed 
before the start of SCS treatment (baseline), at 15’, 30’, 45’ and 60’ min. after stimulation 
was turned on. The investigator was blinded to the stimulation condition throughout the 
whole experiment.  
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Intrathecal administration of GABAA/B Receptor Antagonist (experiment 2) 
The concentration of the GABAA/B -receptor antagonists bicuculline (5µg) (≥97% (NMR); 
Sigma-Aldrich) and phaclofen (5µg) (≥97% (NMR); Sigma-Aldrich) was chosen based on 
literature demonstrating a dose-response curve for both antagonists [39]. As the peak 
dorsal horn drug concentrations occurred after 30 min after intrathecal administration [39], 
antagonists were applied to the spinal cord 30 mins before the SCS and von Frey testing 
protocols were initiated. Intrathecal administration of the GABAA/B -receptor antagonists 
(5µg) was followed by the administration of 20µl saline. Vehicle administration consisted of 
10µl saline followed by the administration of 20µl saline.  
 
 
Fig.1: Timeline of experiment 2: pharmacological intrathecal experiments. 
 
 
Data Analysis 
PWT’s to von Frey filaments are presented as mean ± standard error of the mean (SEM). In 
line with previous Von Frey studies [32, 33, 40], von Frey data were logarithmically 
transformed to obtain a linear scale and to account for Weber’s Law [41]. For statistical 
analysis of differences in the withdrawal thresholds over time within groups of experiment 
1 and 2, the non-parametric Friedman test was used followed by followed by Dunn’s post 
hoc test. For the analysis of differences in the withdrawal thresholds between groups, 
ipsilateral and contralateral withdrawal thresholds, the nonparametric Mann–Whitney-U-
test was used. Before statistical analysis of GABA-IR gray values in experiment 1, a Shapiro-
Wilk normality test was performed. Then, the Kruskal-Wallis test was performed in order to 
assess statistical differences over group means. Dunn’s Multiple Comparison Test followed 
this in order to assess significant differences between the group means. All statistical 
analyses were performed with α = 0.05 using IBM SPSS statistics 23. 
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Results 
 
Development of mechanical hypersensitivity (von Frey), and SCS  
In experiment 1, after PSNL-surgery, ipsilateral hindpaw paw withdrawal thresholds (PWTs) 
were significantly lower than ipsilateral hindpaw PWTs in experiment 1 (p = 0.019); all 16 
animals qualified as hypersensitive due to increased response to mechanical stimulation by 
von Frey filaments (ipsilateral average PWTs: 11.5 ± 0.9 g (pre-lesion) vs. 1.1 ± 0.5 g (post-
lesion); p = 0.0042) (see Methods) (Fig.2A). Burst SCS (n=5), significantly increased PWTs 
compared to baseline PWTs at 15 (p = 0.046), 30 (p = 0.025), 45 (p = 0.016), and 60 mins of 
SCS (p = 0.019) (Fig.3A). For Tonic SCS (n=7), PWTs significantly differed from baseline PWTs 
at 15 (p = 0.027), 30 (p = 0.026), 45 (p = 0.033), and 60 mins of SCS (p = 0.031) (Fig.3A). Sham 
SCS (n=4) did not increase PWTs at any time points (Fig.3A).  
 
Fig.2 A) Development of mechanical hypersensitivity for experiment 1 (n=16) B) Development of 
mechanical hypersensitivity for experiment 2 (n=20). * p < 0.05 for ipsilateral versus contralateral 
PWT’s. DPL=Days Post Ligation.  
 
 
In experiment 2 (see methods), after PSNL-surgery, ipsilateral hindpaw PWTs were 
significantly lower than ipsilateral hindpaw PWTs (p = 0.023): all 20 animals qualified as 
hypersensitive (ipsilateral average PWTs: 10.9± 1.1 g (pre-lesion) vs. 1.3 ± 0.7 g (post-lesion); 
p = 0.0064) (see Methods) (Fig.2B). For Burst SCS (n=10), PWTs significantly differed from 
baseline PWTs at 15 (p = 0.041), 30 (p = 0.027), 45 (p = 0.028), and 60 mins. of SCS (p = 
0.022) (Fig.3B). For Tonic SCS (n=10), PWTs significantly differed from baseline PWTs at 15 
(p = 0.029), 30 (p = 0.028), 45 (p = 0.031), and 60 mins of SCS (p = 0.035) (Fig.3B). No 
significant differences were reported between development of mechanical hypersensitivity 
in experiment 1 and 2. In addition, no significant differences were reported between SCS 
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time points in experiment 1 and 2. When SCS-data of experiment 1 and 2 were pooled, Burst 
SCS (n=15) and Tonic SCS (n=17), significantly increased PWTs compared to baseline PWTs 
at 15 (p = 0.042; p = 0.028 resp.), 30 (p = 0.027; p = 0.026 resp.), 45 (p = 0.021; p = 0.032 
resp.), and 60 mins of stimulation (p = 0.025; p = 0.033 resp.) (Fig.3C). Burst SCS PWTs and 
Tonic SCS PWTs significantly differed at 15 mins of SCS (p = 0.038) (Fig.3C). 
 
 
 
 
 
 
 
 
 
 
Fig.3 A) The effect of Tonic SCS (n=7), Burst SCS (n=5) and Sham SCS (n=4) on PWT’s based on 
sensitivity to von Frey filaments in experiment 1. B)  The effect of Tonic SCS (n=10) and Burst SCS 
(n=10) on PWT’s in experiment 2. C) The effect of Tonic SCS (n=17), Burst SCS (n=15) on PWT’s pooled 
data from experiment 1 and experiment 2. The dotted line represents the average PWT baseline prior 
to sciatic nerve ligation. (^ p < 0.05 for Burst-SCS vs. Tonic SCS; # p < 0.05 for Burst SCS vs. baseline; * 
p < 0.05 for Tonic SCS vs. baseline). 
 
 
Spinal DH GABA-immunoreactivity 
In experiment 1, anti-GABA immunohistochemistry revealed an intense immunoreactivity 
(IR) predominantly in laminae 1–3 of the lumbar spinal dorsal horn with clear identification 
of GABA-IR cell bodies (Fig. 4B). Grayscale values were calculated for these laminae. The 
Shapiro-Wilk normality test was not passed (p = 0.0395). Accordingly, a Kruskal-Wallis test 
was performed which showed a significant difference between mean gray values for the 
Sham-SCS, Tonic-SCS and Burst SCS group (p = 0.0085, KW-statistic= 9.524). Statistical 
testing of GABA staining intensity in spinal DH and gray values revealed that the Tonic SCS 
group, although it showed a strong tendency, did not differ significantly from the Sham-SCS 
group (p = 0.1609), the Burst SCS group differed significantly from the Sham-SCS group (p = 
0.0201), and from the Tonic SCS group  (p = 0.0077).  
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Fig.4: A) SCS-induced alterations in intracellular GABA levels in the L4–L6 spinal dorsal horn. 
Representative grayscale photomicrographs of the upper laminae of the ipsilateral dorsal horn of a 
sham SCS- animal, Tonic SCS animal, and Burst SCS animal. Scale bar = 100 µm. B) Quantified GABA-
IR in laminae 1–3 of the spinal dorsal horn L4-L6 of sham SCS animals (n=4), Tonic SCS (n=7) animals 
and Burst SCS (n=5) animals. * p < 0.05. C) Representative overview of the immunostaining of the left 
and right dorsal horn of the spinal cord. Scale bar = 100 µm. D) Arrowheads point out activated GABA-
IR neuronal profiles, Scale bar = 100 µm. E) Scale bar = 50 µm.  
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Intrathecal GABA-antagonist administration 
In experiment 2 (Fig.1), thresholds for mechanical hypersensitivity were not affected after 
15 mins of Tonic SCS with intrathecal administration of the GABAA-antagonist bicuculline, 
as PWT’s were significantly increased as compared to baseline (p = 0.044) ( (Fig.5A). 
Meanwhile, at 30 mins SCS (p = 0.38), 45 mins SCS (p = 0.65), and 60 mins (p = 0.32) of Tonic 
SCS, thresholds for mechanical hypersensitivity were affected as PWTs did not significantly 
differ from baseline PWTs.  Administration of the GABAA-antagonist bicuculline affected 
thresholds for mechanical hypersensitivity at all time points during Burst SC. PWWs did not 
significantly differ from baseline PWTs at 15 mins (p = 0.74), 30 mins (p = 0.49), 45 mins (p 
= 0.52), and 60 mins of Burst SCS (p = 0.67) (Fig.5A).  
After intrathecal administration of the GABAB -antagonist phaclofen thresholds for 
mechanical hypersensitivity did not differ from baseline for both Tonic SCS and Burst SCS 
(Fig.5B). PWTs at 15 mins SCS (p = 0.35, p = 0.38 resp.), 30 mins SCS (p = 0.56, p = 0.41 resp.), 
45 mins SCS (p = 0.43, p = 0.50 resp.), and 60 mins of SCS (p = 064, p = 0.59 resp.) did not 
significantly differ from baseline PWTs (Fig.5B). 
In a control experiment, administration of vehicle (saline-minus antagonist) was 
administered. Thresholds for mechanical hypersensitivity were not affected as PWT’s 
significantly increased over time for both Tonic-SCS (n=10) and Burst-SCS (n=10) at 15 mins 
(p = 0.01, p = 0.01 resp.), 30 mins  (p = 0.02, p = 0.01 resp.), 45 mins  (p = 0.01, p = 0.03 
resp.), and 60 mins  (p = 0.01, p = 0.01 resp.), as compared to baseline (Fig.5C).  
Administration of the GABAA-antagonist bicuculline(n=5) and the GABAB -antagonist 
phaclofen (n=5) 30 minutes prior to Sham SCS did not increase PWTs, as compared to 
Baseline PWT’s (Fig.5D). 
Administration of the GABAA-antagonist bicuculline (n=5) and the GABAB -antagonist 
phaclofen (n=5) 30 minutes prior to Von Frey testing decreased PWTs of the contralateral 
paw (unaffected by the sciatic nerve ligation) at 15 mins  (p = 0.01, p = 0.01 resp.), 30 mins  
(p = 0.02, p = 0.01 resp.), 45 mins  (p = 0.01, p = 0.03 resp.), and 60 mins  (p = 0.01, p = 0.01 
resp.), of Von Frey testing, as compared to Minus 30 Baseline PWTs (Fig.6).  
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Fig.5: A) The effect of Tonic-SCS (n=10) and Burst-SCS (n=10) on the paw withdrawal thresholds 
(PWT’s) based on sensitivity to von Frey filaments, 30 mins post GABAA-antagonist bicuculline 
administration. PWT’s were assessed at baseline, 15, 30, 45, and 60 mins. of SCS. B) The effect of 
Tonic-SCS (n=10) and Burst-SCS (n=10) on PWT’s, 30 mins post GABAB-antagonist phaclofen 
administration. PWT’s were assessed at baseline, 15, 30, 45, and 60 mins. of SCS. C) The effect of 
Tonic-SCS (n=5) and Burst-SCS (n=5) on PWT’s, 30 mins post vehicle administration. PWT’s were 
assessed at baseline, 15, 30, 45, and 60 mins. of SCS. D)  The effect of Sham-SCS and GABA-antagonists 
bicuculline (n=10) or phaclofen (n=10) administration on PWT’s, 30 mins post antagonist 
administration. The dotted line represents the average PWT baseline prior to sciatic nerve ligation. (# 
p < 0.05 for Burst-SCS vs. baseline; * p < 0.05 for Tonic-SCS vs. baseline. 
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Fig.6: Paw withdrawal thresholds (PWT’s) based on sensitivity to von Frey filaments of the 
contralateral paw 30mins and 15mins pre bicuculline (n=10) or phaclofen administration (n=10), and 
at baseline, 15, 30, 45 and 60 mins post antagonist administration. The dotted line represents the 
average PWT baseline prior to sciatic nerve ligation. (* p < 0.05 for bicuculline vs. minus30 ; # p < 0.05 
for phaclofen vs. minus 30). 
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Discussion 
 
Immunohistochemistry analysis of dorsal horn sections showed a decrease in intracellular 
GABA levels immediately after Burst SCS. Intracellular GABA levels were significantly 
decreased compared to Sham-SCS animals and Tonic SCS animals. In a second experiment, 
administration of a GABAA- and GABAB–receptor antagonist abolished the analgesic effect 
of both Tonic SCS and Burst SCS. Based on these findings we conclude that the analgesic 
effect of Burst-SCS is mediated via a spinal GABAergic mechanism. GABAergic interneurons 
are known to be important players in the pain gate system that is located in the dorsal horn 
of the spinal cord [39, 42, 43], which in its turn is a fundamental component of the working 
mechanisms underlying Tonic SCS [8-11, 13-17, 44]. Both experimental and clinical studies 
have documented the importance of segmental GABA-release by turning SCS non-
responders into responders via intrathecal administration of the GABAB agonist baclofen (in 
subeffective doses)[16] [17] [18]. The majority of experimental studies on the effect of Tonic 
SCS were performed in sciatic nerve injury models including the sciatic nerve ligation model 
(PSNL) and the chronic constriction injury model. [13, 16, 17, 30-33, 37, 38, 45]. Therefore, 
in order to adequately compare and correlate our findings to previous literature, we 
deliberately chose to perform our experiments in the partial sciatic nerve ligation model. 
Initially, we found that intracellular GABA-levels in the rat dorsal horn were significantly 
decreased following 60 mins of Burst SCS, hence, an indication that Burst SCS does induce 
the release of GABA in the dorsal horn. Our notion was further confirmed by the results of 
our second experiment, where we demonstrated that a GABAA-antagonist phaclofen and 
GABAB-antagonist bicuculline both abolished the pain relieving behavioral effect of Burst 
and Tonic SCS. Our findings on the effect and mechanism of Tonic SCS are in line with earlier 
work performed at our laboratory, where it was demonstrated that Tonic SCS decreased 
intracellular GABA-immunoreactivity in the dorsal horn of PSNL-rats [13].  Perhaps even 
more important is that, in line with our study, experimental pharmacological work has 
previously shown that local perfusion with a GABAB-receptor antagonist in the dorsal horn 
of neuropathic rats transiently abolished the Tonic SCS-induced effect [16]. Meanwhile, 
preclinical studies conducted also in a sciatic nerve injury model demonstrated that 
intrathecal administration of the GABAB-agonist baclofen, and the GABAA agonist muscimol, 
administered intrathecally, resulted in a marked and long-lasting increase of withdrawal 
thresholds in rats not receiving adequate pain relief with Tonic SCS (non-responders), 
although muscimol produced a less prominent threshold increase as compared to baclofen 
[48]. This and our data shows that Tonic SCS operates by potentiating the spinal GABAergic 
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systems in general, and that the Tonic SCS effect depends on both GABAA-receptor and 
GABAB-receptor signaling, although the SCS-effect seems to be more linked to the GABAB-
receptor system [45]. In our study, administration of a GABAA- and GABAB–receptor 
antagonist prevented the pain relieving effect of Burst SCS. Our conclusion that the pain 
relieving effect of Burst-SCS is mediated via spinal GABAergic mechanisms may conflict with 
findings reported by Crosby and colleagues (2015). Based on electrophysiological analysis 
of neuronal firing after Burst-SCS, these authors reported that the presence of a GABAB-
receptor antagonist did not block the attenuation of dorsal horn neuronal firing, when SCS 
was applied at 90% of the Motor Threshold (MT) [28]. Based on these findings the authors 
conclude that Burst SCS does not act via a spinal GABAergic mechanism whereas Tonic SCS 
does [31]. However, as the electrophysiological experiments were terminal, no behavioral 
testing was performed during the conscious state of the animals. Yet, behavioral analysis 
and thus assessment of the pain relieving effect is known to be the most important indicator 
of a treatment or compound’s translational value [46]. Furthermore, even though the 
experiments provide novel insights into the working mechanisms underlying Tonic and 
Burst SCS, the fact that the experiments were performed in a painful cervical nerve root 
compression rat model makes it difficult to compare the findings to the majority of 
experimental SCS literature, since most experimental data on pain relief and spinal 
GABAergic mechanism underlying Tonic and Burst SCS have been documented and studied 
in peripheral nerve injury models for mononeuropathy [13-17, 29, 32, 33]. It is interesting 
that in the study by Crosby and colleagues both Burst and Tonic SCS was applied at 90% MT, 
an intensity known to induce unwanted side effects in the animals. Our study and analysis 
was based on previously determined optimal settings for pain relief with Burst SCS (50% 
MT) and Tonic SCS (66% MT) [31, 33]. Moreover, according to the strength-duration curve, 
SCS administered at 90%, MT is above perception-threshold, while Burst SCS in the clinical 
setting is usually applied below perception threshold (paresthesia-free) [24, 25, 47-49]. 
Experimental evidence and clinical observations indicate that Burst SCS has a delayed wash-
in effect as compared to Tonic SCS [32].  An experimental study by Meuwissen et al. (2018) 
demonstrated that after 15 minutes Burst SCS does induce pain relief, however, at a 
suboptimal level, as compared to the plateau-phase which is reached after 30 minutes 
(when Burst and Tonic SCS reach similar levels of pain relief) [32]. It has been proposed that 
Burst SCS is capable of modulating both the medial and the lateral pain pathway [25, 27]. 
As stated by Dr. De Ridder; “the exact mechanism of the selective routing is unknown but 
could be related to diameter differences at a bifurcation, in which only the burst waveform 
is powerful enough to overcome the higher transmission resistance of the smaller C-fibers 
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that make up the medial pain pathway” [33]. Meanwhile, evidence shows that Tonic SCS, 
via descending pathways, exerts an inhibitory GABAergic effect in the spinal cord [50-55]. 
Therefore, it could be hypothesized that 5 minutes of Burst SCS, as applied in the Crosby 
study, was not sufficient to set in motion the delayed supraspinal mechanisms that lead to 
optimal pain relief as observed after the effects of  Burst SCS have plateaued (30+ minutes) 
[32]. Additionally, after only 5 minutes of Burst SCS, Crosby and colleagues might have 
observed a GABA-independent segmental mechanism of Burst SCS, unaffected by the 
GABAB-antagonist, while the supraspinal loop did not yet set in motion the descending 
pathways that exert an inhibitory effect via GABAergic mechanisms in the spinal cord. It 
should be mentioned that in our study we applied biphasic active recharge Burst SCS, while 
Crosby and colleagues applied passive recharge burst SCS. Whether or not there are 
physiological or clinical differences between these burst waveforms is unknown [56, 57]. To 
date, no data from clinical or preclinical studies have been performed that have directly 
compared passive recharge Burst SCS and active recharge Burst SCS, therefore no conclusive  
statements regarding the efficacy of these Burst waveforms can be made. However, future 
research that aims to elucidate the working mechanisms of, and (possible) differences 
between, these waveforms is desired. Interestingly, our results demonstrate that blocking 
of the GABAA -receptor does not prevent a significant increase in PWTs after 15 mins of 
Tonic SCS, while the effect was successfully suppressed during the remaining minutes of 
stimulation. This suggests that Tonic SCS possesses the ability to, initially, activate GABA-
independent pain relieving mechanisms. It is believed that the supraspinal mechanisms of 
Tonic SCS arise from activation of the ‘fast-conducting’ lateral pain pathway. Once 
activated, supraspinal areas activated by the lateral pain pathway may modulate via 
descending pathways the pain-signals coming in on a segmental level, through, for example, 
the release of serotonin and norepinephrine at the spinal dorsal horns [8, 11, 58].  
 
 
Conclusion 
 
In conclusion, our data, based on experiments in a validated commonly used experimental 
chronic neuropathic pain model, demonstrate that spinal GABA plays a role in the working 
mechanisms of Burst SCS in the attenuation of pain. Further analysis of the GABAergic 
mechanisms underlying Burst SCS at different time points could shed more light on the exact 
mechanisms at play. 
Burt and Tonic SCS: Spinal GABAergic mechanisms 
93 
References 
 
1. Kumar, K., S. Rizvi, and S.B. Bnurs, Spinal cord stimulation is effective in management of 
complex regional pain syndrome I: fact or fiction. Neurosurgery, 2011. 69(3): p. 566-78; 
discussion 5578-80. 
2. Kumar, K., M. Abbas, and S. Rizvi, The use of spinal cord stimulation in pain management. Pain 
Manag, 2012. 2(2): p. 125-34. 
3. Health Quality, O., Spinal cord stimulation for neuropathic pain: an evidence-based analysis. 
Ont Health Technol Assess Ser, 2005. 5(4): p. 1-78. 
4. Taylor, R.S., J.P. Van Buyten, and E. Buchser, Spinal cord stimulation for complex regional pain 
syndrome: a systematic review of the clinical and cost-effectiveness literature and assessment 
of prognostic factors. Eur J Pain, 2006. 10(2): p. 91-101. 
5. Reig, E. and D. Abejon, Spinal cord stimulation: a 20-year retrospective analysis in 260 patients. 
Neuromodulation, 2009. 12(3): p. 232-9. 
6. Hou, S., K. Kemp, and M. Grabois, A Systematic Evaluation of Burst Spinal Cord Stimulation for 
Chronic Back and Limb Pain. Neuromodulation, 2016. 19(4): p. 398-405. 
7. Linderoth, B. and R.D. Foreman, Conventional and Novel Spinal Stimulation Algorithms: 
Hypothetical Mechanisms of Action and Comments on Outcomes. Neuromodulation, 2017. 
20(6): p. 525-533. 
8. Sdrulla, A.D., Y. Guan, and S.N. Raja, Spinal Cord Stimulation: Clinical Efficacy and Potential 
Mechanisms. Pain Pract, 2018. 18(8): p. 1048-1067. 
9. Melzack, R. and P.D. Wall, Pain mechanisms: a new theory. Science, 1965. 150(3699): p. 971-
9. 
10. Guan, Y., Spinal cord stimulation: neurophysiological and neurochemical mechanisms of action. 
Curr Pain Headache Rep, 2012. 16(3): p. 217-25. 
11. Vallejo, R., K. Bradley, and L. Kapural, Spinal Cord Stimulation in Chronic Pain: Mode of Action. 
Spine (Phila Pa 1976), 2017. 42 Suppl 14: p. S53-S60. 
12. Janssen, S.P., et al., Differential GABAergic disinhibition during the development of painful 
peripheral neuropathy. Neuroscience, 2011. 184: p. 183-94. 
13. Janssen, S.P., et al., Decreased intracellular GABA levels contribute to spinal cord stimulation-
induced analgesia in rats suffering from painful peripheral neuropathy: the role of KCC2 and 
GABA(A) receptor-mediated inhibition. Neurochem Int, 2012. 60(1): p. 21-30. 
14. Linderoth, B., et al., Gamma-aminobutyric acid is released in the dorsal horn by electrical spinal 
cord stimulation: an in vivo microdialysis study in the rat. Neurosurgery, 1994. 34(3): p. 484-8; 
discussion 488-9. 
15. Stiller, C.O., et al., Release of gamma-aminobutyric acid in the dorsal horn and suppression of 
tactile allodynia by spinal cord stimulation in mononeuropathic rats. Neurosurgery, 1996. 
39(2): p. 367-74; discussion 374-5. 
16. Cui, J.G., et al., Spinal cord stimulation attenuates augmented dorsal horn release of excitatory 
amino acids in mononeuropathy via a GABAergic mechanism. Pain, 1997. 73(1): p. 87-95. 
17. Cui, J.G., et al., Effect of spinal cord stimulation on tactile hypersensitivity in mononeuropathic 
rats is potentiated by simultaneous GABA(B) and adenosine receptor activation. Neurosci Lett, 
1998. 247(2-3): p. 183-6. 
18. Lind, G., et al., Baclofen-enhanced spinal cord stimulation and intrathecal baclofen alone for 
neuropathic pain: Long-term outcome of a pilot study. Eur J Pain, 2008. 12(1): p. 132-6. 
19. Kriek, N., et al., Preferred frequencies and waveforms for spinal cord stimulation in patients 
with complex regional pain syndrome: A multicentre, double-blind, randomized and placebo-
controlled crossover trial. Eur J Pain, 2016. 
Chapter 4 
94 
20. Ahmed, S., et al., Burst and high frequency stimulation: underlying mechanism of action. Expert 
Rev Med Devices, 2018. 15(1): p. 61-70. 
21. De Ridder, D., et al., A 2-center comparative study on tonic versus burst spinal cord stimulation: 
amount of responders and amount of pain suppression. Clin J Pain, 2015. 31(5): p. 433-7. 
22. Tiede, J., et al., Novel spinal cord stimulation parameters in patients with predominant back 
pain. Neuromodulation, 2013. 16(4): p. 370-5. 
23. Deer, T., et al., Success Using Neuromodulation With BURST (SUNBURST) Study: Results From 
a Prospective, Randomized Controlled Trial Using a Novel Burst Waveform. Neuromodulation, 
2018. 21(1): p. 56-66. 
24. De Ridder, D., et al., Burst spinal cord stimulation: toward paresthesia-free pain suppression. 
Neurosurgery, 2010. 66(5): p. 986-90. 
25. De Ridder, D., et al., Burst spinal cord stimulation for limb and back pain. World Neurosurg, 
2013. 80(5): p. 642-649 e1. 
26. de Vos, C.C., et al., Burst spinal cord stimulation evaluated in patients with failed back surgery 
syndrome and painful diabetic neuropathy. Neuromodulation, 2014. 17(2): p. 152-9. 
27. De Ridder, D. and S. Vanneste, Burst and Tonic Spinal Cord Stimulation: Different and Common 
Brain Mechanisms. Neuromodulation, 2016. 19(1): p. 47-59. 
28. Crosby, N.D., et al., Burst and Tonic Spinal Cord Stimulation Differentially Activate GABAergic 
Mechanisms to Attenuate Pain in a Rat Model of Cervical Radiculopathy. IEEE Trans Biomed 
Eng, 2015. 62(6): p. 1604-13. 
29. Seltzer, Z., R. Dubner, and Y. Shir, A novel behavioral model of neuropathic pain disorders 
produced in rats by partial sciatic nerve injury. Pain, 1990. 43(2): p. 205-18. 
30. Truin, M., et al., Successful pain relief in non-responders to spinal cord stimulation: The 
combined use of ketamine and spinal cord stimulation. European Journal of Pain, 2011. 15(10). 
31. Truin, M., et al., Increased efficacy of early spinal cord stimulation in an animal model of 
neuropathic pain. Eur J Pain, 2011. 15(2): p. 111-7. 
32. Meuwissen, K.P.V., et al., Burst Spinal Cord Stimulation in Peripherally Injured Chronic 
Neuropathic Rats: A Delayed Effect. Pain Pract, 2018. 
33. Meuwissen, K.P.V., et al., Conventional-SCS vs. Burst-SCS and the Behavioral Effect on 
Mechanical Hypersensitivity in a Rat Model of Chronic Neuropathic Pain: Effect of Amplitude. 
Neuromodulation, 2018. 21(1): p. 19-30. 
34. Pluijms, W.A., et al., The effect of spinal cord stimulation frequency in experimental painful 
diabetic polyneuropathy. Eur J Pain, 2013. 17(9): p. 1338-46. 
35. Chaplan, S.R., et al., Quantitative assessment of tactile allodynia in the rat paw. J Neurosci 
Methods, 1994. 53(1): p. 55-63. 
36. Magoul, R., et al., Anatomical distribution and ultrastructural organization of the GABAergic 
system in the rat spinal cord. An immunocytochemical study using anti-GABA antibodies. 
Neuroscience, 1987. 20(3): p. 1001-9. 
37. Smits, H., et al., Effect of spinal cord stimulation in an animal model of neuropathic pain relates 
to degree of tactile "allodynia". Neuroscience, 2006. 143(2): p. 541-6. 
38. Smits, H., M. van Kleef, and E.A. Joosten, Spinal cord stimulation of dorsal columns in a rat 
model of neuropathic pain: evidence for a segmental spinal mechanism of pain relief. Pain, 
2012. 153(1): p. 177-83. 
39. Malan, T.P., H.P. Mata, and F. Porreca, Spinal GABA(A) and GABA(B) receptor pharmacology in 
a rat model of neuropathic pain. Anesthesiology, 2002. 96(5): p. 1161-7. 
40. van Beek, M., et al., Spinal cord stimulation in experimental chronic painful diabetic 
polyneuropathy: Delayed effect of High-frequency stimulation. Eur J Pain, 2016. 
41. Mills, C., et al., Estimating efficacy and drug ED50's using von Frey thresholds: impact of weber's 
law and log transformation. J Pain, 2012. 13(6): p. 519-23. 
Burt and Tonic SCS: Spinal GABAergic mechanisms 
95 
42. Hao, J.X., X.J. Xu, and Z. Wiesenfeld-Hallin, Intrathecal gamma-aminobutyric acidB (GABAB) 
receptor antagonist CGP 35348 induces hypersensitivity to mechanical stimuli in the rat. 
Neurosci Lett, 1994. 182(2): p. 299-302. 
43. Sivilotti, L. and C.J. Woolf, The contribution of GABAA and glycine receptors to central 
sensitization: disinhibition and touch-evoked allodynia in the spinal cord. J Neurophysiol, 1994. 
72(1): p. 169-79. 
44. Smits, H., et al., Experimental spinal cord stimulation and neuropathic pain: mechanism of 
action, technical aspects, and effectiveness. Pain Pract, 2013. 13(2): p. 154-68. 
45. Cui, J.G., B. Linderoth, and B.A. Meyerson, Effects of spinal cord stimulation on touch-evoked 
allodynia involve GABAergic mechanisms. An experimental study in the mononeuropathic rat. 
Pain, 1996. 66(2-3): p. 287-95. 
46. Mogil, J.S., Animal models of pain: progress and challenges. Nat Rev Neurosci, 2009. 10(4): p. 
283-94. 
47. Jonathon Miller, S.E., Eric Buchser, Lisa M. Johanek,  Yun Guan, MD, Bengt Linderoth., 
Parameters of Spinal Cord Stimulation and Their Role in Electrical Charge Delivery. 
Neuromodulation: Technology at the Neural Interface, 2016: p. 12. 
48. Abejon, D., et al., Is the introduction of another variable to the strength-duration curve 
necessary in neurostimulation? Neuromodulation, 2015. 18(3): p. 182-90; discussion 190. 
49. Holsheimer, J., et al., The effect of pulse width and contact configuration on paresthesia 
coverage in spinal cord stimulation. Neurosurgery, 2011. 68(5): p. 1452-61; discussion 1461. 
50. Barchini, J., et al., Spinal segmental and supraspinal mechanisms underlying the pain-relieving 
effects of spinal cord stimulation: an experimental study in a rat model of neuropathy. 
Neuroscience, 2012. 215: p. 196-208. 
51. Song, Z., et al., Pain relief by spinal cord stimulation involves serotonergic mechanisms: an 
experimental study in a rat model of mononeuropathy. Pain, 2009. 147(1-3): p. 241-8. 
52. Linderoth, B., et al., Dorsal column stimulation induces release of serotonin and substance P in 
the cat dorsal horn. Neurosurgery, 1992. 31(2): p. 289-96; discussion 296-7. 
53. Saade, N.E. and S.J. Jabbur, Nociceptive behavior in animal models for peripheral neuropathy: 
spinal and supraspinal mechanisms. Prog Neurobiol, 2008. 86(1): p. 22-47. 
54. Foreman, R.D. and B. Linderoth, Neural mechanisms of spinal cord stimulation. Int Rev 
Neurobiol, 2012. 107: p. 87-119. 
55. Linderoth, B. and R.D. Foreman, Physiology of spinal cord stimulation: review and update. 
Neuromodulation, 1999. 2(3): p. 150-64. 
56. Meuwissen, K.P.V., et al., Response to: Fundamental Differences in Burst Stimulation Waveform 
Design: Eliminating Confusion in the Marketplace. Neuromodulation, 2018. 21(7): p. 721-722. 
57. Falowski, S.M., Fundamental Differences in Burst Stimulation Waveform Design: Eliminating 
Confusion in the Marketplace. Neuromodulation, 2018. 21(3): p. 320. 
58. Saade, N.E., et al., Modulation of segmental mechanisms by activation of a dorsal column 
brainstem spinal loop. Brain Res, 1984. 310(1): p. 180-4. 
 

 97 
CHAPTER 5 
 
Burst and Tonic Spinal Cord Stimulation in the 
Mechanical Conflict-Avoidance System:  
Cognitive-Motivational Aspects 
 
Koen P.V. Meuwissen, Maarten van Beek,, Elbert A. J. Joosten. 
 
Accepted in Journal of Neuromodulation: Technology at the Neural Interface 2019  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Supraspinal Mechanisms of Burst and Tonic SCS: a fMRI Study 
99 
Abstract 
 
Background: Clinical research suggests that a novel spinal cord stimulation (SCS) waveform, 
known as Burst-SCS, specifically targets cognitive-motivational aspects of pain. The 
objective of the present study was to assess the cognitive-motivational aspects of Tonic- 
and Burst SCS-induced pain relief, by means of exit latency in the Mechanical Conflict-
Avoidance System (MCAS), in a rat model of chronic neuropathic pain. 
 
Methods: Exit latency on the MCAS operant testing setup was evaluated at various probe 
heights for rats (n = 26) with chronic neuropathic pain induced by a partial sciatic nerve 
ligation (PSNL). Von Frey paw withdrawal analysis was performed to assess mechanical 
hypersensitivity. In a second experiment (n = 12), the behavioral effect of Tonic SCS or 
biphasic Burst SCS on both Von Frey analysis and MCAS exit latency was assessed. 
 
Results: Burst SCS exit latencies differed significantly from Tonic SCS exit latencies at 4 mm 
probe height (3.8 vs 5.8 secs respectively; p < 0.01) and 5 mm probe height (3.2 vs 5.4 secs 
respectively; p < 0.05). This difference was not detected with reflex-based Von Frey testing 
(Tonic-SCS vs. Burst-SCS at 30 mins stimulation: p = 0.73, and at 60 mins stimulation; p = 
0.42) 
 
Conclusions: Testing of MCAS exit latency allows for detection of cognitive-motivational 
pain relieving aspects induced by either Tonic- or Burst-SCS in treatment of chronic 
neuropathic rats. Our behavioral findings strongly suggest that Burst-SCS specifically affects, 
much more than Tonic-SCS, the processing of cognitive-motivational aspects of pain. 
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Introduction 
 
The preclinical Spinal Cord Stimulation (SCS) field calls for an operant testing method able 
to assess cognitive-motivational aspects of pain [1]. This is becoming increasingly important  
now that recent electroencephalography findings suggest that Burst and Tonic SCS may 
have different supraspinal working mechanisms; Burst SCS is hypothesized to selectively 
modulate brain areas associated with the processing of attention-related cognitive-
motivational aspects of pain [2, 3]. Meanwhile, the majority of preclinical SCS studies still 
rely on reflex-mediated Von Frey analysis, a technique unable to assess supraspinal 
cognitive-motivational aspects of pain [4-12]. Recently, an operant testing method was 
introduced which assesses cognitive and motivational aspects of pain in animals: the 
Mechanical Conflict-Avoidance System (MCAS) [13]. With the MCAS the animal is placed in 
a brightly lit compartment which leads to a passage with a height-adjustable array of 
nociceptive probes. The animal needs to cross the nociceptive probes to enter the innately 
preferred dark area. The “lesser of two evils principle” forces the animal to choose between 
two opposing motivational drives: to stay in the aversive, yet non-noxious, brightly lit 
compartment, or, to cross the noxious probes, which is rewarded by the innately preferred 
dark compartment. In order to resolve this conflict it is hypothesized that the animal applies 
a “cost-benefit” analysis including the level of ongoing pain, the height of the probes, and 
the averseness of the light (= negative reinforcement) [14]. In general, as ongoing pain 
intensity and/ or probe height increases, animals require more time to exit the light 
chamber. Latency to exit the light chamber (defined as time from light being turned on to 
having all four paws on the probe bed) has been shown to be a stimulus-dependent 
measure in the Coy-MCAS system. Chronic neuropathic pain, induced by chronic 
constriction of the sciatic nerve, has been shown to affect latency to exit the bright 
compartment in the MCAS [15]. However, other neuropathic pain models still remain to be 
validated in the MCAS-setup. Furthermore, it is of great interest to the preclinical SCS field 
to assess whether the MCAS can shed light on the supraspinal mechanisms of Burst and 
Tonic SCS by addressing the cognitive-motivational aspects of pain that are becoming 
increasingly important for the assessment of novel SCS waveforms [3, 16].  
Our first objective was to assess the effect of the partial sciatic nerve ligation rat model 
for chronic neuropathic pain on exit latency in the MCAS.  As cognitive-motivational aspects 
cannot be detected by reflex-based Von Frey analysis, our second objective was to assess 
the cognitive-motivational aspects of Tonic- and Burst SCS-induced pain relief, by means of 
exit latency in the MCAS operant testing system. We hypothesized that both Tonic- and 
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Burst SCS would reduce MCAS exit latency, which will suggest a role for cognitive-
motivational aspects in SCS-induced pain relief. Furthermore, based on literature indicating 
that Burst SCS selectively modulates brain areas associated with the processing of attention-
related cognitive-motivational aspects of pain, we hypothesized that Burst-SCS would have 
a stronger effect on MCAS exit latency, as compared to Tonic-SCS [2, 3]. 
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Materials and Methods 
 
Ethics Statement 
All experiments were performed in accordance with the European Directive for the 
Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes 
(86/609/EU). The protocol was approved by the Animal Research Committee of the 
Maastricht University Medical Centre (DEC-protocol 2014-086). 
 
Animals  
All experiments were performed using male Sprague Dawley rats (n=38), which were young-
adult (5 weeks of age) at the start of the experiment (150–200 g). Animals were housed in 
groups of 2, in filter-top polycarbonate cages in a climate-controlled vivarium maintained 
under controlled temperature (21 ± 1°C), relative humidity (55 ± 15%) and artificial lighting 
(12:12 hour light/dark cycle) with distilled water and rodent chow available ad libitum. The 
vivarium was equipped with a mobile radio, continuously producing background music at 
45 decibels, in order to desensitize the animals for translocation and experimenter-related 
noise. All procedures were conducted between 09:00 and 16:00 hours.  
 
Partial Sciatic Nerve Ligation (PSNL)  
A unilateral ligation of the left sciatic nerve was performed as described by Seltzer et al. 
1990 [17], and previously applied in our laboratory  [9, 10]. In short, animals were 
anesthetized with 3–5% isoflurane (Abbott Laboratories Ltd., Kent, U.K.). The left sciatic 
nerve was exposed by blunt dissection and carefully freed from surrounding connective 
tissue. For sham-PSNL animals, the sciatic nerve was left unaffected and the wound was 
closed with a 4/0 silk suture. For PSNL animals, distal to the posterior biceps 
semitendinosus, but proximal to the little fat pad that lies a few millimeters distal to this 
site, the sciatic nerve was partially ligated. An 8/0 non-absorbable silk suture was used to 
ligate approximately 1/3 of the diameter of the left sciatic nerve. After ligation, the wound 
was closed with a 4/0 silk suture. The presence of mechanical hypersensitivity was 
considered successful if at 13 days post-surgery, paw withdrawal thresholds (PWTs) to Von 
Frey stimuli (10log (50%)) were decreased by 0.2 units compared with baseline (day 0) [9, 
10].  
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Assessment of mechanical hypersensitivity (von Frey assay)  
Assessment of PWTs was performed according to the standard protocol [7-10]. Mechanical 
hypersensitivity based on PWT was assessed according to the ‘up-down method’ [18]. The 
50% PWT was calculated after completion of a sequence of six consecutive responses. A 
cut-off value of 28.84 g was defined. For statistical analysis, 50% PWTs were logarithmically 
transformed to obtain a linear scale.  
 
Mechanical Conflict-Avoidance System (MCAS) 
Familiarization and Training. Familiarization and Training was conducted as described in 
detail by Harte et al. 2016 [13].  
Testing Procedure. Rats underwent room acclimation for 30 minutes prior to the start of 
behavioral testing each day. Rats were placed individually, in random order, into the start-
compartment with the light turned off and the exit door closed. Animals were acclimatized 
to the dark for 15 seconds, before the compartment light was turned on for the duration of 
the test. Twenty seconds after the light was turned on the exit door was opened. The latency 
to exit the light compartment was recorded by means of a stopwatch, starting from the time 
the exit door was opened until all four paws were placed upon the nociceptive probes. If 
the animal reached the dark compartment, the door was closed and the rat was returned 
gently to its home cage after being rewarded with 20 seconds of darkness. Failure to exit 
the light compartment within 20 seconds after opening of the exit door was marked as 
‘failed exit’, which resulted in the exit door being closed and the rat being returned to its 
home cage. Rats that successfully escaped the light compartment but failed to enter the 
dark compartment after 120 seconds, were marked as failed cross, and were returned to 
their home cage until the next trial. The test procedure was repeated three times (trials) 
per test session (a minimum of 20 minutes between trials), with one test session per probe 
height, per day. It was decided to introduce the different probe heights in a non-randomized 
ascending order over the six test days (starting with 0.5 mm on test day 1, followed by 1 
mm on test day 2, 2 mm on test day 3, 3 mm on test day 4, 4 mm on test day 5, and 5 mm 
on day 6). All test sessions were video-recorded with an ultra-wide angle glass lens camera. 
Recordings were started immediately after the animal was placed inside the start-
compartment (with the light turned off), and were continued until the animal was returned 
to its home cage. After finalization of the entire experiment all recordings of exit latency 
were re-timed with a stopwatch, and compared with the manually collected data acquired 
during the experiment.  
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Implantation of spinal cord stimulation device 
The implantation of the SCS device was performed according to the standard protocol [4, 6, 
7, 10-12, 19]. In short, the spinal cord was exposed by a midline, lumbar incision, followed 
by laminectomy at level T13. During the full procedure, the dura was kept intact. A custom-
made cylindrical 4-contact lead (0.72 mm diameter; Boston Scientific Neuromodulation, 
Valencia, CA, USA) was introduced into the epidural space as previously was performed in 
Meuwissen et al. [6, 7]. The electrode was located caudally below the adjacent one or two 
lamina. Electrode configuration was set at alternating cathode and anode settings (rostral 
to caudal: + - + -). After implantation of the electrodes, the rats were given 2 days for 
recovery prior to the initiation of SCS. 
 
Spinal cord stimulation (SCS) 
Tonic-SCS was performed according to the protocol described in Meuwissen et al. [6, 7]. 
The stimulator was set to deliver constant current biphasic stimulation, with a frequency of 
50 Hz and a pulse width of 200 µS at 66% of the Motor Threshold for Tonic SCS (n = 5) [7, 
10]. For biphasic Burst SCS (n = 5) the stimulator was set to an interburst-frequency 40 Hz, 
a pulse width 1000 μS, and 5 active biphasic spikes at 449 Hz intraburst frequency at 50% 
of the Motor Threshold [6, 7]. Animals were stimulated for 30 min. in the MCAS-set-up, with 
the light turned off and the door closed. Subsequently stimulation was continued during 
the MCAS-testing session, which was performed according to the standard MCAS-testing 
protocol. The animals were randomized across experimental groups, and the investigator 
was blinded to the experimental condition during behavioral testing. SCS in the MCAS-
system was performed with use of a custom-made experimental apparatus. The cables from 
the stimulator were guided to a swivel, which allowed 360◦ free movement. The cable was 
then further guided to the SCS connectors in the neck of the animal by means of a fender-
tension spring system which generated the appropriate amount of tension in order to 
prevent any slacking of the cables. The upper cover of the MCAS crossing area was removed 
to create access for the SCS-system. Removal of the upper cover was performed at the start 
of the experiment, before the training phase, to prevent distraction of the animal due to 
removal. Furthermore, animals underwent an additional training period of three days with 
the complete experimental apparatus before start of the SCS experiment, for the animals 
to become familiarized with the experimental apparatus before testing. To control for the 
effects of SCS in the MCAS-system, a sham-SCS group was included (n=2).  
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Timeline of experiments 
After acclimatization to the vivarium, a two-day familiarization period was initiated, 
followed by a five-day training period [13]. This was followed by a two-day rest period, after 
which the baseline (pre-PSNL) test period was initiated, which consisted of six subsequent 
days of testing as described above. Subsequently, animals received either PSNL (n = 18) or 
sham-PSNL surgery (n = 8). Following a 14 day observation period, during which animals 
underwent von Frey behavioral analysis in order to assess whether mechanical 
hypersensitivity was successfully induced, animals were subjected to a two-day “refresher” 
training period (PSNL [n = 17] and sham-PSNL [n = 8]). During these two days it was noted 
whether animals still displayed stable exit behavior. Finally, a six day, post-PSNL, testing 
period was initiated, identical to the baseline test period (PSNL [n = 17] and sham-PSNL [(n 
= 8]) (Fig.1). In a second experiment (Fig.2), 12 animals received PSNL surgery and were 
subjected to the training- and testing period as described above. This period was followed 
by the implantation of the SCS-electrode, and a post-implantation (Pre-SCS) test week to 
assess possible implantation-related effects on the MCAS-outcome. Subsequently, two 
animals received Sham SCS, and the other animals (n = 10) were placed in the MCAS-system 
after which simultaneous MCAS-SCS testing was performed as described in section 2.7. Five 
animals received Burst SCS (n = 5), while the other five animals received Tonic SCS (n = 5).   
 
 
Fig.1: Timeline experiment 1 
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Data Analysis 
The PWTs to von Frey filaments are presented as mean ± standard error of the mean (SEM). 
For statistical analysis von Frey data were logarithmically transformed to obtain a linear 
scale to account for Weber’s Law [20]. For the analysis of differences in the withdrawal 
thresholds between groups, ipsilateral and contralateral PWTs were compared using 
paired-sampled T-tests. To account for skewness of data at higher probe heights MCAS exit 
latencies were logarithmically transformed. Effects of probe height on exit latencies were 
analyzed using repeated-measures Analysis Of Variance (ANOVA). Probe height (6 levels: 0, 
1, 2, 3, 4, and 5 mm) was assigned as within-subjects factor and the experimental group 
(Sham-PSNLvs PSNL or Pre-SCS vs SCS) was assigned as between-subjects factor. If the 
assumption of sphericity was violated, the Greenhouse-Geisser correction was used to 
correct the degrees of freedom in subsequent univariate analyses. Multivariate analyses 
were used to test for differences between groups at specific probe heights. To assess within-
group differences for the Sham-PSNL vs PSNL group, pre- vs post-surgery, and the Pre-SCS 
vs SCS group, paired-samples T-tests were performed. Furthermore, bivariate correlation 
between bodyweights, von Frey data, and MCAS exit- latencies were performed to identify 
possible causalities between the different outcome measures. All statistical analyses were 
performed with α = 0.05 using IBM SPSS statistics 23. 
 
 
Fig.2: Timeline experiment 2 
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Results 
 
Development of mechanical hypersensitivity (von Frey) in chronic neuropathic rats  
Pre-nerve injury, PWTs of the ipsilateral hind paws were comparable with the PWTs of the 
contralateral hind paws (ipsilateral 11.6  ± 1.5 g vs. contralateral 11.1 ± 1.3g) in all animals 
(at day 16 ) in experiment 1 (Fig.3A), and in experiment 2 (ipsilateral 10.9 ±1.1g vs. 
contralateral 11.4±1.5g) (see Fig.3B). Out of the 18 animals that received a unilateral PSNL 
in experiment 1, one animal did not develop mechanical hypersensitivity, and was excluded 
from the study (pre- and post-surgery). The remaining 17 animals qualified as 
hypersensitive to mechanical stimulation by von Frey filaments (ipsilateral average PWTs: 
11.6 ± 1.5 g [pre-lesion] vs. 1.6 ± 0.9 g [post-lesion]; p = .0057) (see Methods) and were 
selected for the PSNL-group (Fig. 3A). The ipsilateral hindpaw PWTs of the PSNL-group were 
significantly lower than the ipsilateral hindpaw PWTs of the sham-operated animals (p = 
0.012). In the Sham-PSNL group, no significant difference between ipsilateral and 
contralateral PWTs was observed (p = 0.27), following the Sham-PSNL surgery, therefore, 
all 8 animals were selected for the Sham-PSNL group. Out of the 12 PSNL-animals in 
experiment 2, all 12 animals were qualified as hypersensitive due to increased response to 
mechanical stimulation by von Frey filaments (ipsilateral average PWTs: 10.9 ± 1.1 g (pre-
lesion) vs. 1.3 ± 1.6 g (post-lesion); p = 0.0042) (see Methods) and were selected for the SCS-
group (Tonic or Burst SCS) (Fig.3B).  
 
 
Fig. 3 A: The effect of a Partial Sciatic Nerve Ligation (PSNL) (n = 17) on PWTs in Experiment 1. After 
PSNL, the ipsilateral PWTs of the PSNL-group were significantly decreased at day 20, 25, 31 and 38, 
compared to the contralateral PWTs. B: The effect of a PSNL (n = 12) on PWTs in Experiment 2. After 
PSNL, the ipsilateral PWTs were significantly decreased at day 20, 25, 31, 38 and 43 compared to 
contralateral PWTs.  
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Effect of SCS: von Frey analysis 
In animals of the SCS-group paw withdrawal thresholds (PWTs) to von Frey filaments was 
assessed before the start of SCS treatment (Tonic or Burst SCS) and at 30 and 60 mins after 
stimulation was turned on. No significant differences were observed in ipsilateral paw PWTs 
at baseline, pre-SCS, between groups (p = 0.54; Tonic-SCS 1.2 ± 0.5g [n = 5] vs. Burst-SCS 1.3 
± 0.4g [n = 5]). After 30 mins of stimulation, PWTs of both the Burst-SCS group (p = 0.0021; 
1.3 ± 0.4 g vs. 9.1 ± 1.1 g) and Tonic-SCS group (p = 0.028; 1.2 ± 0.5 g vs. 9.5 ± 1.5 g) 
significantly differed from baseline PWTs (Fig.5). After 60 mins of stimulation, PWTs of both 
the Burst-SCS group (p = 0.0016; 1.3 ± 0.4 g vs. 10.4 ± 1.3 g) and Tonic-SCS group (p = 0.034; 
1.2 ± 0.5 g vs.9.1 ± 1.4 g) significantly differed from baseline PWTs (Fig. 5). PWTs of the 
Burst-SCS group and Tonic-SCS group did not significantly differ at 30 mins of stimulation (p 
= 0.73; Tonic-SCS 9.5 ± 1.5 g [n = 5] vs. Burst-SCS 9.1 ± 1.1 g [n = 5]) and 60 mins of 
stimulation (p = 0.42; Tonic-SCS 9.1 ± 1.4 g [n = 5] vs. Burst-SCS 10.4 ± 1.3 g [n = 5]) (Fig.5).  
 
 
Fig. 5: The effect of Tonic-SCS (n = 5) and Burst-SCS (n =5) on PWTs based on sensitivity to von Frey 
filaments. PWTs were assessed at baseline (stimulation off) and 30 and 60 mins of SCS. The dotted 
line represents the average PWT baseline prior to sciatic nerve ligation (*p < 0.05 for Tonic SCS 
compared with pre-SCS baseline PWTs, # p < 0.05 for Burst SCS compared with pre-SCS baseline 
PWTs). 
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Mechanical Conflict-Avoidance Test in chronic neuropathic rats 
 
Exit Latency 
Stimulus-response functions were obtained for PSNL (n = 17) and sham-PSNL rats (n = 8) in 
the MCAS both at pre-surgery (days 9–14) and at post-surgery (days 33–38). Pre-surgery: a 
significant main effect of probe height (F3.264 = 21.971; p < 0.001), but no significant 
interaction between probe height and group was found, suggesting that both PSNL and 
Sham-PSNL animals exhibited equal increase in exit latency as a function of probe height. 
Post-surgery: a significant main effect of probe height was noted (F3.089 = 19.722; p < 
0.001) (Fig 4). No significant interaction effect between probe height and group was 
observed. Tests of Between-subject effects approached significance (F1=3.427; p = 0.077), 
suggesting that exit latencies were different for PSNL- and sham-PSNL animals, post-
surgery. Furthermore, at 4 mm probe height, the exit latencies of the PSNL group and sham-
PSNL group significantly differed (18.84 vs 10.62 s; p =.038), whereas exit latencies of the 
PSNL group and sham-PSNL group at 3 mm probe height closely approached significance 
(9.64 vs 5.5 s; p = 0.053).  
 
 
Fig. 4: Stimulus response relationship of escape latency as a function of probe height between, PSNL-
rats (n = 17), and sham-PSNL rats (n = 8). As probe height increases, escape latency also increases in 
both experimental groups (p < 0.001). Escape latencies of PSNL rats were significantly greater than 
those of sham-PSNL rats at 4 mm probe height (18.84 vs 10.62 s; p = 0.038). 
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Effect of SCS: MCAS exit latency 
 
Post-PSNL and Pre-SCS MCAS exit latencies did not significantly differ (F1 = 0.2717; p = 
.6069). Thus, the implantation of the electrode itself did not have a significant effect on 
MCAS exit latency. Group differences in MCAS exit latency were assessed for the Pre-Tonic 
SCS group (the Tonic SCS group pre-stimulation) and Tonic SCS group (n = 5); a significant 
main effect of probe height (F5 = 21.92; p < 0.0001), and a significant interaction between 
probe height and group (F5 = 3.255; p = 0.0147) was noted (Fig 6), which indicates that 
MCAS exit latencies were different pre-Tonic SCS and during Tonic SCS. This was confirmed 
by a significant between subjects effect, where the pre-Tonic SCS group and Tonic SCS group 
significantly differed overall in exit latencies (F1= 22.42; p =.0015). Furthermore, Pre-Tonic 
SCS and Tonic SCS groups significantly differed at 2 mm probe height (6.2 vs 3.0 secs; p < 
.05), 3 mm probe height (7.8 vs 3.4 secs; p < .001), and 4 mm probe height (10.0 vs 5.8 s; p 
< .01). 
Group differences in MCAS exit latency were also assessed for the pre-Burst SCS (the 
Burst SCS group pre-stimulation) and Burst SCS group (n = 5); a significant main effect of 
probe height (F5 = 13.78; p < 0.0001), and a significant interaction between probe height 
and group (F5 = 7.797; p = 0.0001) was noted (Fig 7), which indicates that MCAS exit 
latencies differed between pre-Burst SCS and during Burst SCS. This was confirmed by a 
significant between subjects effect, where the pre-Burst SCS group and Burst SCS group 
significantly differed overall in exit latencies (F1= 31.49; p = 0.0005).  Furthermore, pre-
Burst SCS and Burst SCS groups significantly differed at 2 mm probe height (7.2 vs 2.4 secs; 
p < 0.01), 3 mm probe height (9.0 vs 2.8 secs; p < 0.001), 4 mm probe height (9.6 vs 3.8; p < 
0.001), and 5 mm probe height (10.8 vs 3.2 secs; p < 0.001).   
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Fig. 6: Stimulus response relationship of escape latency as a function of probe height between Pre-
SCS group and Tonic SCS group (n = 5). Escape latencies of SCS rats were significantly lower than those 
of Pre-SCS group rats at 2 mm probe height (6.2 vs 3.0 secs; p  < 0.05), 3 mm probeheight (7.8 vs 3.4 
secs; p < 0.001), 4 mm probe height (10.0 vs 5.8 secs; p < 0.01), and 5 mm probeheight (8.2 vs 5.0 
secs; p < 0.05). 
 
 
 
Fig. 7: Stimulus response relationship of escape latency as a function of probe height between Pre-
SCS group and Burst SCS group (n = 5). Escape latencies of SCS rats were significantly lower than those 
of Pre-SCS group rats at 2 mm probe height (7.2 vs 2.4 secs; p < 0.01), 3 mm probe height (9.0 vs 2.8 
secs; p < .001), 4 mm probe height (9.6 vs 3.8 secs; p < 0.001), and 5 mm probe height (10.8 vs 3.2 
secs; p < 0.001). 
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Area Between the Curve (ABC) analysis revealed a significant difference between the ABC 
for Pre-Burst and Burst and the ABC for Pre-Tonic and Tonic SCS (24.6 vs 15.4 secs 
respectively; p = 0.0225). Furthermore, post-hoc analysis revealed a significant difference 
between the Tonic-SCS group and the Burst-SCS group at 4 mm probe height (5.8 vs 3.8 secs 
respectively; p < .01) and 5 mm probe height (5.4 vs 3.2 secs respectively; p < 0.05) (Fig.6+7). 
No significant differences were observed between the Pre-Sham-SCS group and the Sham-
SCS group (F 1= 63.02; p = 0.481; n = 2). 
 
 
 
Fig. 8: Area Between the Curves for escape latency for the Pre-Tonic SCS group and Tonic SCS group 
(n = 5) and for the Pre-Burst SCS group and Burst SCS group (n = 5). Area Between the Curve (ABC) 
analysis revealed a significant difference between the ABC for Pre-Burst and Burst and the ABC for 
Pre-Tonic and Tonic SCS (24.6 vs 15.4 respectively; p= 0.0225). 
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Discussion 
 
Our first objective was to assess the effect of the partial sciatic nerve ligation (PSNL) rat 
model for chronic neuropathic pain on exit latency in the MCAS. A significant difference at 
4 mm probe height between exit latencies of neuropathic animals and sham-animals, 
demonstrates that the MCAS-setup is a valid operant testing method for the assessment of 
affective-motivational aspects of pain in neuropathic PSNL-rats. The second objective was 
to assess the cognitive-motivational aspects of Tonic- and Burst SCS-induced pain relief, by 
means of exit latency in the MCAS. This revealed significant differences in cognitive-
motivational behavior for Burst-SCS and Tonic-SCS, and these differences could not be 
detected by reflex-based von Frey testing. Burst-SCS furthermore seems to specifically 
modulate, much more than Tonic-SCS, cognitive-motivational aspects of pain behavior. 
 
MCAS Exit Latency                                                                                                                                                             In 
this study, it was demonstrated how latency to exit from the light compartment in the MCAS 
was significantly increased in chronic neuropathic PSNL-rats, indicating a stimulus-response 
relationship. At 4 mm probe height PSNL-animals required significantly more time to exit 
the light compartment, compared with sham animals. In this respect, use of 4 mm probe 
height provides the most optimal window, allowing for discrimination between injured 
versus sham control animals and thus, for assessment of peripheral neuropathic pain. These 
findings are in line with those reported by Harte et al. (2016): here a similar significant 
difference in exit latency at 4 mm probe height was noted between naïve animals and CCI-
animals [13]. At 5mm probe height, we observed a sharp drop in exit latency for PSNL-
animals. Unfortunately, in the study performed by Harte et al. 2016, results from 5mm 
probeheight were not presented. Therefore, we were unable to compare data at 5mm 
probeheight with previous literature. Since we presented the probeheights in incremental 
order there is the possibility that the PSNL-animals went through a learning curve. Hence, 
at the fifth probeheight, the “cost-benefit” analysis including the level of ongoing pain, the 
height of the probes, and the averseness of the light might have been overruled by a primal 
instinct to carry through with the oncoming painful stimulus as quickly as possible.  Another 
important difference between our findings and the findings of Harte and colleagues is that 
the animals in our study exhibit overall lower exit latencies. This could be related to the fact 
that Harte and colleagues performed their experiments in the inactive (light) phase of the 
rodent circadian rhythm, as compared to our experiments which were performed during 
the active (dark) phase [21]. 
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In 2008, Vierck and colleagues already addressed the relevance of operant testing, after 
reviewing several dissociations between reflex-based testing methods and operant testing 
methods. Interestingly, after closer examination of the aforementioned dissociations they 
discovered that operant testing more often resulted in a clinically concordant outcome [1, 
22]. It is furthermore known that various experimental manipulations do not affect reflex 
and escape responses in a similar manner, including but not limited to, morphine, naloxone, 
stress, subcutaneous formalin injection, cutaneous application of mustard oil, and chronic 
constrictive nerve injury [22-27]. Therefore, although reflex-based testing has contributed 
in many ways to the preclinical SCS field, it has become apparent that analysis of cognitive-
motivational aspects of pain needs to be included. Thus, the MCAS may complement 
current behavioral testing methods [13]. In the MCAS, for exit latency, the animal is forced 
to choose between two opposing motivational drives: 1) escape an aversive, yet non-
noxious setting (light compartment) by subjecting itself to noxious stimuli (the nociceptive 
probes), or 2) avoid the noxious probes but remain in the aversive bright light compartment 
[13]. This process requires a cost-benefit analysis, which requires input from cortical areas 
that process objective aspects of pain. In line with this, we made several observations of 
animals investigating the nociceptive probes with their forelimbs right before the exit 
process in the MCAS testing system. Thus, the fact that MCAS exit latency testing may 
recruit ascending pathways creates an opportunity to assess the involvement of supraspinal 
elements, for instance, as suggested with Tonic-SCS and in particular with Burst-SCS. From 
a broader perspective, including operant testing methods in preclinical assessment 
batteries could provide a valid measurement for the cognitive-motivational aspects of pain, 
which in its turn could prove to be an answer to the lack of translational progress in the pain 
field [1]. 
 
MCAS Exit Latency and Spinal Cord Stimulation 
When Tonic and Burst SCS were administered 30 minutes prior, and during MCAS-testing, a 
significant overall decrease in exit latency was observed for both Tonic and Burst SCS. 
Furthermore, at 4 mm probe height and 5 mm probe height the Tonic SCS group and the 
Burst SCS group significantly differed. The latter seems to suggest that Burst SCS has a more 
profound cognitive-motivational effect when the severity of the nociceptive stimulus is 
increased. Animals that received sham SCS showed no variations in exit latencies. In the 
clinical setting, questionnaires regarding quality of life and patients’ preference tend to lean 
towards Burst SCS, as compared to other SCS-waveforms [28-30]. However, these days, 
there is still no clear consensus in literature, neither preclinical [4, 6, 7] nor clinical [2, 3, 28-
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37], regarding the objective analgesic efficacy of Burst SCS (as measured on the VAS-scale), 
as compared to other SCS-waveforms. A recent clinical study by Kriek and colleagues has 
shown that the preferred stimulation setting is not solely driven by the amount of pain 
reduction, but is also influenced by which stimulation setting feels most comfortable and 
provides the best user-friendliness [35]. Therefore, it is pivotal that we aim to elucidate the 
(supraspinal) mechanisms responsible for the level of comfort, the sensation, that 
accompanies SCS-waveforms. As the MCAS can provide critical insight into cognitive-
motivational processing of SCS, it could serve as a preclinical tool that allows for the 
optimization of supraspinal mechanisms of Burst-SCS. It is important to note that the 
difference between Tonic SCS and Burst SCS, as observed for the exit latencies, was not 
present in the reflex-based Von Frey analysis. This suggests that the MCAS allows for 
assessment of behavioral changes in pain that are not detected by reflex-based testing. 
Interestingly, this is in line with clinical observations that show a similar effect for Burst SCS 
and Tonic SCS on objective measures such as the VAS-scale (no clinically relevant difference) 
[30]. Yet, a subset of patients expresses a preference for Burst SCS, over Tonic SCS, due to 
combination of improved psychological (cognitive-motivational) pain-aspects and the 
absence of unpleasant perceptions such as paresthesia [3, 28, 30, 31, 33-35, 37]. The 
supraspinal properties of Burst SCS were first discovered in 2013 when it was reported that 
Burst SCS could decrease the amount of attention patients paid to pain, in a statistically 
significant way, while Tonic SCS did not show a similar decrease [3]. This was in 2016 
corroborated by a source-localized EEG-study that demonstrated how Burst SCS was able 
to normalize the ‘pain supporting-suppressing balance’ by having a greater effect on the 
dorsal anterior cingulate cortex, as compared to Tonic SCS [2]. From the aforementioned 
studies it was hypothesized that Burst SCS had a specific supraspinal effect on areas 
associated with the medial pain system, a system associated with the affective components 
of the pain experience [3, 38, 39]. Thus, it seems that Burst-SCS not only modulates the 
unpleasant sensory aspects of pain, but also affects the cognitive-motivational, mostly 
supraspinal, aspects of pain. Therefore, it is important that we now have a tool, the MCAS, 
which allows us to adequately assess these supraspinal aspects in a preclinical setting. A 
better understanding of the supraspinal aspects will allow further analyzing and optimizing 
of the emotional/motivational properties of the Burst-SCS-protocol. In conclusion, 
combined use of reflex-based von Frey analysis and the MCAS operant testing method 
provides us with the opportunity to work towards an optimal balance between sensory 
aspects and cognitive-motivational aspects of SCS-induced pain relief [40]. 
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Limitations 
Only male rats were used in order to prevent a potential bias associated with sex-related 
differences in neuropathic pain development in rats [41], and to avoid a potential bias 
related to ovarian sex steroid-induced anti-nociception in female rats [42]. Second, in 
contrast to Harte et al. 2016, we chose to present the various probe heights in incremental 
order, as previous studies have shown that initial exposure to extreme stimuli can result in 
large data variability, which can have a deterrent effect [43].  
 
 
Conclusion 
 
We conclude that the MCAS is a valid and reproducible method for the assessment of SCS-
induced cognitive-motivational behavioral aspects of pain relief. Use of the MCAS operant 
testing method revealed significant differences in cognitive-motivational behavior for Burst 
SCS and Tonic SCS, and this difference could not be detected with reflex-based Von Frey 
testing. Our behavioral findings strongly suggest that Burst-SCS specifically affects, much 
more than Tonic-SCS, the processing of cognitive-motivational aspects of pain. 
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Abstract 
 
Introduction: Spinal Cord Stimulation (SCS) is a last-resort treatment option for a variety of 
intractable neuropathic pain disorders. Pain relief induced by Tonic SCS acts via local spinal 
activation and is known to include supraspinal activation of sensorimotor brain areas. It is 
suggested that a more recently introduced mode of SCS, Burst SCS, modulates cognitive-
motivational aspects of pain. In order to understand supraspinal mechanisms and the 
different aspects of pain relief induced with Tonic or Burst-SCS we used functional magnetic 
resonance imaging (fMRI) in chronic neuropathic rats. Based on literature, we hypothesized 
that both Tonic SCS and Burst SCS would result in increased BOLD-signal in brain regions 
associated with location and intensity of pain, and cognitive-emotional aspects of pain. 
Furthermore, we also hypothesized that Burst SCS would induce a more profound BOLD-
increase in brain areas associated with cognitive-emotional aspects of pain, as compared to 
Tonic SCS. 
 
Methods: Sprague Dawley Rats (n=17) received a unilateral partial sciatic nerve ligation 
which resulted in chronic neuropathic pain. Two weeks after the ligation quadripolar SCS-
electrodes were epidurally positioned on top of the dorsal columns at T13. Isoflurane-
anesthetized (1.5%) rats received either Tonic-SCS (n=8; 200 µs pulse width, 50Hz) or Burst-
SCS (n=9; 5 pulses, 1 ms pulse width, 449 Hz intra-burst, 40Hz inter-burst) at 66% of motor-
threshold (MT). BOLD fMRI was conducted pre-, during and post-SCS using a 9.4T horizontal 
bore scanner (Varian, Palo Alto, CA, USA). SCS was applied in a block-design, which consisted 
of three times 5 minutes of SCS, alternated with three times 5 minutes resting period. 
 
Results: Overall, Tonic SCS resulted in a moderate increase of BOLD signal levels in areas 
associated with the location and intensity of pain such as the primary somatosensory cortex 
(z= 2.7), and the premotor cortex (z=2.8) and areas associated with cognitive-emotional 
aspects of pain such as the anterior cingulate cortex (z=3.2), amygdala (z=3.2) and insular 
cortex (z=4.4). Burst SCS resulted in a larger and more robust increase of BOLD signal levels 
in areas associated with the location and intensity of pain such as the primary 
somatosensory cortex (z= 12.8), and the premotor cortex (z=14.2) and areas associated with 
cognitive-emotional aspects of pain such as the anterior cingulate cortex (z=15.1), amygdala 
(z=11.9) and insular cortex (z=18.4). Additionally, Burst SCS increased BOLD-signal in the 
raphe nuclei (z=8.1), and areas associated with the reward system such as the nucleus 
accumbens (z=13.4), and the caudate putamen (z=17.1). Tonic SCS did not induce a 
significant increase in BOLD-amplitude in these areas.  
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Conclusions: Burst and Tonic SCS have different effects on the intensity and localization of 
SCS-induced changes in BOLD-levels in the brain. Overall, both Tonic SCS- and Burst SCS 
increased BOLD-signal in brain regions associated with location and intensity of pain, and 
cognitive-emotional aspects of pain. However, Burst SCS induced a more profound BOLD-
increase in brain areas associated with cognitive-emotional aspects of pain, as compared to 
Tonic SCS. 
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Introduction 
 
Damage or disease affecting the somatosensory nervous system may result in chronic 
intractable neuropathic pain: a debilitating physical status that greatly influences the quality 
of life. Over the last two decades, Tonic spinal cord stimulation (SCS) with a frequency within 
the range of 40-80 Hz and a pulse width in between 200-500 µSec [1-3], has been 
successfully applied as a last-line treatment option for patients with refractory chronic pain 
syndromes such as failed back surgery syndrome [4-6], complex regional pain syndrome [7-
16] and painful diabetic polyneuropathy [17-19]. Electrical stimulation of the dorsal column 
with Tonic SCS results in action potentials propagating, antidromically, via Aβ-fibers into the 
spinal cord nociceptive network [20-22]. The antidromic stimulation of Aβ-fibers results in 
changed (decreased) release of glutamate, and at the same time, an increased release of 
GABA [23-25]. At the same time, action potentials travel orthodromically via the Aβ-fibers 
in rostral direction to supraspinal centers [26]. Early clinical fMRI-work on the supraspinal 
effects of Tonic SCS has shown modulation of brain regions associated with the lateral 
spinothalamic tract (STT) [27-29]. The lateral STT is responsible for the transmission of 
objective pain-aspects such as the intensity and location of the painful stimulus. This 
pathway projects via the thalamus to cortical areas such as the somatosensory cortex [30, 
31]. An fMRI study performed in eight patients receiving Tonic SCS demonstrated that Tonic 
stimulation increased BOLD-levels in somatosensory cortices, sensorimotor cortex and the 
insula. Furthermore, it was reported that Tonic SCS induced decreased BOLD-signal in the 
primary motor cortices and the primary somatosensory cortex [28]. A more recent fMRI-
study, with twenty patients who received Tonic-SCS treatment for FBSS, reported 
deactivation of the bilateral medial thalamus and its connections to the rostral and caudal 
cingulate cortex and the insula [27]. Interestingly, Deogaonkar and colleagues recently 
reported a decreased connection strength between somatosensory and limbic areas with 
Tonic SCS. This led them to conclude that pain relief from Tonic SCS may also reduce 
negative emotional processing associated with pain [32]. Recently, a novel SCS-mode has 
been introduced able to specifically modulate cognitive-emotional aspects of pain with 
periodic bursts of electric pulses [33, 34]. Electroencephalography-analysis of 5 patients 
who received the SCS-mode, known as Burst SCS, showed a greater normalization of the 
pain supporting/ suppressing balance, and with that better modulation of cognitive-
emotional aspects of pain, as compared to Tonic stimulation mode [35]. In 2013, a small 
clinical study demonstrated that patients who received Burst SCS significantly improved on 
cognitive-emotional pain-aspects like ‘the amount of attention the patients paid to pain’ 
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and ‘changes in pain’ (measured by the Pain Vigilance and Awareness Questionnaire 
(PVAQ)) [33]. Meanwhile, patients who received Tonic or placebo stimulation did not show 
significant differences on the cognitive-emotional pain-aspects. From this, it was suggested 
that Burst SCS might activate both the lateral and the medial STT; as the latter is known to 
contribute specifically to the emotional affective aspects of pain via the cingulate and 
insular cortices and its connections in the brainstem (parabrachial nucleus) and amygdala 
[31, 35].  Nevertheless, the mechanisms underlying the pain relieving effect of Burst SCS 
remain largely unknown, especially on a supraspinal level, and elucidating the 
cognitive/emotion-modulating effects of Burst SCS could aid its optimization process. 
Therefore, we designed an experimental study on SCS-induced pain relief in chronic 
neuropathic animals in which we assessed the Blood-Oxygenation-Level Dependent (BOLD) 
activation patterns in supraspinal brain regions both for both Burst-SCS and for Tonic-SCS. 
Based on literature, we hypothesized that both Tonic SCS- and Burst SCS-induced pain relief 
in chronic neuropathic animals would result in increased BOLD-signal in brain regions 
associated with location and intensity of pain, and cognitive-emotional aspects of pain. 
Furthermore, we also hypothesized that Burst SCS would induce a more profound BOLD-
increase in brain areas associated with cognitive-emotional aspects of pain, as compared to 
Tonic SCS. 
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Methods and Materials 
 
Ethics Statement 
All experiments were performed in accordance with the European Directive for the 
Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes 
(86/609/EU). The protocol was approved by the Animal Research Committee of the 
Maastricht University Medical Centre (DEC-protocol 2014-086). 
 
Animals  
All experiments were performed using male Sprague Dawley rats (n=19), which were 
young-adult (5 weeks of age) at the start of the experiment (150–200 g). Animals were 
housed as groups of 2, in polycarbonate cages in a climate-controlled vivarium maintained 
under controlled temperature (21 ± 1°C), relative humidity (55±15%) and artificial lighting 
(12:12 light/dark cycle) with distilled water and rodent chow available ad libitum. All 
procedures were conducted between 08:00 and 18:00 hours during the light phase of the 
animal facility.  
 
Partial Sciatic Nerve Ligation (PSNL) 
A unilateral ligation of the left sciatic nerve was performed as described by Seltzer et al. 
1990 [36], as previously applied in our laboratory  [37-40]. In short, animals were 
anesthetized with 3–5% isoflurane (Abbott Laboratories Ltd., Kent, U.K.). The left sciatic 
nerve was exposed by blunt dissection and carefully freed from surrounding connective 
tissue. For sham-PSNL animals, the sciatic nerve was left unaffected and the wound was 
closed with a 4/0 silk suture. For PSNL animals, distal to the posterior biceps 
semitendinosus, but proximal to the little fat pad that lies a few millimeters distal to this 
site, the sciatic nerve was partially ligated. An 8/0 non-absorbable silk suture was used to 
ligate approximately 1/3 of the diameter of the left sciatic nerve. After ligation, the wound 
was closed with a 4/0 silk suture. The presence of mechanical hypersensitivity was 
considered successful if at 13 days post-surgery, paw withdrawal thresholds to Von Frey 
stimuli (10log (50%)) were decreased by 0.2 units compared with baseline (day 0) [37-40].  
 
Assessment of mechanical hypersensitivity (von Frey assay) 
Assessment of paw withdrawal threshold (PWT) was performed according to the protocol 
described in Meuwissen et al.[39, 40]. PWT was assessed according to the ‘up-down 
method’ [41]. The 50% PWT was calculated after completion of a sequence of six 
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consecutive responses. A cut-off value of 28.84 g was defined. For statistical analysis, 50% 
WTs were logarithmically transformed to obtain a linear scale.  
 
Implantation of spinal cord stimulation device 
The implantation of the SCS device was performed according to the protocol which is 
applied as standard implantation procedure in our institution [38-40, 42, 43], based on, and 
identical to the method originally developed at the Karolinska Institute [44]. In short, a small 
laminectomy was made at the thoracic level 13 (Th13). The laminectomy was followed by 
careful exposure the spinal cord by use of a surgical rotary tool. Subsequently, a custom-
made cylindrical 4-contact lead (0.72mm diameter; Boston Scientific Neuromodulation, 
Valencia, CA, USA) was inserted into the epidural space on top of the spinal cord and then 
carefully positioned in the caudal direction. Electrode configuration was set at alternating 
anode and cathode settings (rostral to caudal: + - + -). Lastly, the electrode was secured to 
a spinous process with tissue adhesive (Histoacryl®, B Braun Medical BV, Oss, the 
Netherlands) to prevent electrode migration.  Before the wound was closed, electrode wires 
were tunneled subcutaneously to the animal’s hips and the stimulator-connectors were 
attached to the skin. After implantation of the electrodes, the rats were given 2 days for 
recovery prior to the initiation of SCS. 
 
Spinal cord stimulation 
Spinal cord stimulation (SCS) was performed according to the protocol described in 
Meuwissen et al. [40]. The Arduino Uno stimulator was set to deliver constant current 
biphasic stimulation for both the Tonic and Burst SCS modes. Tonic SCS Motor Threshold 
(MT) was determined at the following settings: pulse width of 200µS administered at a 
frequency of 2 Hz. Burst SCS MT was determined at the following settings: pulse width of 
1000µS, five pulses (449 Hz intra-burst frequency) administered at an inter-burst frequency 
of 2 Hz. The amplitude was gradually increased until symmetrical contractions of the hind 
limbs were perceived by hand and/or visually observed. Then, either a Tonic SCS paradigm 
at 66% of MT (frequency 50 Hz, pulse width 200 µS) [23], or a biphasic Burst-SCS paradigm 
at 66% MT (inter-burst-frequency 40 Hz, pulse width 1000 µS, 5 spikes at 449 Hz intra-burst 
frequency) was applied for 60 minutes [39, 40]. 
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MRI acquisition 
All MR experiments were performed in a 9.4 T horizontal bore scanner (Varian, Palo Alto, 
CA, USA) equipped with a 20.5 cm gradient with gradient strengths up to 400 mT/m. An 
actively decoupled and inductively coupled custom-made surface coil (diameter 25 mm) 
was used for reception of the MR signal and for excitation an Helmholtz design actively 
decoupled excitation coil (diameter 80 mm) was used. Rats were intubated and actively 
ventilated while restrained in the scanner by a stereotactic holder with ear plugs and a tooth 
holder. Body temperature was maintained at 37° C with a warm water mat. Oxygen 
saturation and heart rate and end-tidal CO2 were continuously monitored with a pulse 
oximeter and a capnography respectively. After correct positioning of the rat in the scanner 
and shimming the isoflurane level was decreased to 1.5 % and anatomical images were 
obtained using a balanced gradient echo sequence (TR/TE 5/2.5 ms, flip angle 20°, FOV 
40*32*24 mm, 160*128*96 points, slab 14.4mm, nt=3, repeated 4 times with pulse angle 
shifts of 0°,90°,180° and 270°). This acquisition took about 12 minutes and 18 seconds in 
which the new isoflurane level could be established. The anatomical scan was followed by 
a resting state fMRI acquisition of 800 images using a gradient-echo EPI sequence in which 
the phase-encode direction was encoded within the EPI-train and the slice direction was 
phase-encoded, obtaining a 3D image every 862.4 ms (TR/TE 30.8/16 ms, FOV 36*36*16.8 
mm3, 60*60*28 points, flip angle 13°). After the resting state fMRI a series of 660 images 
was acquired using the same EPI acquisition, where the first 180 images were obtained in 
rest condition, followed by 300 images with spinal cord stimulation and ending with 180 
images without stimulation. This sequence was repeated three times with intervals of about 
1 to 2 minutes and followed by a final resting state fMRI acquisition of 800 images.  
 
Experimental design 
The animals received Von Frey testing prior to the partial sciatic nerve ligation (PSNL) as 
described in section 2.3. After the subsequent 14 day observation period, animals received 
Von Frey measurements in order to assess the development of mechanical hypersensitivity. 
All animals that received a unilateral PSNL developed mechanical hypersensitivity measured 
by von Frey filament assays at day 14 post ligation (n=19). These 19 animals received 
implantation of an SCS-electrode, as described in section 2.5. Animals for which the SCS-
electrode was successfully implanted (n=19) were given two days to recover from the 
surgery before the Motor-Threshold (MT) was assessed. Prior to MT-assessment, animals 
were connected to the stimulator as if to receive stimulation. Animals which did not show 
a robust MT (n=2), hence, did not show clear symmetrical contractions of the hind limbs, 
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were excluded from the study and did not receive SCS. The remaining animals (n=17), were 
randomly divided over the Tonic-SCS (n=8) or Burst-SCS group (n=9). Animals were placed 
in the scanner, and received SCS in the scanner as described in section 2.7. Anesthesia was 
induced with 3-5% isoflurane in O2/air (1:4) and animals were endotracheally intubated for 
mechanical ventilation. Anesthesia during scanning was kept at a maintenance-dose of 1.5% 
isoflurane in O2/air (1:4). Animals were placed in the scanner and attached to an Arduino 
Uno stimulator by means of a Mu-metal shielded cable set-up connected to the external 
electrode contacts on the hips.  Stimulator software was linked and synchronized with the 
MRI-acquisition software for adequate timing of stimulation-onset and offset. Animals 
received SCS in the scanner in a block-design that consisted of three times 5 minutes of SCS, 
alternated with three times 5 minutes resting period.  
 
Image processing 
FMRIB’s Software Library (FSL) v5.0 was used for all MRI analyses, unless mentioned 
otherwise. After Fourier transforming of the stimulation EPI-data the first 5 images were 
removed to reduce initial saturation effects. Motion correction was applied using MCFLIRT 
[45]. A median image was obtained from 155 motion corrected images before start of the 
stimulation and this image is corrected for image intensity non-uniformity (caused by the 
surface coil) using the MINC tool N3 [46].This was followed by brain extraction using the 
BET tool implemented in FSL [47]. Additional erosion and expansion steps were added to 
improve the brain mask. The resulting median image and its extracted brain mask were used 
for all later registration steps, including registration of the anatomical image to the fMRI 
image. The motion-corrected fMRI data were low-pass filtered in the Fourier-domain using 
a cut-off frequency of 0.1 Hz using home-made software, after which the first and last 15 
images were removed. To create a template for all block-design fMRI data of the 
experiments, the median image of the first stimulation fMRI data was registered to a 
reference fMRI image using the linear registration tool FLIRT [45, 48], followed by the non-
linear registration Tool FNIRT [49, 50]. The second and third stimulation were first linearly 
registered to the first stimulation data set after which the warp-file of the first stimulation 
series was used for registration to the reference. A two-level generalized linear model 
(GLM) analysis was performed. For this, an on-period of 300 images (after 155 images off) 
convolved with a hemodynamic response function was used as a regressor. This resulted in 
three activation maps (z-maps) per animal. A lower threshold of 5 was used as cut-off value 
for the activation maps. To allow analysis of time series data from specific regions of interest 
(ROIs) a template image for morphometry analysis based on the Paxinos and Watson atlas 
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[51] was used [52, 53]. Non-linear registration (FNIRT) of the fMRI images to the rat 
anatomical image followed by non-linear registration of the anatomical image to the 
template image was performed to allow the projection of the ROIs defined in the Paxinos 
and Watson atlas on the fMRI data. The mean signal of the ROI over time was obtained for 
each rat and each stimulation (activation traces). It was normalized for display by dividing 
the signal with the mean of the first 150 images. Activation traces were also used as input 
for a two-level GLM analysis and the resulting z-values (three per animal) were analyzed. 
 
Data Analysis 
The WTs to von Frey filaments are presented as mean ± standard error of the mean (SEM). 
For statistical analysis Von Frey data were logarithmically transformed to obtain a linear 
scale and to account for Weber’s Law [54]. For the analysis of differences in the withdrawal 
thresholds between groups, ipsilateral and contralateral withdrawal thresholds were 
compared using paired-sampled T-tests. All statistical analyses were performed with α = 
0.05 using IBM SPSS statistics 23. Analysis of BOLD-Amplitude was conducted on normalized 
data by means of a Two-Way ANOVA with Bonferroni Post-hoc analysis. Data for each ROI 
was averaged for all animals of each stimulation-protocol, and subsequently compared for 
the Tonic-SCS group and Burst-SCS group. Two-Way ANOVA with Bonferroni Post-hoc 
analysis was performed for BOLD-Amplitude pre-SCS and during SCS for the Tonic-SCS group 
and Burst-SCS group. Furthermore, Two-Way ANOVA with Bonferroni Post-hoc analysis was 
performed for BOLD-Amplitude of the Tonic-SCS group and Burst-SCS group during SCS. 
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Results 
 
Development of mechanical hypersensitivity in chronic neuropathic rats  
Pre-nerve injury, PWTs of the ipsilateral hind paws were comparable with the PWTs of the 
contralateral hind paws (ipsilateral 15.3 ±1.9g vs. contralateral 15.0±1.4g) in all animals 
(Fig.1A).  All animals that received a unilateral PSNL developed mechanical hypersensitivity 
to stimulation by von Frey filaments (ipsilateral average PWTs: 15.6 ± 1.7g (pre-lesion) vs. 
1.6 ± 0.6g (post-lesion); p = .0045) (Fig 1A). 
 
Effect of SCS: von Frey analysis 
In animals of the SCS-group (n=17) paw withdrawal thresholds (PWTs) to von Frey filaments 
was assessed before the start of SCS treatment (Tonic or Burst SCS), at 30’, 60’ min. after 
stimulation was turned on. No significant differences were observed in ipsilateral paw PWTs 
at baseline, pre-SCS, between groups (p = 0.61; Tonic-SCS 1.6 ± 0.3g [n=8] vs. Burst-SCS 1.7 
± 0.6g [n=9]). After 30 mins of stimulation, PWTs of both the Burst-SCS group (p = 0.031; 1.7 
± 0.6g vs. 12.5 ± 2.8g) and Tonic-SCS group (p = 0.038; 1.6 ± 0.3g vs. 10.7 ± 2.9g) significantly 
differed from baseline PWTs (Fig.1B). After 60 mins of stimulation, PWTs of both the Burst-
SCS group (p = 0.034; 1.7 ± 0.6g vs.11.8 ± 2.1g) and Tonic-SCS group (p = 0.035; 1.6 ± 0.3g 
vs.11.1 ± 2.5g) significantly differed from baseline PWTs (Fig.1B). PWTs of the Burst-SCS 
group and Tonic SCS group did not significantly differ at 30 mins of stimulation (p = 0.44; 
Tonic-SCS 10.7 ± 2.9g [n=5] vs. Burst-SCS 12.5 ± 2.8g [n=5]) and 60 mins of stimulation (p = 
0.67; Tonic-SCS 11.1 ± 2.5g vs. Burst-SCS 11.8 ± 2.1g) (Fig.1B). 
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Fig. 1A: Development of mechanical hypersensitivity, based on paw withdrawal threshold s (PWT) and 
sensitivity to von Frey filaments, after unilateral sciatic nerve ligation in adult rat (n=17). * p < 0.05 for 
ipsilateral versus contralateral. B: The effect of Tonic SCS (n=8) and Burst SCS (n=9) on the paw 
withdrawal thresholds (PWT) based on sensitivity to von Frey filaments. PWT’s were assessed at 30 
and 60 mins. of stimulation. The dotted line represents the average WT baseline prior to sciatic nerve 
ligation. (^ p < 0.05 for Tonic SCS time points compared to pre-SCS baseline PWTs, # p < 0.05 for Burst 
SCS compared to pre-SCS baseline PWTs). 
 
Spinal Cord Stimulation in the MRI-scanner 
 
Neural responses to Burst SCS and Tonic SCS 
The group average brain activation patterns in response to Tonic SCS and Burst SCS are 
shown in Figure 2. Z-scores per stimulation protocol for regions of interest are listed in Table 
1. Tonic SCS induced significant brain activation (z-value > 1.96, p < 0.05) in regions of 
interest (ROIs) associated with location and intensity of pain such as the primary 
somatosensory cortex (hind limb region) (z= 2.7), and the premotor cortex (z=2.8) (Figure 
2; Table 1). Tonic SCS also induced significant brain activation in areas associated with 
cognitive-emotional aspects of pain such as the anterior cingulate cortex (z=3.2), amygdala 
(z=3.2) and insular cortex (z=4.4). Burst SCS resulted in a larger and more robust increase of 
BOLD signal levels in all ROIs, as compared to Tonic SCS. Burst SCS increased BOLD-levels in 
areas associated with the location and intensity of pain such as the primary somatosensory 
cortex (hind limb region) (z= 12.8), and the premotor cortex (z=14.2) and areas associated 
with cognitive-emotional aspects of pain such as the anterior cingulate cortex (z=15.1), 
amygdala (z=11.9) and insular cortex (z=18.4) (Figure 2; Table 1). Additionally, Burst SCS 
increased BOLD-signal in the dorsal raphe nucleus (z=8.1), and areas associated with the 
reward system such as the nucleus accumbens (z=13.4), and the caudate putamen (z=17.1).  
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Fig.2: Mean z-values and ROIs projected onto reference image for Tonic SCS (third row), Burst SCS 
(fourth row), and for areas that showed larger BOLD signal changes for Burst SCS as compared to Tonic 
SCS (fifth row). 
 
 
 
Table 1: Z-scores for Tonic and Burst stimulation per region of interest. 
  
   Regions of Interest Tonic SCS Z-scores         Burst SCS Z-scores 
Anterior Cingulate Cortex     3.2 15.1 
Caudate Putamen     5.4 17.1 
Hippocampus     4.2 11.7 
Nucleus Accumbens      3.7 13.4 
Amygdala      3.2 11.9 
Raphe Nuclei     2.2 8.1 
Insular Cortex     4.4 18.4 
Primary Motor Cortex     3.7 15.1 
          Premotor Motor Cortex     2.8 14.2 
Thalamus     4.8 17.4 
Periaqueductal Gray     5.3 18.0 
S1 Cortex (Hindlimb)     2.7 12.8 
                  S1 Cortex (Forelimb)     4.2                        17.4 
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BOLD Amplitude Response Curves 
Figure 3  and 4 display the normalized BOLD signal time-course in ROIs in brain-regions 
associated with the processing of location and intensity of pain (Fig.3) and cognitive-
emotional aspects of pain (Fig.4). For both the brain-regions associated with the processing 
of location as well as brain regions associated with the cognitive-emotional aspects of pain 
Burst SCS induced a more profound increase in BOLD amplitude. Figure 5 displays the 
normalized BOLD signal time-course in ROIs in brain-regions associated with the processing 
of reward (caudate putamen and nucleus accumbens) and the raphe nuclei. A strong 
increase in BOLD amplitude was observed in these regions with Burst SCS, however, this 
was not observed for Tonic SCS (Fig.5+6, Table 2).  
 
 
Fig.3: BOLD signal (%). Average time-courses (mean ± SEM) from representative brain regions 
associated with the processing of location and intensity of pain for Tonic SCS (A+C) and Burst SCS 
(B+D). Figure demonstrates a change of the BOLD signal response during SCS. The stimulus “on” period 
is shown by the dotted line. 
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Fig.4: BOLD signal (%). Average time-courses (mean ± SEM)  from representative brain regions brain 
regions associated with the processing of cognitive-emotional aspects of pain for Tonic SCS (A+C+E) 
and Burst SCS (B+D+F). Figure demonstrates a change of the BOLD signal response during SCS. The 
stimulus “on” period is shown by the dotted line. 
 
 
Fig.5: BOLD signal (%). Average time-courses (mean ± SEM) from representative brain regions 
associated with the processing of reward (nucleus accumbens and caudate putamen) and descending 
pain signals (raphe nuclei) for Tonic SCS (A+C+E) and Burst SCS (B+D+F). Figure demonstrates a change 
of the BOLD signal response during SCS. The stimulus “on” period is shown by the dotted line. 
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Bold Amplitude of Burst and Tonic SCS  
Analysis of Burst and Tonic SCS amplitude during stimulation showed that Burst SCS had, 
overall, a significantly stronger effect in the selected ROI’s (Fig. 6). Two-Way ANOVA 
comparison of Burst pre-stimulation and Burst during stimulation showed that BOLD 
amplitude was significantly increased in the OFC, mPFC, ACCPFC, CPU, HIP, NucACC, Amy, 
Raphe, M1, M2, S1FL, S1HL, S2, as compared to pre-Burst stimulation (Table 2.) Two-Way 
ANOVA comparison of Tonic pre-stimulation and Tonic during stimulation showed that 
during stimulation showed that BOLD amplitude was significantly increased in the OFC, 
mPFC, ACCPFC, HIP, NucACC, Amy,  M1, M2, S1HL, S2, as compared to pre-Tonic stimulation. 
No significant activation differences were shown for the CPU, Raphe and S1FL (Table 2.). 
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Fig.6:  BOLD signal amplitude (% change from baseline) in different ROIs during Burst and Tonic SCS. 
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TONIC SCS      
PRE VS. PLATEAU STIM       
Difference (%)   P value  Significance 
ACCPFC 0.2428   P<0.001       *** 
CPU 0.05059   P>0.05        ns 
HIP -0.1950   P<0.001       *** 
NUCACC 0.3931   P<0.001       *** 
AMY -0.5487   P<0.001       *** 
RAPHE -0.06078   P>0.05        ns 
INSC 0.3323   P<0.001       *** 
M1 0.9622   P<0.001       *** 
S1FL 0.01319   P>0.05        ns 
S1HL 0.7154   P<0.001       *** 
THALA 0.1356   P<0.001       *** 
    
BURST SCS    
PRE VS. PLATEAU STIM    
 Difference (%)   P value Significance 
ACCPFC 2.818        P<0.001       *** 
CPU 2.199   P<0.001       *** 
HIP 0.7168   P<0.001       *** 
NUCACC 2.286   P<0.001                    *** 
AMY 2.029   P<0.001       *** 
RAPHE 2.011   P<0.001       *** 
INSC 3.192   P<0.001       *** 
M1 2.143   P<0.001       *** 
S1FL 2.195   P<0.001       *** 
S1HL 4.064   P<0.001       *** 
THALA 3.271   P<0.001       *** 
 
Table 2: BOLD signal amplitude (stimulation plateau BOLD signal minus pre-stimulation BOLD signal, 
% of baseline) for Tonic SCS (n=8) and Burst SCS (n=9). 
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Discussion 
 
The objective of the present study was to assess whether both Tonic SCS- and Burst SCS-
induced pain relief in chronic neuropathic animals would result in increased BOLD-signal in 
brain regions associated with location and intensity of pain, and cognitive-emotional 
aspects of pain. We found that, overall, both Tonic SCS- and Burst SCS increased BOLD-signal 
in brain regions associated with location and intensity of pain (somatosensory cortex and 
premotor cortex), and cognitive-emotional aspects of pain (amygdala, anterior cingulate 
cortex, insular cortex). However, Burst SCS induced a more profound BOLD-increase in brain 
areas associated with cognitive-emotional aspects of pain, as compared to Tonic SCS. 
Additionally, we found that Burst SCS had a more profound BOLD-effect in the raphe nuclei 
and brain regions associated with the reward-system such as the nucleus accumbens and 
the caudate putamen. This was not observed in animals that received Tonic SCS.  
Past research has demonstrated that fMRI can be a powerful tool for understanding and 
mapping of brain areas involved in the pain relieving effect of SCS [27, 28, 32]. FMRI has 
contributed, along with other neuro-imaging tools, to a deeper understanding of the 
mechanisms underlying Tonic SCS.  It has been shown that Tonic SCS increases BOLD-levels 
in the secondary somatosensory cortex, primary sensorimotor cortex and the insula, while 
decreased BOLD-signals were reported in the primary motor cortex and primary 
somatosensory cortex. [28]. In line with these findings, in our study, we also observed 
increased BOLD-levels in the secondary somatosensory cortex and the insula during Tonic 
SCS. However, we did not observe decreased BOLD-signal during SCS in the primary motor 
cortex and primary somatosensory cortex. Yet, because physicians usually decrease the 
paresthesia threshold, in consultation with the patient, to a comfortable level, the animals 
in our study could have experienced higher levels of paresthesia, which would result in 
increased BOLD-signals in the primary somatosensory cortex. A more recent fMRI-study, 
with twenty patients that received Tonic-SCS treatment for FBSS, reported decreased BOLD-
signal in the insula, the medial thalamus and the rostral and caudal cingulate cortex [27]. 
Another important finding from their study was that lesser BOLD-changes in the rostral ACC, 
inferior olivary nucleus and the cerebellum seemed to mark direct pain relief due to short-
term Tonic SCS. This emphasizes the role of the cerebello–thalamo–cortical circuit as a key 
regulator for Tonic SCS-induced pain relief and implicating the modulation and regulation 
of averse and negative affect related to pain with Tonic SCS [27]. This is partially in line with 
the findings of Deogaonkar and colleagues (2015) who demonstrated that Tonic SCS 
reduced affective components of pain when providing optimal pain relief. They reported a 
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decreased connection strength between somatosensory and limbic areas and increased 
connection strength between somatosensory and default mode network with Tonic SCS 
[32]. This led them to hypothesize that pain relief from Tonic SCS could be induced by 
reduction of negative emotional processing associated with pain, allowing somatosensory 
areas to become more integrated into default mode activity [32]. This seems to suggest, in 
line with the aforementioned study and our results, that pain relief from Tonic SCS may be 
reducing negative emotional aspects of pain by activation of areas associated with the 
medial STT, be it to a lesser extent as compared to Burst SCS. Yet, this notion was challenged 
by De Ridder et al., who pondered whether Tonic-SCS really influences the medial pain 
system [55]. In response to the work of Deogaonkar and colleagues (2015), it was argued 
that pain unpleasantness is not correlated to a functional connectivity change between 
somatosensory cortex and dorsal anterior cingulate cortex/limbic areas. Therefore, they 
considered it premature to conclude that tonic stimulation does indeed exert its effect on 
pain suppression by modulating the emotional processing of pain. It thus seems that more 
neuro-imaging work is required in order to reach a clear consensus on the supraspinal 
working mechanisms of SCS. 
Recently, Burst SCS was introduced to the field of neuromodulation [33, 34]. It is 
hypothesized that the Burst provides a more complete and adequate attenuation of the 
pain-experience, as initial clinical findings suggest that Burst SCS activates both the lateral 
and the medial STT [33]. The lateral STT is responsible for the transmission of objective pain-
aspects such as the intensity and location of the painful stimulus. This pathway projects via 
the thalamus to cortical areas such as the somatosensory cortex [30, 31]. At the same time, 
brain signals travel along medial STT projection neurons to engage the cingulate and insular 
cortices via connections in the brainstem (parabrachial nucleus) and amygdala; contributing 
to the affective component of the pain experience. Thus, additional activation of medial STT 
with Burst SCS would also improve cognitive-emotional pain-aspects of neuropathic 
patients [33, 35]. In this study, we found that, overall, stronger BOLD differences were 
observed for Burst stimulation as compared to Tonic stimulation. We observed a 
significantly increased BOLD-signal in the Amygdala, a key region of the medial STT-system, 
during Burst SCS, as compared to pre-stimulation. Meanwhile, Tonic SCS did not induce a 
significantly increased BOLD-signal in the Amygdala, as compared to pre-stimulation. 
Furthermore, two additional key-regions of the medial pain network, the insula and the 
cingulate cortex, showed a more profound increase in BOLD-signal during Burst SCS, as 
compared to Tonic SCS. This suggests that Burst stimulation indeed activates areas 
associated with the medial STT, which is in line with the work from the Ridder and 
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colleagues who showed with encephalogram analysis that Burst SCS normalized the pain 
supporting/suppressing balance in contrast to Tonic SCS mode by a greater effect on the 
dorsal Anterior Cingulate Cortex (ACC) [35]. Meanwhile, in our study, Tonic SCS induced an 
increase in BOLD-levels in the primary somatosensory cortex and the premotor cortex, 
which is in line with previous studies which suggest that Tonic SCS mainly has an effect on 
cortical areas associated with the lateral STT [28]. Additionally, in our study, Tonic SCS 
increased BOLD-signal in areas associated with the medial pain pathway, although to a 
lesser extent than is seen with Burst SCS. It thus seems that both stimulation designs modify 
brain activity differently. It is important to mention that this in in contrast to the von Frey 
data obtained in this study and past literature, where Burst SCS and Tonic SCS did not 
significantly differ in optimal pain relieving effects [39, 40]. Yet, it is conceivable that reflex-
based assessment methods such as the von Frey are not sensitive to supraspinal cognitive-
emotional aspects of pain, as reflexes are known to be processed (initially) on a spinal level 
[56-58]. 
Additionally, we found that Burst-SCS also activated brain areas associated with the 
reward-system; the caudate putamen and the nucleus accumbens [59]. This is not 
surprising, as the reward circuit play a vital role in the motivational-affective experience 
of pain [60].  In fact, chronic neuropathic pain is an extremely complex experience that 
requires the recruitment of an intricate set of central nervous system components. 
DosSantos and colleagues have highlighted brain areas associated with reward circuitry that 
play a role in the processing of pain, including the nucleus accumbens (NAc), ventral 
tegmental area, and the medial prefrontal cortex [60]. A study with healthy subjects has 
shown that at the offset of painful heat stimuli (rewarding) there is a decrease in BOLD 
signal in the NAc, while at the onset (aversive) an increase of BOLD-signal can be observed 
[61]. It could be hypothesized that part of the additional analgesic properties reported with 
Burst-SCS, as compared to Tonic SCS, are related to the activation of  reward/motivational 
circuitry, and thus a feeling of reward [61].  Interestingly, the caudate putamen and the 
nucleus accumbens are also associated with the experience of motivation, a psychological 
aspect know to be affected by (neuropathic) pain [62-64]. Both acute and chronic pain can 
have a significant impact on the experience of motivation. More specifically, several studies 
have demonstrated how anatomical and functional changes in these motivational brain 
circuits contribute to the transition from acute to chronic pain [62]. In addition, a recent 
meta-analysis has reported that anhedonia is significantly associated with a reduced neural 
response to reward anticipation in the caudate nucleus, putamen and the nucleus 
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accumbens [65]. Furthermore, the modulation of motivational pain aspects is in line with a 
recent experimental behavioral pain study (Meuwissen et al. 2019). By use of an operant 
testing method for rats, it was demonstrated that Burst SCS modulated cognitive-
motivational aspects of pain behavior to a greater extent than Tonic SCS. It could be 
hypothesized that the increased activation levels observed in the nucleus accumbens and 
caudate putamen with Burst SCS are responsible for the pleasant feeling often described by 
patients who receive Burst stimulation. In line with this, De Ridder and Vanneste described 
the following:  “Even though pain is commonly considered an aversive signal, in specific 
contexts (usually erotic) pain can be perceived as pleasurable”. With this they referred to a 
study which showed that when pain is perceived as pleasurable, the anti-nociceptive system 
is activated, including the nucleus accumbens, pregenual anterior cingulate cortex and 
ventromedial prefrontal cortex as well as the caudate nucleus [35, 66]. Nevertheless, the 
precise role the cognitive-motivational system plays in the supraspinal mechanisms 
underlying Burst SCS should be confirmed by future neuroimaging studies that include the 
complete subset of regions associated with the reward/motivation system. In our study, 
Burst SCS also activated the raphe nuclei. With Tonic SCS we did not observe significant 
BOLD-changes in this region. The raphe nuclei are an important set of nuclei in pain 
modulation. They have a great number of 5-HT neurons, and the vast fiber connections to 
other parts of the central nervous system provide the morphological basis for its pain-
modulating function. The descending projections of the raphe nuclei, via the nucleus raphe 
magnus or directly, modulate the processing of noxious stimuli in the spinal dorsal horn 
[67]. Interestingly, the nucleus raphe magnus receives descending afferents from the 
central nucleus of the amygdala, a brain region where we observed a substantial amount of 
activation with Burst SCS [68]. With this study, we provide a framework for future (fMRI) 
research on the supraspinal elements involved in pain relief during SCS. A deeper 
understanding of the neural pathways implicated in the neurophysiology of SCS-induced 
pain-relief will likely result in the development of new and alternative modalities with 
improved efficacy [69]. 
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Conclusion 
 
Burst and Tonic SCS-induced pain relief is accompanied with different effects on the 
intensity and localization of SCS-induced increase of BOLD-signal in the brain. From this, we 
concluded that Burst SCS-induced pain relief is due to activation of brain regions associated 
with both objective aspects of pain and with cognitive-emotional aspects of pain relief. 
Secondly, we were able to demonstrate that Tonic SCS also induced increases in BOLD-signal 
in the aforementioned areas, but to a lesser extent. Additionally, our data suggest that Burst 
SCS might have additional analgesic properties over Tonic SCS in treatment of chronic 
neuropathic pain via the activation of brain areas associated with the reward-system and 
the raphe nuclei.  
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CHAPTER 7 
 
SUMMARY, DISCUSSION, AND CONCLUSION 
 
Aims and Research questions 
The primary aim of this academic thesis was to elucidate the spinal and supraspinal 
mechanisms underlying Burst spinal cord stimulation induced pain relief in an 
experimental neuropathic pain model based on the understanding of the underlying 
mechanism. 
 
RESEARCH QUESTIONS (RQ) 
 
Based on the aims of this academic thesis, the following research questions are formulated: 
1. What is the effect of amplitude on the analgesic efficacy of Burst- and Tonic SCS in an 
experimental animal model of chronic neuropathic pain? 
2. Does the anti-nociceptive effect over time differ for Burst SCS and Tonic SCS? 
3. Is GABA involved in the spinal pain relieving mechanism of Burst SCS? 
4. Is it possible to discriminate between Burst and Tonic SCS on cognitive-motivational 
aspects of pain relief, with use of MCAS operant testing? 
5. Which brain areas are involved in the pain relieving effect of Burst SCS, as compared 
to Tonic SCS, in an animal model of chronic neuropathic pain? 
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The conclusions that have been formulated based on the experiments as described in the 
various chapters will be discussed in broader and future perspectives and related to the 
aims of this thesis.  
 
The first research question formulated was: 
 
What is the effect of amplitude on the analgesic efficacy of Burst- and Tonic SCS in an 
experimental animal model of chronic neuropathic pain? 
 
To answer this question, we assessed mechanical hypersensitivity in 12 Sprague Dawley rats 
using paw withdrawal thresholds (WTs) to von Frey monofilaments, at various SCS 
intensities (amplitudes) and multiple time points during 60 minutes of stimulation and 30 
minutes post stimulation. We found that Burst SCS requires significantly more charge per 
second (CPS) in order to achieve similar pain relief compared to Tonic SCS, in an 
experimental model of chronic neuropathic pain. Increasing amplitude with Tonic SCS 
improved its efficacy, whereas the efficacy of Burst SCS showed a non-monotonic relation 
with amplitude. Interestingly, Tonic SCS at 66% MT and Burst SCS at 50% MT had a 
statistically similar maximum pain relieving effect, assessed as decrease in mechanical 
hypersensitivity. However, Burst SCS required higher mean CPS in order to achieve this 
maximum pain relieving effect. Moreover, when Burst SCS and Tonic SCS were applied at a 
comparable mean CPS Tonic SCS had a superior behavioral outcome. Our findings further 
demonstrate that Burst- and Tonic SCS exhibit an essentially different behavioral pattern of 
pain relief, in relation to amplitude (at 66%, 50% and 33% MT). For Tonic SCS, amplitude is 
positively correlated with behavioral outcome, as an increase in amplitude is accompanied 
by an increase in pain relief. Contrarily, Burst SCS amplitude does not appear to have a 
positive correlation with the behavioral outcome, as 66% MT, the highest applied 
amplitude, did not produce optimal pain relief. This implies a non-monotonic relation with 
amplitude. Furthermore, the range of amplitudes for Burst SCS in order to achieve an 
optimal behavioral effect (therapeutic window) appeared to be relatively narrow given that 
the behavioral outcome was shown to decline rather rapidly once 50% MT (= optimal Burst 
MT) is surpassed. This is consistent with the findings of Courtney and colleagues who 
reported that the therapeutic range of Burst SCS is considerably smaller (perception 
amplitude 0.3mA, max tolerable amplitude 2.5mA) compared to Tonic SCS (perception 
amplitude 4.2mA, max tolerable amplitude 8.9mA) [1]. However, we cannot exclude the 
assumption that a gradual decrease of the behavioral outcome is enclosed within the two 
highest amplitudes applied with Burst SCS in our study. Thus, Burst SCS is effective at smaller 
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amplitudes, yet the overall CPS necessary to obtain a therapeutic effect is significantly 
higher when compared to Tonic SCS. Remarkably, the large quantities of charge delivered 
with Burst SCS do not result in a superior behavioral outcome, compared with Tonic SCS 
(the maximum WT of the optimal Burst amplitude (50%) and Conventional amplitude (66%) 
did not significantly differ). This is in line with recent clinical findings from which it was 
concluded that stimulation with Tonic SCS and Burst SCS are equally effective in relieving 
neuropathic pain related to complex regional pain syndrome  [2]. It is, therefore, reasonable 
to assume that both Tonic- and Burst SCS modes are able to induce significant pain relief; 
despite there being significant differences in CPS necessary for similar pain relief. With the 
recent focus on new frequencies and waveforms in the SCS field, there is a growing 
appreciation for the impact of energy delivery on the central nervous system [3]. A recent 
clinical study suggested a possible dose-related response between the amount of energy 
delivered to the spinal cord and the clinical effect [4]. Understanding the physiological 
consequences of delivering energy to the spinal cord could aid the optimization process of 
(Burst) SCS and therefore deserves more future research.  
When all parameters are considered together, stimulation is characterized by “charge 
over time,” which can be delivered through various dosing strategies (Burst SCS, Tonic SCS, 
HF-SCS). For example, Tonic SCS “doses” therapy with a high “charge per pulse.” In contrast, 
a dosing strategy that uses higher frequencies and/or wider pulse widths produces a more 
consistent delivery of energy, providing a higher CPS. Thus, stimulation parameters can be 
characterized as having a low or high concentration of current, and the delivery of energy 
could be characterized as involving low or high dose. The basic unit of electrical stimulation 
in neuromodulation is the pulse. The pulse consists of a specific amount of current 
amplitude (measured in milliAmperes, mA) for a specific amount of time (pulse width). Each 
pulse is followed by an equal flow of current in the opposite direction in order to balance 
the charge delivered to the spinal cord and thereby safeguard against overstimulation 
(buildup of charge) which is known to result in tissue damage [5]. The “recharge” phase can 
be active (producing a biphasic appearance) or passive (balanced but asymmetric); in most 
SCS systems, charge balancing occurs after each individual pulse and in a passive manner 
[3]. With the introduction of the Burst waveform however, the passive recharge balancing 
should not be taken for granted. The Burst waveform as it was introduced to the SCS-field 
by Dr. De Ridder, also known as the BurstDR waveform is a passive-recharge form of Burst 
SCS (as opposed to an active recharge waveform applied in our studies presented in this 
thesis), where the built-up charge period is discharged during the interburst-period [6, 7]. 
In our studies, we applied biphasic Burst waveform, that discharges in an active recharge 
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fashion, during the intraburst-period, in order to maintain the charge balance. It is proposed 
that this difference between active and passive Burst SCS can have physiological 
repercussions: the ‘plateau’ that occurs during the ‘active phase’, followed by a period of 
relative quiescence called the ‘silent phase’” with BurstDR-SCS is generated by calcium 
influx via T-type calcium channels, generating a low threshold Ca2+ potential upon the crest 
of which sodium and potassium channel-mediated action potentials fire, creating low 
threshold bursts. This is hypothesized to mimic ‘natural’ burst firing [8-10]. However, while 
the burst waveform used in our study has a different shape from the one utilized in other 
studies, physiological or clinical differences between these burst waveforms are unknown. 
To date, no data from clinical or preclinical studies support the claim that passive recharge 
burst is more effective than active recharge burst, and future studies aiming to directly 
compare active and passive recharge Burst waveforms should be conducted in order to shed 
light upon this matter. In order to more accurately interpret the effect specific parameter 
variations can have on energy delivery to the spinal cord one should consult the “strength-
duration curve” as presented in the review by Miller and colleagues [3]. The strength-
duration curve demonstrates that short pulse widths require high amplitudes to activate a 
neuron or axon, while wider pulse widths require less amplitude. In vivo, each individual 
axon has its own strength-duration curve based on its size, grade of myelination, and 
distance from the locus of stimulation. The concept of the strength-duration curve has been 
demonstrated in studies testing activation of spinal cord axons in animal models [11], and 
in patients implanted with SCS systems [12, 13]. Generally, amplitude impacts the number 
of fibers recruited in the spinal cord, and results in a perceived increase or decrease in the 
intensity and/or area of paresthesia sensation. On the other hand, pulse width is typically 
considered a secondary factor in controlling energy delivery, however, an increase in this 
parameter can also recruit a larger number of fibers, and decreases the need for amplitude.  
An understanding of the strength-duration curve also elucidates how a substantial amount 
of current can be delivered to an axon without necessarily producing an action potential. 
When the current delivered is below the activation threshold for a neuron, the neuron may 
locally depolarize, but no action potential is generated. Furthermore, large amounts of 
charge could theoretically be administered at extreme ends of the curve (with narrow or 
wide pulse width), while still remaining below threshold and avoiding the development of 
intense paresthesia [3]. Therefore, Burst or HF stimulation may be subthreshold with 
respect to neuronal activation, and sub-perception with respect to the patient’s experience, 
yet large amounts of charge is delivered to the spinal cord and thus can manipulate spinal 
neural functioning. Altogether, the findings presented in Chapter 2 of this thesis suggest 
Summary, Discussion, and Conclusion 
149 
that a more complex relationship defines the interplay between the parameters of SCS, the 
charge delivered to the spinal cord, and the therapeutic efficacy of SCS. With our study, 
where we investigated the effect of amplitude variation, we have presented a framework 
for future parameter variation studies. We believe that greater insight into the various 
parameter combinations will help to optimize (Burst) SCS. 
 
Research question 2: Does the anti-nociceptive effect over time differ for Burst SCS and 
Tonic SCS? 
 
To answer the second research question 43 neuropathic animals received either Burst or 
Tonic SCS for 60 minutes, while undergoing behavioral von Frey assessment during 60 
minutes of stimulation and 30 minutes post stimulation. We reported a delayed anti-
nociceptive effect of Burst SCS after onset of the stimulation, as compared with Tonic SCS. 
Furthermore, Burst SCS seemed to exhibit a delayed washout of analgesia after stimulation 
was turned off. However, no difference in maximum anti-nociceptive effect of Burst SCS, as 
compared with Tonic SCS, was noted in our study.  
t has previously been suggested that Burst SCS provides a more complete and adequate 
attenuation of the pain-experience, as initial clinical findings suggest that Burst SCS 
activates both the lateral and the medial STT [6]. This is in line with our findings presented 
in Chapter 6, where we described that Burst SCS induced a more profound BOLD-increase 
in brain areas overall, and in brain areas associated with cognitive-emotional aspects of 
pain, as compared to Tonic SCS. These results corroborate the prevailing hypothesis that 
Burst SCS stimulates supraspinal pathways able to activate brain areas associated with 
cognitive-motivational aspects of pain [6, 14]. Modulation of cognitive-motivational aspects 
of pain with Burst SCS is also in line with our findings presented in Chapter 5, where we 
discussed the outcome of our behavioral study performed with use of the Mechanical 
Conflict Avoidance System (MCAS). With the MCAS-system, we studied operant behavior 
specifically correlated with cognitive-motivational aspects of pain. From this, we concluded 
that Burst SCS specifically affects, much more than Tonic SCS, the processing of cognitive-
motivational aspects of pain. On the other hand, the main mechanism of action underlying 
the analgesic effect of Tonic SCS has been shown to act through antidromic activation of 
Aβ-fibers at a segmental, spinal, level [15, 16]. Supraspinal processes, set in motion by 
orthodromic activation of Aβ-fibers with Tonic SCS, eventually lead to secondary analgesic 
aspects of Tonic SCS [17]. Following this line of reasoning, it could be hypothesized that 
activation of supraspinal pathways, as suggested with Burst SCS, requires a different 
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timeframe in order to fully establish its anti-nociceptive properties, as compared to 
segmental mechanisms observed with Tonic SCS. Thus, the anatomical location of the main 
mechanisms of action might underlie the delayed onset and timing difference between the 
behavioral effects of Burst SCS and Tonic SCS as observed in our study (Chapter 3). 
Furthermore, Burst SCS has been shown to modulate attention to pain, as shown by studies 
that utilized the Pain Vigilance and Awareness questionnaire [6]. It is conceivable that such 
an attention-modulation effect, mediated by brain structures associated with the limbic 
system, reverberates after cessation of stimulation, as compared to direct modulation of 
segmental mechanisms at a spinal level. Therefore, one could hypothesize that the 
attention-modulating effect of Burst SCS might echo on after the stimulation is terminated, 
which is reflected by a delayed washout effect, as compared with Tonic SCS. Computer 
modelling has indicated that SCS frequency, at least partly, determines the firing of Wide 
Dynamic Range (WDR) neurons projecting to the brain [18]. It was demonstrated that SCS 
with frequencies above 100 Hz (as with Burst SCS) do not result in inhibition of WDR 
signaling; this strongly suggests that higher SCS frequencies induce pain relief via alternative 
mechanisms.  If future research demonstrates that certain parameters are indeed involved 
with the modulation of specific physiological components, SCS-modes could be ‘tailor-
made’ for each patient, which would result in optimal pain relief for each individual patient 
through specific targeting of the underlying pathology. Yet, future experiments should be 
performed in order to shed more light on the differences in pathway activation associated 
with different waveforms. 
  
Research question 3: Is GABA involved in the spinal pain relieving mechanism of Burst 
SCS? 
 
For the third RQ, which was addressed in Chapter 4, experiments were performed in a 
widely recognized rat model for SCS and chronic neuropathic pain: partial sciatic nerve 
ligation (PSNL) model [19].  
In our study, anatomical analysis based on detailed quantitative immunohistochemistry of 
spinal dorsal horn GABA revealed that 60 minutes of Tonic SCS induced a decrease (trend) 
of intracellular GABA-levels. This is in line with past research performed in the PSNL-model 
[20, 21]. During the development of neuropathic pain Janssen and colleagues observed, in 
the partial sciatic nerve ligation model, increased intracellular levels of GABA in the dorsal 
horn [20]. In a follow-up study they then showed that Tonic SCS decreased intracellular 
GABA-immunoreactivity in the dorsal horn of these PSNL-rats [21]. Quantitative 
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immunohistochemistry of spinal dorsal horn GABA-levels in our study further revealed a 
significant decrease in intracellular GABA levels after 60 minutes of Burst SCS. Intracellular 
GABA levels were significantly decreased compared to Sham-SCS animals and Tonic SCS 
animals. Intrathecal administration of the GABAA- and GABAB–receptor antagonist 
bicuculline and phaclofen revealed that blocking the spinal GABAergic mechanisms 
abolishes the pain relieving effect of both Tonic SCS and Burst SCS. Based on these findings, 
we concluded in Chapter 4 that the pain relieving effect of Burst SCS includes a spinal 
GABAergic mechanism. In line with our study, preclinical studies, conducted in a sciatic 
nerve injury model, demonstrated that intrathecal administration of the GABAB-agonist 
baclofen, and the GABAA-agonist muscimol, administered intrathecally, resulted in a 
marked and long-lasting increase of withdrawal thresholds in rats not receiving adequate 
pain relief with Tonic SCS (non-responders), although muscimol produced a less prominent 
threshold increase as compared to baclofen [48]. This, and our data, shows that Tonic SCS 
operates by potentiating the spinal GABAergic systems in general, and that the Tonic SCS 
effect depends on both GABAA-receptor and GABAB-receptor signaling, although the SCS-
effect seems to be more linked to the GABAB-receptor system [22]. In our study, 
administration of a GABAA- and GABAB–receptor antagonist also abolished the pain relieving 
effect of Burst SCS. Our observations, which led us to conclude that Burst SCS is mediated 
via spinal GABAergic mechanisms, seem not to be in line with findings reported by Crosby 
and colleagues (2015). Based on electrophysiological analysis of neuronal firing after Burst 
SCS, these authors reported that the presence of a GABAB-receptor antagonist did not block 
the attenuation of dorsal horn neuronal firing, when SCS was applied at 90% of the Motor 
Threshold (MT) [23]. Yet, because they made use of a rather unconventional rat model of 
pain, and because they applied SCS at 90% MT (an intensity known to induce unwanted side 
effects in the animals), it remains difficult to compare their findings to the bulk of 
experimental SCS studies performed with use of peripheral nerve injury models [8, 19, 21, 
24-28], and SCS applied below 90% MT.  
Since Burst SCS is known to modulate structures at a supraspinal level in a different 
manner as compared to Tonic SCS [6, 14], it is remarkable that the segmental GABAergic 
mechanisms of these waveforms, at the spinal level, show similarities. Evidence has shown 
that Tonic SCS, via descending pathways, exerts an inhibitory GABAergic effect in the dorsal 
horn of the spinal cord [29-34]. It thus might be possible that Burst SCS via similar 
descending pathways is able to release GABA in the spinal dorsal horn. Taking into 
consideration the findings described in Chapter 3, where we observed a delayed onset for 
the analgesic effect of Burst SCS, the onset of GABAergic mechanisms activated by Burst 
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SCS, if induced by the supraspinal loop, could be responsible for the delayed effect. On the 
other hand, according to existing literature it could be hypothesized that the mechanism of 
Burst SCS might include antidromic actions that lead to direct release of GABA in the spinal 
dorsal horn. Initially, the lack of paresthesia as observed with Burst and HF SCS brought 
forward the notion that these waveforms do not activate Aβ-fibers, neither orthodromically 
nor antidromically. Yet, Aβ-fibers are thickly myelinated, and thus very susceptible for 
depolarization with any form of SCS [35, 36]. Furthermore, Burst SCS is known to deliver a 
high charge per second to the spinal cord, and studies have reported that (naturally 
occurring) bursts have a higher probability to generate postsynaptic potentials, as 
compared to single tonic action potentials (which activate Aβ-fibers) [37]. Therefore, it is 
not inconceivable that Aβ-fibers absorb a great amount of the charge delivered with Burst 
SCS, which could potentially lead to subthreshold activation of said fibers [3]. Subthreshold 
Aβ-fiber activation might be insufficient for the patient to perceive paresthesia with Burst 
SCS, however, it might be sufficient enough for the release of GABA in the dorsal horn via 
antidromic activation of inhibitory GABAergic interneurons [16]. 
The majority of experimental studies on the effect of Tonic SCS were performed in sciatic 
nerve injury models including the sciatic nerve ligation model (PSNL) and the chronic 
constriction injury model [8, 15, 21, 22, 24, 27, 28, 38-40]. Therefore, in order to adequately 
compare and correlate our findings to previous literature, we deliberately chose to perform 
our experiments in the partial sciatic nerve ligation (PSNL) model. Animal models are pivotal 
for understanding the mechanism of NPP and for the development of effective analgesic 
therapies. Over the years, a battery of NPP models has been developed to simulate clinical 
NPP conditions with diverse etiology. Use of these models has contributed immensely to 
the understanding of NPP and underlying pathogenic mechanisms [41]. An example is the 
experimental study performed by Cui and colleagues who, in a sciatic nerve lesion model, 
demonstrated that rats not receiving adequate pain relief with Tonic SCS (non-responders) 
could be turned into responders via administration of sub-effective doses of the GABAB-
receptor agonist baclofen [24]. The aforementioned preclinical finding, the synergistic 
effect between Tonic SCS and baclofen application in PSNL rats, was successfully translated 
to the clinic where neuropathic pain patients, not responding adequately to Tonic SCS, 
showed improved pain relief following the intrathecal administration of baclofen [42]. Yet, 
despite the aforementioned example, progress in the field of translational pain research 
remains very limited [43]. Novel insights and analgesic treatments successful in 
experimental setting, acquired via basic science and animal models for NPP, have not led to 
equal development of novel clinically effective compounds. A careful re-examination of 
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animal models of pain is therefore warranted, and it is all the more important that there 
will be consistency and a consensus on the animal models used to investigate specific areas 
of pain research including SCS for the treatment of NPP. 
 
Research question 4: Is it possible to discriminate between Burst and Tonic SCS on 
cognitive-motivational aspects of pain relief, with use of MCAS operant testing? 
 
To answer this RQ, which was described in Chapter 5, a novel Mechanical Conflict Avoidance 
System (MCAS) was used to study operant behavior specifically correlated with cognitive-
motivational aspects of pain.     
Escape latency on the MCAS operant testing setup was evaluated at various probe 
heights for rats (n = 26) with chronic neuropathic pain induced by a partial sciatic nerve 
ligation (PSNL). From this, we concluded that the MCAS is a valid and reproducible method 
for the assessment of SCS-induced cognitive-motivational behavioral aspects of pain relief. 
Use of the MCAS operant testing method revealed significant differences in cognitive-
motivational behavior for Burst SCS and Tonic SCS, and this difference could not be detected 
with reflex-based Von Frey testing. Furthermore, our behavioral findings strongly suggested 
that Burst SCS specifically affects, much more than Tonic SCS, the processing of cognitive-
motivational aspects of pain.  Our experimental data are in line with, and partly confirm,  
observations with Burst SCS in the clinical setting, where questionnaires regarding attention 
to pain and affective aspects of pain (PVAQ) and patients’ preference all tend to lean 
towards Burst SCS, as compared to other SCS-waveforms [44-46]. Nevertheless, till today, 
there is still no clear consensus in literature, neither preclinical [8, 28, 47] nor clinical [6, 7, 
14, 44-46, 48-53], regarding the objective analgesic efficacy of Burst SCS (as measured on 
the VAS-scale), as compared to other SCS-waveforms. Interestingly, a recent clinical study 
by Kriek and colleagues has shown that the preferred stimulation setting is not solely driven 
by the amount of pain reduction, but is also influenced by which stimulation setting feels 
most comfortable [51]. Therefore, it is vital that we aim to elucidate the (supraspinal) 
mechanisms responsible for the level of comfort, the sensation, that accompanies SCS-
waveforms. As the MCAS can provide critical insight into cognitive-motivational processing 
of SCS, it could serve as a preclinical tool that allows for the optimization of supraspinal 
mechanisms of Burst SCS. It is important to note that the difference between Tonic SCS and 
Burst SCS, as observed for the exit latencies, was not present in the reflex-based Von Frey 
analysis. This suggests that the MCAS allows for assessment of behavioral changes in pain 
that are not detected by reflex-based testing. The importance of adding operant testing 
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methods to the standard preclinical assessment battery for NPP has already been 
pinpointed by Vierck and colleagues [54]. In an extensive review they described numerous 
disparities between results for reflex-based testing and operant escape measures. 
Interestingly, the results of operant testing were often more consistent with the clinical 
setting, as compared to reflex-based measures. As NPP is a complex phenomenon, that is 
characterized by both sensory and affective disturbances [55], it is important that we now 
have a tool, the MCAS, which allows us to adequately assess  supraspinal, cognitive-
motivational aspects of NPP in a preclinical setting. A better understanding of the cognitive-
motivational pain relieving aspects will allow further analysis and optimization of these 
specific characteristics of the Burst SCS-protocol. 
 
Research question 5: Which brain areas are involved in the pain relieving effect of Burst 
SCS, as compared to Tonic SCS, in an animal model of chronic neuropathic pain? 
 
In order to understand the supraspinal mechanisms and different aspects of pain relief 
induced with Burst SCS we used functional magnetic resonance imaging (fMRI) which 
allowed us to assess Blood-Oxygenation-Level Dependent (BOLD) signals in the brain of 17 
chronic neuropathic (PSNL) rats. We specifically looked at brain regions associated with 
location and intensity of pain, as well as cognitive-motivational aspects of pain. The results 
can be summarized as follows: for both Tonic SCS and Burst SCS we observed an increase in 
BOLD-signal in brain regions associated with location and intensity of pain (somatosensory 
cortex and premotor cortex), and cognitive-emotional aspects of pain (amygdala, anterior 
cingulate cortex, insular cortex). However, Burst SCS induced a more profound BOLD-
increase in brain areas overall, and brain areas associated with cognitive-emotional aspects 
of pain, as compared to Tonic SCS. The results from our study corroborate the prevailing 
hypothesis that Burst SCS stimulates pathways able to activate brain areas associated with 
cognitive-emotional aspects of pain [6, 14] and are in line with the behavioral outcome of 
our study described in Chapter 5. The cognitive-emotional brain areas are most likely 
activated by signals that travel along medial STT projection neurons in order to engage the 
cingulate cortex, the insula, and the amygdala. Significantly increased BOLD-signal was 
observed in the Amygdala, a key region of the medial STT-system, during Burst SCS, as 
compared to pre-stimulation and Tonic SCS. Furthermore, two additional key-regions of the 
medial pain network, the insula and the cingulate cortex, showed a much more profound 
increase in BOLD-signal during Burst SCS, as compared to Tonic SCS. This is in line with 
clinical work from the Ridder and colleagues who showed with encephalogram analysis that 
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Burst SCS normalized the pain supporting/suppressing balance in contrast to Tonic SCS 
mode by a greater effect on the dorsal Anterior Cingulate Cortex (ACC) [14]. Nevertheless, 
it should also be noted that in our study Tonic SCS also increased BOLD-signal in areas 
associated with the medial spinothalamic pain pathway, although to a lesser extent than 
observed for Burst SCS. This suggests that the different stimulation paradigms, Burst and 
Tonic, are able to activate specific brain areas to a different extent. In the second chapter 
of this thesis, we discussed the behavioral effect of chronic neuropathic animals in response 
to various amplitudes of Burst SCS and Tonic SCS. From this, we concluded that a more 
complex relationship defines the interplay between the parameters of SCS and the 
therapeutic efficacy of SC, as the analgesic efficacy of Burst SCS showed a non-monotonic 
relation with Burst-amplitude. It seems that with the studies described in this thesis we 
have only just scratched the surface of parameter variations. More research into parameter 
variations for Burst SCS might reveal novel differences, yet also, commonalities, with 
existing and future waveforms. Moreover, it has been postulated that no one waveform will 
be optimal for all neuropathic pain patients, therefore the field might eventually move 
towards a more personalized waveform, ‘tailor-made’ for each patient. Yet, this requires a 
thorough understanding of the spinal and supraspinal mechanisms underlying (most) 
optimal pain relief. Extensive research has been performed, and it still being performed, in 
order to decipher the mechanisms responsible for the experience of pain. This has led to 
the formulation of solid frameworks such as the ‘Pain Matrix’ [56-59]. Future neuroimaging 
studies should aim to build a framework representative of the ‘optimal pain relief 
signature’. This can then serve as a guideline for future SCS-waveform design. 
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Conclusion 
 
In summary, the results presented in this academic thesis show that a more complex 
relationship defines the interplay between parameters of Burst SCS, the charge delivered 
to the spinal cord, and the analgesic efficacy. Burst SCS exhibits a delayed anti-nociceptive 
effect after onset of stimulation, and a delayed washout of analgesia after stimulation is 
turned off, as compared with Tonic SCS. We also found, in a well-established chronic 
neuropathic animal model, that the analgesic effect of both Burst SCS and Tonic SCS is 
mediated via spinal GABAergic mechanisms. In a behavioral experiment, we were able to 
demonstrate that Burst-SCS specifically affects, much more than Tonic-SCS, the processing 
of cognitive-motivational aspects of pain. Lastly, we reported that both Tonic SCS and Burst 
SCS increase BOLD-signals in brain regions associated with cognitive-emotional aspects of 
pain. Yet, Burst SCS induced a more profound effect in these brain areas. Mechanism based 
insights and experimental studies as described in this thesis can lead to further optimization 
of the Burst-paradigm and eventually lead to better treatment of neuropathic pain in 
patients (CRPS/FBSS).   
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Valorization 
 
Chapter 2 
The burst waveform has many parameters that can be explored and optimized, one such 
parameter being amplitude. Our research found that while both waveforms are equally 
effective, their optimal effects are achieved at different amplitude settings. To our surprise, 
the study received a number of critical comments; dr. De Ridder and dr. Vanneste criticized 
our study based on the shape of the waveform we used. Instead of a rebuttal, we would 
like to take this opportunity to underline the importance of objective and unbiased 
research, especially when it comes to assessing the various parameter variations of (burst) 
SCS. When objectivity is lost firm beliefs that lack substantial scientific foundation will 
prevail, causing further polarization, which will inevitably bring the progression of the field 
to a halt. 
 
Chapter 3  
Our investigation of the analgesic effect of burst and tonic SCS, over time, led to the 
observation that burst SCS requires significantly more time for its analgesic effect to fully 
wash in. The delayed wash-in, and subsequently delayed wash-out, had important 
consequences for the application of burst SCS in the clinical setting. For example, it is now 
corroborated by clinical observations that the burst waveform is not optimal for patients 
that require immediate pain relief. However, burst SCS simultaneously delivered with a 
waveform that does not exhibit a delayed wash-in (if the technology permits) could still 
yield successful outcomes in the aforementioned patient group.  
 
Chapter 4 
We demonstrated that GABA plays a key role in the analgesic mechanisms underlying burst 
SCS. In the past, similar experimental findings were successfully translated to the clinical 
setting; neuropathic pain patients with a deficient tonic SCS effect showed improved pain 
relief following intrathecal administration of subeffective doses of baclofen. Interestingly, 
our results were not in line with a study that investigated the GABAergic mechanisms 
underlying burst SCS in 2015. Taking into account the important role GABA plays in the 
mechanisms underlying tonic SCS we encourage further investigation of the GABAergic 
mechanisms underlying SCS waveforms. 
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Chapter 5 
We investigated a novel operant testing method able to assess motivational and cognitive 
aspects of pain processing. The pain field, especially the neuromodulation niche, is currently 
undergoing a shift of focus towards supraspinal processing. With the introduction of novel 
SCS-paradigms, that are hypothesized to have strong supraspinal effects, the preclinical 
field is in need of assessment methods able to address such hypotheses. In this chapter, we 
have paved the way for preclinical pain assessment able to address both the sensory and 
emotional aspects of pain. We believe that implementation of operant testing methods 
such as these can significantly improve the translation to the clinic. 
 
Chapter 6 
In the last chapter, by means of fMRI, we assessed the supraspinal mechanisms of tonic and 
burst SCS in a chronic pain model. We found that burst SCS and tonic SCS both activate brain 
areas associated with the medial and lateral pain pathways. Additionally, we found that 
burst SCS might have additional analgesic properties over tonic SCS by the activation of 
brain areas associated with the reward-system and the raphe nuclei. In light of these new 
findings, we believe that more research is still required before we can advocate the use of 
specific waveforms for specific patient populations. 
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